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Summary
1. The technique of high performance liquid chromatography (h.p.l.c.) was employed 
to determine the degree of influence of ectonucleotidases, responsible for the 
extracellular degradation of purine and pyrimidine mono- and dinucleotides, on the 
levels of these pharmacologically active compounds in smooth muscle tissues which 
have previously been shown to possess receptors for both these compounds and/or 
their breakdown products.
2. The rat colon muscularis mucosae, a tissue which contains receptors for both ATP, 
UTP and adenosine, was shown to degrade ATP, UTP and adenine dinucleotides, 
although the latter to a much lesser extent. The P2 receptor antagonist, suramin, 
resulted in an inhibition of this degradation in all cases except that of ATP, with an 
accompanying increase in the half-life of each substrate.
3. The PI receptor antagonist, 8 -SPT, the adenosine deaminase inhibitor EHNA, the 
potent inhibitor of nucleoside membrane transport mechanisms NBTI and the xanthine 
oxidase inhibitor allopurinol had no significant effects on the half-life for the 
degradation of ATP by this tissue. However preincubation with, EHNA resulted in the 
observation of adenosine accumulation in the incubation medium, which is completely 
absent in the presence of control tissues. In contrast NBTI resulted in a significant 
accumulation of AMP in the incubation buffer although, interestingly, no adenosine 
was detected in the presence of these tissues. A decrease in the pH of the extracellular 
environment of the rat colon muscularis mucosae results in a decrease in the levels of 
AMP detected in the incubation medium with a simultaneous increase in the amount of 
inosine detected in these tissues, which appears to indicate that the lower levels of AMP 
observed in these tissues is due to an increased rate of inosine production from AMP,
IV
presumably via rapid deamination of adenosine, as opposed to a decrease in the rate of 
production of AMP from ATP via ADP.
4. The rat vas deferens was shown to rapidly degrade extracellular ATP with a half-life 
of 5.83 ± 0.4 minutes. The major breakdown products initially were ADP and AMP, 
with inosine as the ultimate product. Little or no adenosine was detected in the 
incubation buffer. The half-life of ATP was unaffected by preincubation with NA, 
A23187, forskolin, sodium nitroprusside, glibenclamide or glipizide. However, 
preincubation with both forskolin and sodium nitroprusside resulted in a significant 
increase in the levels of AMP detected in the buffer. In addition, sodium nitroprusside 
also resulted in a simultaneous decrease in the level of inosine detected in the buffer, 
although there was no corresponding change in the adenosine levels observed with 
these tissues.
5. In the case of the guinea-pig vas deferens ATP, Ap^A and Ap^A were all degraded, 
resulting in the formation of ADP, AMP, adenosine and inosine from ATP; ATP, ADP, 
AMP, adenosine and inosine from Ap^A and AP^, ADP, AMP, adenosine and inosine 
from ApgA. In addition, the breakdown of ATP, Ap^A and Ap^A was inhibited by 
preincubation of tissues with suramin.
6 . The bisected guinea-pig vas deferens degraded extracellular ATP, with a similar 
pattern of breakdown products detectable in the incubation medium as in the presence of 
the whole tissue. Although the half-lives for ATP in the presence of the prostatic and 
epididymal portions were significantly different, when the relative weights of the two 
halves were taken into consideration the rate constants for each of these reactions did 
not show any significant differences. Interestingly, there was a significant correlation 
between tissue weight and the extracellular half-life for ATP in the presence of the 
epididymal, but not the prostatic portion of the guinea-pig vas deferens, indicating that
an additional factor other than tissue weight may influence the rate of extracellular ATP 
by the prostatic portion of this tissue.
7. Preincubation of the rat whole duodenum with A3’P5’PS caused a dose-dependent 
relaxation of the carbachol precontracted tissue, which was inhibited by suramin. Both 
ATP and A3’P5’PS were degraded by the rat duodenum, although A3’P5’PS to a much 
lesser extent. The degradation product of A3’P5’PS metabolism was A3’P5’P, with no 
other metabolite detected in the incubation buffer. Preincubation with suramin resulted 
in no detectable degradation of A3’P5’PS.
VI
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Chapter 1
GENERAL INTRODUCTION
1.1. Historical Background
It was recognised as early as the 1920s that extracts from heart, brain, kidney and 
spleen were able to produce physiological effects upon the cardiovascular system 
when injected into whole animals (Drury & Szent-Gyorgyi, 1929). They discovered 
that tissue extracts induced bradycardia and reduced the force of contraction of the 
heart (a negative ionotropic effect) when injected intravenously, accompanied by a 
lowering of blood pressure due in part to systemic arterial dilatation. Adenosine 5’- 
monophosphate (adenylic acid; AMP) was isolated and identified as the active 
component of the extracts. However, the observation that there was a perceptible lag 
phase between administration and the onset of physiological effects, combined with 
the fact that adenosine, extracted from yeast, was found to produce similar effects in 
vivo led Drury & Szent-Gyorgyi to conclude that the activity of AMP was due to its 
subsequent dephosphorylation to adenosine in the animal.
These findings were investigated only sporadically and not significantly expanded on 
until the 1960s when Berne (1963) first postulated adenosine as a metabolic modulator 
of coronary blood flow. It was suggested that during periods of ischaemia adenosine 
was released and caused either a reduction in metabolic demand of the tissue and/or 
increased oxygen availability by lowering heart rate and inducing coronary 
vasodilatation, respectively. In addition the products of adenosine metabolism 
(inosine and hypoxanthine) were identified in the perfusate from isolated cat heart and 
from the coronary sinus outflow of the hypoxic canine heart following severe 
ischaemia. This was followed by a second major observation that adenosine caused an 
increase in cyclic adenosine 5’-monophosphate (cAMP) accumulation in guinea-pig 
cerebral cortical slices (Sattin & Rail, 1970). They also found that cAMP 
accumulation induced by adenosine was antagonised by the presence of the 
methylxanthine, theophylline. This was the first evidence that the action of
methylxanthines may be due to the antagonism of specific cell-surface receptors for 
adenosine as opposed to their proposed activity as phosphodiesterase inhibitors.
The actions of adenosine are not confined to the cardiovascular system, but have been 
implicated in the modulation of neurotransmitter release in the central nervous system. 
Adenosine has been shown to inhibit the release of several neurotransmitters including 
acetylcholine (ACh), aspartate, dopamine, y-aminobutyric acid (GABA), 5- 
hydroxytryptamine (5-HT), glutamate and noradrenaline (NA) (Fredholm & 
Heldqvist, 1980; Phillis & Wu, 1981; Stone, 1981; Williams, 1984; Fredholm, 1995 
a, b).
Pharmacologically adenosine has an anxiolytic effect (Williams, 1983), a sedative and 
anticonvulsant action (Dunwiddie & Worth, 1982) and due to its inhibitory effect on 
the release of the major excitatory amino acids aspartate and glutamate it may be of use 
in reduction of neuronal damage accompanying cerebrovascular stroke and 
neurodegenerative disorders such as Huntington’s chorea (Bowmer & Yates, 1989).
Adenosine has been implicated as a mediator in acute renal failure (Churchill & Bidani, 
1982) and adenosine receptor antagonists appear to offer some protection against the 
damaging effects of adenosine (Jacobson et ah, 1991). However, adenosine can have 
a beneficial action in the kidney as damage to the kidney often results in the generation 
of an inflammatory response. Inflammatory cells release a number of factors that can 
cause tissue damage, including cytokines and free radicals. Adenosine possesses 
immunosupressing properties and acts to reduce inflammatory responses and 
subsequent tissue damage (Samet, 1985; Cronstein et al., 1990). Hence there may be 
a balance between the physiological and pathological effects of adenosine in disease.
During the 1950s it was suggested that the vasodilatation caused by stimulation of 
sensory nerves supplying the rabbit ear artery was similar in both nature and time 
course to that observed following injection of adenosine 5’-triphosphate (ATP) 
(Holton & Holton, 1954). It was susequently found that antidromic stimulation of the 
auricular nerves resulted in vasodilatation of rabbit ear vessels accompanied by 
extracellular release of ATP (Holton, 1959). Despite these observations it was 
assumed that they could be explained within the classical framework of adrenergic and 
cholinergic neurotransmission and the idea that nucleotides and nucleosides, such as 
ATP and adenosine, could act as neurotransmitters was highly controversial and not 
widely accepted.
The physiological importance of ATP emerged from the recognition that the autonomic 
nervous system did not comprise entirely of adrenergic and cholinergic nerves, and 
that ATP had a role as a neurotransmitter. It was observed that intramural nerve 
stimulation of the guinea-pig taenia caeci produced a relaxation that was resistant to 
blockade by the cholinergic antagonist, atropine and the adrenergic neurone blocker, 
guanethidine (Bumstock et ah, 1963; 1964). This led to the investigation of other 
smooth muscle tissues, and a number of responses which were resistant to known 
adrenergic and cholinergic antagonists. Bumstock (1969) first called these nerves 
“non-adrenergic, non-cholinergic (NANC)” fibres. It was not until 1972 that 
Bumstock first used the term “purinergic” to describe these neurones when he 
observed that ATP produced either similar or identical responses, both in terms of type 
and time course , as those seen on stimulation of NANC nerves in gastrointestinal tract 
and urinary bladder preparations fronia number of species. It was proposed that the 
active substances released from at least some NANC nerves was the purine nucleotide 
ATP, and the term “purinergic” was tentatively used for these NANC nerves. In 
addition to ATP a number of other substances have also been shown to be putative
neurotransmitters at NANC nerves, including dopamine, 5-HT and substance P, nitric 
oxide (NO) and other peptides (Bumstock, 1981).
In addition to these findings, adenosine and ATP have been shown to influence a 
number of biological processes (for review see White, 1988). The mechanisms by 
which the extracellular actions of purine and pyrimidine nucleotides are mediated and 
the mechanisms by which their actions are terminated are reviewed in detail in the 
following sections of this thesis.
1.2. Release and Extracellular Metabolism of Nucleosides and 
Nucleotides
Adenine and uridine nucleosides and nucleotides are universally present within almost 
all prokaryotic and eukaryotic cells. However, the release and, therefore, the 
extracellular significance of these compounds is associated with a restricted number of 
mechanisms, including nerve-mediated release, release from endothelial cells, release 
in response to shear stress, hypoxia (i.e. cell damage) and from platelets.
The first reports of a physiologically significant release of adenine nucleotides 
resulting in the activation of cell surface receptors appeared several decades ago 
(Bumstock, 1972; 1978). The nucleotide triphosphate, ATP, is present within the 
cytoplasm of all cells where it has a multitude of physiological roles. It is synthesised 
by glycolysis of both simple and complex carbohydrates and by mitochondrial 
oxidative phosphorylation as well as by the purine salvage pathway. However, ATP 
is stored within secretory vesicles within nerves from which it is released as a 
neurotransmitter or co-transmitter by exocytosis when the vesicle contents are
secreted, and it is principally its action as an extracellular mediator and 
neurotransmitter and the mechanisms underlying the termination of these actions which 
we are concerned with in the following studies.
One of the most important inhibitory modulators of synaptic transmission in 
mammalian brain is adenosine. At some cholinergic terminals, adenosine is known to 
inhibit further release of ACh. However, it was not known whether adenosine was 
released directly at the synapse or whether ATP is co-released with ACh and 
hydrolysed to adenosine in the synaptic cleft (De Mey et al., 1979; Silinsky, 1980; 
Moody & Bumstock, 1982; Stone, 1983). Studies on immunoisolated cholinergic 
nerve terminals from the rat striatum, synaptic ectonucleotidases sequentially 
dephosphorylate ATP to adenosine, which inhibits further ACh release, but this 
inhibitory effect is not seen in cortical cholinergic terminals lacking the complete 
ectonucleotidase pathway (Richardson et al., 1987).
The release of ATP in the vascular system from perivascular nerves has been 
demonstrated (Zimmermann, 1994), causing the release of prostacyclin and nitric 
oxide (N0/endothelium-derived relaxant factor). Stimulation of vascular prostacyclin 
synthesis by mediators such as ATP, generated and released during a haemostatic 
response, constitutes a potentially useful feedback mechanism, limiting the number of 
platelets involved and localising any thrombus formation (Boeynaems & Galand, 
1983; Kelm gf a/., 1988).
The use of the fluorescent dye, quinacrine; has revealed the presence of ATP within 
nerves supplying a number of tissues such as the rabbit stomach and ileum (Crowe & 
Bumstock, 1981). Studies using radiolabelled pH]-adenosine has also shown that 
ATP is stored in other tissues in the gastrointestinal tract such as the guinea-pig taenia
caeci (Su eîMl., 1971).j In addition, the highly sensitive and specific luminescence 
method for thé detection of ATP, the luciferin-luciferase assay, which is able to detect 
the presence of ATP prior to any significant degree of degradation occuring in the 
presence of smooth muscle preparations, has demonstrated the presence of vesicular 
storage of ATP (Israel etal., 1976; White e ta l, 1981). Using this approach evidence 
has been gathered that ATP is co-stored with a number of neurotransmitters, including 
acetylcholine within cholinergic synaptic vesicles (Dowdall et al., 1974), with 
noradrenaline in sympathetic vesicles (Von Kiigelgen & Starke, 1991; Kennedy, 
1993), with both noradrenaline and adrenaline in adrenal chromaffin granules (Winkler 
et al, 1987) and with 5-HT and ADP in platelets (Da Prada et al, 1978).
Regulation of uridine and uracil nucleotide levels is important when considering the 
receptor-mediated effects of these compounds. Cells can synthesise uracil nucleotides 
de novo or by the salvage of uridine. UTP made from the salvage pathway might be 
preferentially used for RNA synthesis within the nucleus, whereas UTP synthesised 
de novo seems to be used for UDP-sugar and CDP-phospholipid production (see 
Anderson & Parkinson, 1997). UTP from both pathways may enter a free pool of 
UTP, from which UTP can be released from cells. UTP and UDP can activate P2 
receptors, but metabolism by ectonucleotidases limits their effects. Alternatively, UTP 
may be a substrate for ecto-protein kinases, and this could contribute to its extracellular 
regulation. Cells can reclaim uridine, via nucleoside transporters, following 
dephosphorylation of UTP, UDP and UMP.
UTP is present within cells at approximately one tenth of the levels of ATP, but at 
equal or greater levels of other nucleotide triphosphates (Lea et a l, 1988). The levels 
of UTP will determine the amounts of UTP available for release and subsequent 
activation of P2 receptors.
The de novo pathway of pyrimidine nucleotide synthesis is most active during periods 
of growth and development, after which its importance seems to decrease in direct 
comparison with the salvage pathway in the majority of tissues, with the notable 
exceptions of the liver and kidney (Traut & Jones, 1996).
Regulation of de novo UMP synthesis is achieved by both feedback and feed forward 
metabolic effectors. ATP is a positive effector of carbamoyl phosphate synthetase 
(CPSase; EC 2.7.2.9.) activity, and phosphoribosyl pyrophosphate, a common 
requirement for both purine and pyrimidine nucleotide synthesis, can activate both 
CPSase and orotate phosphoribosyl transferase (EC 2.4.2.10.) to increase synthesis 
of UMP. A decrease in UMP synthesis occurs when UTP, UDP or UMP-sugars feed 
back to inhibit CPSase activity or when UMP and/or AMP competitively inhibit orotate 
monophosphate decarboxylase (EC 4.1.1.23.) (Jones, 1980). The xanthine 
derivative, caffeine, has been shown to increase the activities of three of the enzymes 
involved in pyrimidine metabolism; dihydroorotase (EC 3.5.2.3.), dihydroorotate 
dehydrogenase (EC 1.3.3.1.) and aspartate carbamoyl transferase (EC 2.1.3.2.) 
(Minana et al., 1984). De novo synthesis of pyrimidine nucleotides does not normally 
lead to the accumulation of concentrations of any of the intermediates greater than IjxM 
(Jones, 1980). This is believed to be due to redirecting of products from different 
CPSases into arginine and/or UMP synthesis (Cheng et al., 1986). Therefore, 
metabolic regulation of the first enzyme in this pathway, CPSase, results in a net 
increase or decrease in UMP production.
Intracellular uracil nucleotides are incorporated into RNA, used to synthesise CTP or 
deoxy-thymidine triphosphate (dTTP), metabolised to UDP-sugars or CDP- 
phospholipids, or stored as nucleotides. There is evidence that UTP from de novo
synthesis is preferentially used for the synthesis of UDP-sugars and CDP- 
phospholipids, while UTP from the salvage pathway is used for RNA synthesis. 
Both pathways may contribute to a free UTP pool, a potential source of UTP for 
extracellular P2 receptor activation, which is why, despite the fact that they are 
intracellular mechanisms, they are reviewed here (Slingerland et al., 1995; Pels 
Rijcken et al., 1993).
Almost all cell types which have been studied are capable of salvaging uracil 
nucleotides from uridine: Uridine kinase (EC 2.7.1.48.), which catalyses the rate- 
limiting step of the salvage pathway, is regulated according to its oligomerisation. The 
active form of uridine kinase is a tetramer. Feedback inhibition by UTP or cytidine 
triphosphate (CTP) causes dissociation of the tetramer to its inactive subunits, while 
ATP can cause reassociation to the active form (Davis, 1972). The activity of uridine 
kinase has been shown to be increased by serum growth factors and insulin can 
activate uridine kinase in vivo (Wharton & Pledger, 1981; Haugaard et a l, 1990).
There has been a report of a salvage mechanism for pyrimidine nucleotides in 132INI 
astrocytoma cells which can synthesise UTP from extracellular UDP, while utilising 
ATP by a nucleoside diphosphate kinase (Harden et al., 1997). This is an example of 
the interconnection of the ATP and UTP salvage pathways, which in some way 
demonstrates the intimate link between extracellular purine and pyrimidine metabolism 
and transport.
Uridine and uracil nucleotides are important for numerous intracellular metabolic 
processes. Both UTP and UDP are stored in granules in chromaffin cells and platelets 
at approximately 10% of the levels of ATP. ATP is known to enter granules by a non­
specific carrier-mediated process that also transports both UTP and GTP with similar 
affinities (Bankston & Guidotti, 1996).
Release of nucleotides from cells may occur by a number of processes other than by 
^exoC}^sis. For example, haemodynamic shear stress from blood cells (Hassessian et 
al, 1996), mechanical stimulation (Lazarowski et al., 1995) and metabotropic receptor 
activation (Katsuragi et al., 1996) have all been shown to cause release of ATP from 
cells. Since the release of ATP is readily quantifiable by the luciferin-luciferase assay 
while the presence of other nucleotides is more difficult to ascertain, few studies have 
examined whether or not other nucleotides are released. However, mechanical 
stimulation of cultured mammary epithelial cells induced the release of ATP, UTP and 
UDP in sufficient quantities to result in P2 receptor activation (Enomoto et al., 1994).
The molecular mechanism underlying nucleotide release remains unknown, however 
transporters with ATP-binding motifs have been identified. The presence of multidrug 
resistance protein (P-glycoprotein; MDRl) and cystic fibrosis transmembrane 
conductance regulator has been shown to correlate with ATP release from cells 
(Abraham et al., 1993; Reisin et al., 1994).
Clark et al. (1990) described the release of uric acid and uracil from the perfused rat 
hindlimb, along with lower levels of uridine, hypoxanthine, xanthine, inosine and 
guanosine. Uric acid and uracil increased between 2- and 5-fold in the presence of 
noradrenaline, vasopressin or angiotensin II, coinciding with an increase in both 
perfusion pressure and oxygen uptake. Further, sciatic nerve stimulation caused 
skeletal muscle contraction but did not have any effect on the levels of release of uric 
acid or uridine. It did, however, result in increased release of inosine (7-fold) and 
hypoxanthine (2-fold). The authors concluded that since the UTP content and the
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UTP/ATP ratios are higher in smooth muscle than in skeletal muscle, the release of 
uric acid and uracil arises from an increase in the metabolism of the respective adenine 
and uridine nucleotides during periodsjconstriction of smooth muscle.
The overall negative charge carried by adenine and uridine nucleotides is believed to 
prevent their entry into most cells (Dubyak, 1991), although there are reports that 
adenine nucleotides are able to cross cell plasma membranes in rat soleus muscle and 
hemidiaphragm preparations (Chaudry & Baue, 1980). It is thought unlikely, 
therefore that released nucleotides are able to be metabolised intracellularly. The 
extracellular location of these ectonucleotidases has been confirmed by the use of 
diazotised sulphanilic acid which binds to and inactivates the exposed protein (De 
Pierre & Karnovsky, 1974).
The sequential dephosphorylation of ATP occurs via a series of enzyme-catalysed 
reactions (Pearson, 1985). These enzymes have been identified and classified in a 
number of cells and tissues. ATP is dephosphorylated to ADP by ecto-ATPases, ADP 
to AMP by ecto-ADPase and AMP to adenosine by ecto 5'-nucleotidase. In addition 
there is a further enzyme which exhibits equal affinity for both ATP and ADP and 
results in the dephosphorylation of both substrates to AMP, namely ecto-ATP 
diphosphohydrolase (sometimes referred to as ecto-apyrase and/or ecto-ATPDase). It 
has been shown that this enzyme is of importance in preparations such as the mouse 
liver and canine kidney (Knowles et al., 1983). The enzymes involved in the 
synthesis and degradation of adenine and uridine nucleotides are discussed in detail 
below with especial reference to their significance to extracellular PI and P2 receptor 
activation.
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1.2.1. Ectonucleotidases
The receptor-mediated effects of adenine and uridine nucleotides are attenuated by their 
sequential hydrolysis catalysed by ectonucleotidases, plasma membrane-bound 
enzymes which have the active site orientated to the extracellular surface. Unpurified 
ATPase activity has been described in a number of blood cells, including neutrophils, 
eosinophils, monocytes and macrophages (Plesner, 1995).
Four significant enzymatic reactions are collectively termed nucleotidase reactions 
(where N represents a nucleotide): NTP->NDP, NDP->NMP, NMP->N and NTP- 
>NMP. The enzymes which are responsible for catalysing each of these reactions are 
reviewed separately in the following sections (1 .2 .1 . 1  through I . 2 .I . 6 .).
The activity of ectonucleotidases is highly dependent on the presence of the divalent 
cations Ca^ "^  and/or Mg^ "^ , and different forms of ectonucleotidases exhibit different 
sensitivities towards these cations. Other cations are able to activate ectonucleotidases 
with a much lower potency (Pearson, 1985; Ziganshin et al., 1994; 1995). The 
normally negatively charged nucleotides are known to form complexes with divalent 
cations in physiological salt solutions. For example, approximately 70% of ATP 
complexes with Mg^ '^ , 2 0 % with Ca^ '^  and the remaining 1 0 % is complexed to a 
number of other cations, including H^, and Na"^  along with a small percentage 
existing as a fully unionised form (ATP"^ ‘) (Fine et al., 1989; Lustig et al., 1992).
There are a number of additional enzyme activities which are well documented, but 
which are not believed to be involved in the degradation of extracellular nucleotides in 
most tissues, including ATP-pyrophosphatase and other non-specific phosphatases 
(Pearson, 1985; Ziganshin e ta l, 1994) and ecto-protein kinases which utilise ATP as
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a substrate for the phosphorylation of specific membrane proteins (Ehrlich et al., 
1986).
Ectonucleotidases are widespread and have been shown to be present on most cells, 
including arterial endothelial cells, smooth muscle cells of blood vessels and the 
gastrointestinal tract, synaptosomes, cardiac myocytes, hepatocytes and a number of 
blood cells (Pearson, 1985; Meghji, 1993; Ziganshin et al., 1994). In pig aortic 
endothelial cells distinct ecto-ADPase and ecto-ATPase activities have been 
demonstrated by their abilities to selectively dephosphorylate the non-terminally 
substituted phosphorothioate analogues of ATP (adenosine-5'-0-(2-thiotriphosphate); 
ATP-p-S) and ADP (adenosine-5'-0-( 1 -thiodiphosphate); ADP-a-S), respectively. In 
addition, ATP-a-S and ADP-a-S exist as Rp and Sp diastereoisomers and ecto- 
ATPases and ecto-ADPases show stereospecificity between the two forms. In 
contrast, the terminally substituted phosphorothioate analogues of ATP (adenosine-5'- 
0-(3-thiotriphosphate); ATP-y-S) and ADP (adenosine 5'-0-(2-thiodiphosphate); 
ADP-P-S) are resistant to degradation. Similarly, while AMP is degraded by ecto- 
5'nucleotidase, resistance to degradation is seen for the terminally substituted 
analogue, adenosine 5'-0-monophosphorothioate (AMPS). Stereoselectivity of ecto- 
ATPases, ecto-ADPases and ecto-5'nucleotidase is shown for the naturally occurring 
D-enantiomers of ATP, ADP and AMP, respectively, although to different extents. L- 
ATP and L-ADP are dephosphorylated at one fifth and one fifteenth the rates of their 
respective D-enantiomers, whereas L-AMP is not dephosphorylated to any quantifiable 
degree (Cusack et al., 1983; Pearson & Cusack, 1985; Pearson, 1986).
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Figure 1 .1 . Schematic Diagram of Adenosine Metabolism
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1.2.1.1. Ecto-ATPases (EC 3.6.1.15.)
Ecto-ATPase, or E-type ATPase catabolises nucleotide triphosphates with broad 
specificity for adenine and uridine nucleotides, and for this reason is distinct from the 
intracellular ion-pump ATPases and the mitochondrial ATPases which selectively 
dephosphorylate ATP as their substrate. In addition the classical inhibitors of 
intracellular ATPases, vanadium ions, ouabain or oligomycin have no effect on the 
activity of extracellular ATPases.
The ecto-ATPase protein has proved difficult to purify and characterise, partly due to 
due to the low abundance of the protein on the cell surface and partly due to its 
susceptibility to inactivation by many detergents commonly used in enzyme 
purification studies (Plesner, 1995). In spite of these difficulties. E-type ATPases 
have been purified from numerous tissues including rat liver (Lin, 1985; Lin, 1990), 
rabbit skeletal muscle (Treuheit et al., 1992) and chicken gizzard (Stout et at., 1995).
A Ca "^ -^ATPase has been purified from rat liver plasma membrane (Lin & Fain, 1984). 
This was found not to be the Ca^^-pump which was described later by Lin (1985), but 
a plasma membrane ecto-ATPase (Lin & Russell, 1988). The rat liver plasma 
membrane ecto-ATPase is a glycoprotein and from the amino acid sequence was found 
to contain 519 residues with a calculated molecular mass of approximately 57kDa (Lin 
& Guidotti, 1989).
However, studies on these enzymes have revealed that rather than ecto-ATPase activity 
being due to a single enzyme, it is much more probable that a family of related proteins 
exist. Whereas the rat liver ecto-ATPase was reported to be a 120kDa protein, the 
rabbit skeletal muscle and chicken gizzard enzymes were monomers of 6 6 kDa.
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Believed to be similar to the rabbit skeletal muscle and chicken gizzard enzyme was the 
ecto-ATPase activity on activated NK cells, which was found to be due to a 68-80kDa 
protein in photoaffinity labelling experiments (Dombrowski et al, 1993).
Dombrowski et al. (1997) demonstrated that ecto-ATPase is a marker of B cell 
activation expressed by immortalised human and murine B cells. Characterisation of 
the kinetic parameters of the B cell ecto-ATPases and immunological crossreactivity of 
antibodies generated against the chicken gizzard ecto-ATPase demonstrated that there 
was significant interspecies conservation of the enzymic and immunological molecular 
characteristics in this class of enzymes (Stout et al., 1995).
Ecto-ATPase activity has also been demonstrated on visceral smooth muscle cells. 
The structure-activity relationships for these enzymes have previously been determined 
in the guinea-pig taenia caeci and urinary bladder (Welford et al., 1986; 1987). In 
both the taenia and urinary bladder ATP, ADP and AMP are degraded to adenosine. 
Purine ring-substituted analogues, such as 2-methylthioadenosine triphosphate (2- 
MeSATP) had a similar rate of dephosphorylation to ATP. Stereoselectivity was 
observed for the D- over the L-enantiomer, in a manner similar to that of pig aortic 
endothelial cells (Pearson et al., 1980; 1985). In addititon, the purine nucleoside 
triphosphates ATP and guanosine 5'-triphosphate (GTP), and the pyrimidine 
nucleoside triphosphates uridine 5'-triphosphate (UTP) and cytidine 5'-triphosphate 
(CTP) were all degraded at a similar rate to their corresponding nucleosides, namely 
adenosine, guanidine, uridine and cytidine, respectively. Non-terminally subsitituted 
phosphorothioate analogues, such as ATP-p-S and ADP-a-S also showed 
stereoselectivity between the two diastereoisomeric forms,whereas terminally 
substituted analogues, namely ATP-y-S and ADP-p-S, were resistant to degradation 
(Welford etal., 1986; 1987).
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In addition, the methylene-substituted derivatives of ATP and ADP, AMPCPP, 
AMPPCP and adenosine 5'-(a,P-methylene)diphosphonate (AMPCP), were found to 
be completely resistant to degradation from the point at which the methylene group 
replaces the oxygen in the phosphate chain (Welford et al., 1986; 1987). However, 
the guinea-pig taenia caeci was unable to dephosphorylate adenosine 5'-0-(l- 
thiotriphosphate (ATP-a-S) (Welford et al., 1986) whereas the guinea-pig urinary 
bladder could degrade this analogue (Welford etal., 1987), although at a much slower 
rate than that for ATP.
Smooth muscle cells and endothelial cells have been shown to dephosphorylate ATP 
via ecto-ATPase with similar activity, although in smooth muscle cells the production 
of adenosine occurs rapidly, whereas in endothelial cells adenosine is produced much 
more slowly. In endothelial cells the production of adenosine requires the 
dephosphorylation of ADP to AMP prior to the formation of adenosine, indicating the 
presence of both an ecto-diphosphohydrolase and ecto 5’-nucleotidase of higher 
activity and/or greater expression on smooth muscle cells (Gordon etal., 1986; 1989). 
However, there is a suggestion that another reason for this difference may be that there 
is differential delivery of intermediates between ectonucleotidases at the surface of 
smooth muscle and endothelial cells {Gordon et al., 1989; Slakey et al., 1990; Meghji 
etal., 1995).
Meghji & Bumstock (1995) demonstrated that the ATPase activity on the human 
umbilical vein endothelial cell (HUVEC; ECV304) was an ectonucleotidase which was 
insensitive to oligomycin, vanadate, ouabain and N-ethylmaleide, compounds which 
are known to inhibit the intracellular ion-pumping ATPases. In the same study it was 
shown that the inhibitors of non-specific phosphatases, (3-glycerophosphate and p- 
nitrophenyl phosphate had no effect on ATP degradation. ATP degradation by
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ECV304 was found to be Ca^ ''"- and Mg^^-dependent and inhibited by suramin. 
Gramicidin S, chlorpromazine, trifluoperazine and thioridazine by 45-80%. Further, 
when the activity of ecto 5’-nucleotidase was inhibited by a,(3-methyleneADP by 
90%, the percentage inhibition produced by these substances remained unaltered. The 
authors concluded that the compounds were inhibiting either ecto-ATPase and/or ecto- 
ADPase (Meghji & Bumstock, 1995).
Ecto-ATPase activity in primary cultures of guinea-pig vas deferens smooth muscle 
cells has been demonstrated by measurement of the production of inorganic phosphate 
(Pj) from ATP. The ecto-ATPase activity was found to be insensitive to a number of 
inhibitors, including ouabain, oligomycin, sodium azide, p-nitrophenol and (3- 
glycerophosphate. The enzyme activity was found to be Ca^ -^ and Mg^  ^ -dependent. 
The same study revealed that antagonists of P2X receptors suramin, pyridoxal- 
phosphate-6-azophenyl-2,4’-disulphonic acid (PPADS), 4,4’-diisothiocyanostilbene- 
2,2’-disulphonic acid (DIDS) and pyridoxal-5-phosphate significantly inhibited ecto- 
ATPase activity, whereas the PI receptor antagonists DPCPX and 8 -SPT had no 
effects on the activity of the enzyme (Ziganshin et al, 1995).
Rat brain synaptosomes have been shown to sequentially dephosphorylate extracellular 
ATP to ADP, AMP and adenosine (James & Richardson, 1993). The ecto-ATPase 
activity of synaptosomes was found to decay exponentially with time and to be highly 
dependent on the presence of Mg^ "^  cations. AMPPCP, a non-hydrolysable analogue 
of ATP, did not produce inactivation of the ecto-ATPase activity. Interestingly, 
feedback inhibition of ecto-ATPase activity by products of ATP degradation was 
discounted, as ADP, AMP and adenosine up to a concentration of ImM had no effect 
on the inactivation of ecto-ATPase. The lectin, concanavalin A partially reversed the 
ATP-dependent inactivation of ecto-ATPase, while alkaline phosphatase completely
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reversed the ecto-ATPase inactivation indicating that the ATP-induced inactivation is 
partially mediated by the phosphorylation of membrane proteins (Martin-Romero et 
al., 1996).
Xenopus laevis folliculated oocytes have been widely used in the expression cloning 
of a number of foreign membrane receptors and ion channels (Snutch, 1988; Segel,
1990). In addition, Xenopus oocytes possess native receptors for ATP on their 
enveloping follicle cell layer (Lotan et al., 1986). Ziganshin et al. (1994a) 
demonstrated the presence of an oocyte ecto-ATPase which limits the potency of 
agonists at the native receptor and set about characterising the properties of the enzyme 
activity. They described an ecto-enzyme with a broad substrate specificity for ATP, 
ADP and AMP, which was highly dependent on extracellular Ca^  ^and Mg^ .^ Further, 
the ecto-ATPase activity of the oocyte was inhibited by the P2 receptor antagonists 
suramin, (PIT) and (TNP-ATP) (Ziganshin et al., 1994b; Ziganshin et al., 1995). The 
inhibitory action on extracellular ATP degradation of some P2 receptor antagonists, 
such as suramin, DIDS and Reactive blue 2 (sometimes named Cibacron blue), had 
already been demonstrated on smooth muscle cells, endothelial cells and hepatocytes 
(Knowles, 1988; Hourani & Chown, 1989; Yagi et al., 1994).
However, in Xenopus oocytes the degradation of ATP and ADP was decreased 
significantly by several P2 receptor antagonists, including suramin, PPADS, reactive 
blue 2, coomassie brilliant blue, Evans blue, trypan blue, Congo red and PIT. Each 
was found to inhibit ATP degradation by up to 60%, whereas the hydrolysis of ADP 
was inhibited by Congo red and PIT by 75-80%. In addition, DIDS and TNP-ATP 
selectively inhibited the degradation of ATP, and sodium azide selectively inhibited the 
breakdown of ADP. The PI receptor antagonist 8 -SPT had no effect on the rate of
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degradation of either ATP or ADP. The degradation of AMP was abolished by PIT 
and significantly inhibited by Congo red (Ziganshin et al, 1996).
A recently identified selective inhibitor of ecto-ATPase, FPL67156 (6 -N,N-diethyl-D- 
P,y-dibromo-methyleneATP) is a structural analogue of ATP (Beukers e ta l, 1994). 
Studies have shown that in some tissues FPL67156 resulted in a leftward shift of the 
concentration effect (B/[A]) curves to the hydrolysable agonists ATP and UTP (Crack 
et a l, 1995). In the rabbit ear artery the potency order for agonists at P2X receptors 
was found to be AMPCPP »  ATPyS > 2MeSATP > ATP > UTP, whereas in the 
presence of FPL67156 the potency order for these same agonists was altered to: 
AMPCPP > 2MeS ATP = ATP > ATPyS > UTP. In the same study it was found that 
the potency order for agonists at P2Y receptors on guinea-pig aortic rings was: 
2MeSATP »  ATPyS > ATP »  AMPCPP = UTP. However, in the case of P2Y 
receptors the potency order of agonists were unchanged in the presence of FPL67156 
(McKechnie et a l, 1995). In both the rabbit ear artery and the guinea-pig aorta 
leftward shifts in the agonist concentration-effect curves together with the alterations in 
the agonist potency orders at P2X receptors may indicate that there are different levels 
of ecto-ATPase activity in the two tissues.
The P2 receptor agonists ATP-y-S, a ,(3-MeATP and AMPPNP have been reported to 
inhibit the ecto-ATPase activity of bovine artery endothelial cells. The pIC^  ^values for 
these ligands were found to be, 5.2, 4.5 and 4.0, respectively (Chen & Lin, 1997). In 
addition, the selective ecto-ATPase inhibitor FPL67156 inhibited ecto-ATPase activity 
in these cells with a pIC^ Q value of 4.0. Each of the above agonists also exhibited high 
agonist potency for causing increased phosphoinositide (PI) turnover in these cells and 
the authors concluded from this that their action as ecto-ATPase inhibitors accounted 
for their high agonist potency.
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Ecto-ATPase activity has been demonstrated on polymorphonuclear cells (DePierre & 
Karnovsky, 1974a, b), macrophages (Steinberg etal., 1990), mast cells and NK cells 
(Bajpai & Brahmi, 1993). However, no ecto-ATPase activity has so far been shown 
in resting or non-activated peripheral blood B- or T-lymphocytes or resting NK cells 
(Dombrowski et al., 1993; Dombrowski et al., 1995). However, activated CD8 + 
CTL, tonsilar B cells and cytokine-stimulated NK cells are known to express 
significant ecto-ATPase levels (Barankiewicz et al., 1989a; Barankiewicz et al., 
1989b; Fillipini etal., 1990). Therefore, expression of ecto-ATPase activity correlates 
well with the activation of lymphocytes.
The actions of most neurotransmitters are limited by their removal from the 
extracellular compartment via one of two processes. For amines and amino acids, 
such as glutamate, 5-HT and noradrenaline, specific, high-affinity transporters mediate 
their reuptake back into the nerves or their surrounding support cells (Amara & Kuhar, 
1993). ACh and ATP are degraded by extracellular enzymes, ACh by 
acetylcholinesterase within the synaptic cleft from where choline is taken back up into 
the nerve where ACh can then be resynthesised. As has already been described, 
extracellular membrane-bound nucleotidase enzymes sequentially dephosphorylate 
ATP to ADP, AMP and adenosine, and it has generally been assumed that these 
enzymes are primarily responsible for the termination of the action of ATP in the brain 
(Edwards etal., 1992) and the periphery (Bumstock, 1990; Westfall et al., 1996). 
However, it has also been reported that in some tissues, most notably the guinea-pig 
vas deferens, innervated by NANC nerves that when these nerves are stimulated, they 
release not only neuronal ATP but also soluble nucleotidases which are capable of 
degrading ATP to adenosine (Todorov et al., 1997). This release of specific ecto­
nucleotidases represents an as yet novel mechanism for the termination of
2 1
neurotransmitter action. On superfusion of the guinea-pig vas deferens with 
exogenous ATP almost no detectable degradation occurred. However, on stimulation 
of the sympathetic nerves the exogenous ATP was almost all degraded. Further, when 
neurotransmission was inhibited by the addition of Cd^ "" or omission of Ca^ + no 
appreciable breakdown was observed. Electrical stimulation in the absence of any 
tissue did not result in breakdown of ATP. In addition, superfusate collected during 
nerve stimulation was able to degrade ATP when added latterly. This effect was lost 
on addition of tetrodotoxin, guanethidine or omission of Ca^  ^ from the perfusate 
during nerve stimulation. Further evidence that nerve stimulation was the mechanism 
by which ectonucleotidases were being released from the nerves was that exogenously 
added ATP, AMPCPP, noradrenaline, methoxamine and phenylephrine all caused the 
guinea-pig vas deferens to contract but failed to produce release of soluble 
ectonucleotidases into the bathing medium. Finally, soluble ectonucleotidase activity 
was not inhibited by known inhibitors of intracellular ATPases, such as vanadium, 
oligomycin or sodium azide, whereas ARE 67156 (lOOuM) reduced the soluble 
ATPase activity by approximately 50% (Todorov et al, 1997).
Soluble ectonucleotidases are believed to be stored within vesicles in the nerve 
endings, since their release is Ca^ + dependent. However, it is assumed that ATP and 
nucleotidase enzymes are not co-stored since this would be likely to result in vesicular 
breakdown of ATP. There has been a suggestion, however, that the ATP and 
nucleotidases are co-stored, but that the enzymes are in an inactive state due to the 
acidic pH environment within the vesicles (Schuldiner et a l, 1995). Only on release 
into the less acidic extracellular compartment would the soluble ectonucleotidases be 
activated. Alternatively, ATP and nucleotidases may be stored within different 
vesicles, since it is known that a heterogeneous population of synaptic vesicles exist in 
sympathetic nerves (Todorov et al, 1996). Electrical stimulation of the guinea-pig vas
2 2
deferens (Todorov et al., 1997), guinea-pig urinary bladder, rat vas deferens, mouse 
vas deferens and rabbit vas deferens (Westfall etal., 2000a; b), but not the guinea-pig 
taenia coli (Westfall et al., 2000a) results in the release of ATP and NA as 
cotransmitters and also ectonucleotidase enzymes which degrade ATP to adenosine, [ 
with the greatest enzyme activity observed on stimulation of the guinea-pig vas 
deferens. It is not clear whether these differences in activity reflect differences in the 
density of innervation of these tissues or if other factors may be involved. The 
molecular identity of this ecto-ATPase activity is yet to be elucidated, although it has 
similar characteristics to ectonucleoside triphosphate diphosphohydrolases (Westfall et 
al., 2 0 0 0 a).
In addition, there are a number of reports of soluble ectonucleotidases being released 
from secretory cells in the reproductive tract. In several species, including humans, an 
ecto-ATPase is secreted into the lumen of the oviduct and prostate gland in the form of 
enzymatically active lipid/protein microvesicles and is thought to play a role in 
fertilisation of the ovum (Rhea et al., 1974; Ronquist & Brody, 1985; Strobel et al., 
1996).
In rat portal vein it has been demonstrated that responses to ATP and other P2 receptor 
agonists, such as 2-MeSATP and 2-ClATP, but not those to AMPCPP, were inhibited j 
by the Aja receptor antagonist ZM241385, indicating that in this tissue ATP and 
certain other hydrolysable P2 agonists exert relaxant effects due to ectonucleotidase 
activity leading to the formation of ADP, AMP and adenosine which activates A2 A 
receptors (Guibert etal., 1998).
Bovine pulmonary artery epithelial cells possess a heterogeneous population of P2Y 
receptors, rat C6  glioma cells have P2 Y2  receptors and mouse RAW 264.7 cells have
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P2 Y4  receptors (Chen et al., 1996; Lin & Chuang, 1994; Lin & Lee, 1996) and all 
these receptors have been shown to be coupled to phosphoinositide-specific 
phospholipase C (PLC). In bovine pulmonary artery endothelial cells, rat C6  glioma 
cells and mouse RAW 264.7 cells, suramin, reactive blue 2 and PPADS inhibited ecto- 
ATPase activity with IC5 0  values of 4, 4.4 and »  4jiM for suramin; 4, 4.8 and 
4.7|iM for PPADS; and 4.5, 4.7 and 4.7jlM for reactive blue 2 (Chen et al., 1996). 
The trypanocidal drug, suramin has been shown to be an inhibitor of a wide variety of 
enzymes (Voogd et al., 1993), including ecto-ATPases on the guinea-pig urinary 
bladder (Hourani & Chown, 1989).
Lin & Rand (1988) described the presence of at least two Ca^^-Mg^^-ATPases on rat 
liver membranes. The first was characterised as a plasma membrane Ca^^-pump (Lin, 
1985a). However, the second was purified (Lin & Fain, 1984) and characterised 
(Lin, 1985b) but initially, at least, the function remained unidentified. The external 
localisation of the active site of the ATPase was confirmed since intact cells and cell 
homogenates had the same Ca^ -^ and Mg^^-ATPase activities. Both the Ca^ -^ and 
Mg^^-ATPase and the ecto-ATPase have broad nucleotide-hydrolysing activity since 
both hydrolysed ATP, UTP, CTP, GTP, ADP and GDP to similar extents. The effect 
of Ca^  ^and Mg^ '^  on the ecto-ATPase activity is not additive indicating that both Ca^ -^ 
and Mg^" -^ATPase activities are part of the same enzyme (Lin & Russel, 1988).
The ecto-ATPase and Ca^^-Mg^^-ATPase are insensitive to the intracellular ATPase 
inhibitors oligomycin and vanadate, again indicative of an extracellular location for the 
active site of the enzymes. Further, treatment with proteases had no significant effects 
on either the ecto-ATPase or the purified Ca^^-Mg^^-ATPase. The authors suggest that 
the previously purified Ca^^-Mg^^-ATPase is an ecto-ATPase and that its main function
24
is to regulate the effects of ATP and ADP on hepatocyte Ca^ "^  mobilisation (Charest et 
a l, 1985).
Immunochemical studies later revealed the presence of two isoforms of the rat liver 
ecto-ATPase and that they exhibit an immunological and structural identity with a 
glycoprotein cell-adhesion molecule (CAM). One of the CAMs responsible for rat 
hepatocyte aggregation (Ocklind & Obrink, 1982) has been characterised as a 
glycoprotein with an M^  of 105,000 and designated cell-CAM105 and has very similar 
biochemical properties and localisation as that of the rat liver ecto-ATPase previously 
described (Lin, 1989).
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1.2.1.2. Ecto-ADPases (EC 3.6.1.6.)
Platelet activation, as a consequence of vascular injury, is counteracted by an 
antithrombotic endothelial cell response which results in the limitation or even reversal 
of potentially occlusive thrombus formation (Marcus, 1996; Marcus etal., 1995). It is 
known that platelets become unresponsive to agonists when they come into intimate 
contact with endothelial cells (Broekman et al., 1991; Marcus et al., 1991). The 
inhibition of platelet responsiveness is due to at least three distinct thromboregulatory 
systems: the eicosanoids, such as prostaglandin (PGI^ or prostacyclin),
endothelium-derived relaxant factor (nitric oxide, NO) and to ectonucleotidase activity 
on endothelial cells which metabolises the released platelet agonist ADP (Marcus et al.,
1991). This removal of ADP eliminates platelet recruitment and results in the return of 
platelets to their resting state. Therefore, endothelial cell ecto-ADPase is a critical 
component of thromboregulation. Initially the ecto-ADPase activity on human 
umbilical vein endothelial cell line (HUVEC) was classified as a membrane-bound 
ectonucleotidase of the E-type (Plesner, 1995). The enzyme displayed Ca^  ^ and Mg^ "^  
dependence, was not inhibited by classical intracellular F-, P- and V-type ATPase 
inhibitors and the capacity to dephosphorylate ATP and ADP but not AMP. These 
characteristics were subsequently used to reclassify the HUVEC enzyme as an ecto- 
ATPDase (ectodiphosphohydrolase, ecto-apyrase) (Marcus et al., 1993; Plesner, 
1995).
The ecto-ADPases present on vascular endothelial cells has been shown to be inhibited 
by nucleotides such as AMPPCP and ATP-y-S (Pearson et al., 1986). It was noted, 
however that these compounds were also P2 receptor agonists and this action would 
complicate their use as ectonucleotidase inhibitors.
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1.2.1.3. EctoATP-Diphosphohydrolases (EC 3.6.1.5.)
Extracellular ATP diphosphohydrolase (ATPDase) has been variously described as 
ecto-diphosphohydrolase, ectoapyrase, ecto-ATPase, ecto-ADPase, nucleotide 
phosphohydrolase or ATP pyrophosphohydrolase (Plesner, 1995), and is a plasma 
membrane-bound enzyme which hydrolyses extracellular ATP and ADP to AMP. 
ATPDases are generally of low abundance and this, coupled with their susceptibility to 
detergents and their tendency to co-isolate with other proteins, has meant that they are 
difficult to purify and, therefore, characterise (Plesner, 1995). For this reason ecto- 
ATPDases have predominantly been studied in the vascular endothelium and smooth 
muscle, cardiac myocytes, lymphocytes and platelets. Membrane-bound ecto- 
diphosphohydrolases are capable of hydrolysing extracellular di- and tri-phosphates 
with equal affinities. There are two isoforms so far identified, type I a 54kDa protein 
and the type II 78kDa protein found in pig kidney cortex. N-terminal amino acid 
sequencing of the type II 78kDa protein has demonstrated its homology to the CD39 
(cluster of differentiation) surface antigen (Lemmens et al., 1998). Further, 
expression of CD39 parallels the ecto-ATPDase activity present on activated immune 
cells, such as cytotoxic T cells and natural killer (NK) cells, but is absent from 
lymphomas, resting thymocytes and T lymphocytes. (Wang & Guidotti, 1996).
Studies using monoclonal antibodies against human lymphocyte CD39 has failed, 
however, to identify this surface antigen in numerous myeloid leukocytes, including 
KG-1, U-937, HL-60 and THP-I cell lines (Kansas et al., 1991; Ikewaki et al.,
1992). In contrast, CD39 protein has been observed in tissue macrophages and 
dendritic cells (Kansas etal., 1991). This may indicate that the levels of CD39 protein 
in less differentiated myeloid cell types may be lower than that detectable by currently 
available anti-CD39 antibodies. This may underlie the previously reported absence of
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CD39 expression on human neutrophils and monocytes. Further, the evidence from 
the variable antigenicity of CD39 from these studies (Kansas et a l, 1991; Ikewaki et 
al, 1992) and differences in the biochemistry of the ecto-ATPDases from various 
tissues indicates that there is likely to be a family of related CD39/ecto-ATPDases 
rather than a single enzyme (Cote et a/., 1992; Dombrowski et a l, 1993; Sevigny et 
fl/., 1995; Pichererûf/., 1996).
KG-1 myeloblasts and later myeloid progenitors, including HL-60 promyelocytes and 
THP-1 monocytes, display different levels of activity and expression of ecto- 
ATPDases. Extracellular ATP was found to be rapidly dephosphorylated by HL-60 
cells but not by KG-1 cells (Clifford et al., 1997). Further, mRNA for CD39, a 
protein with ecto-diphosphohydrolase activity was present on HL-60 but not KG-1 
cells. The authors also noted that ecto-diphosphohydrolase activity increased with 
increasing differentiation of myeloid progenitors induced by PMA or dibutyryl cAMP 
(DBcAMP), and that differentiation of HL-60 cells with PMA but not DBcAMP also 
resulted in an increased ecto 5'-nucleotidase activity and CD73 mRNA expression 
(Clifford gr aZ., 1997). This would indicate that developmental changes in myeloid 
leukocytes result in changes in expression of both P2Y receptor subtypes and multiple 
ectonucleotidase enzymes which in turn regulate signal transduction by ATP.
The increase in ecto-ATPDase activity with progressive differentiation of myeloid 
progenitors is the same trend as had been previously reported to be exhibited by 
lymphoid leukocytes. Late pre-B and mature B lymphocytes possess high ecto- 
ATPDase activity compared with early pre-B lymphocytes (Borankiewicz et al., 1988; 
Wang & Guidotti, 1996).
35
Vigne et al. (1998) demonstrated that ecto-ATPDase can prevent P2Y, receptor 
activation in brain capillary endothelial cells of the BIO clone by dephosphorylating 
ADP, but that they may also contribute to P2Y, receptor activation by generation of 
ADP from ATP.
The biochemical characterisation of purified ATPDase has revealed a highly 
glycosylated protein of molecular mass in the range 70-100kDa (Plesner, 1995). The 
ATPDases from human placenta, porcine pancreas, bovine aorta and chicken gizzard 
have been cloned and sequenced (Christophoridis et al., 1995; Sevigny et al., 1995; 
Sevigny et al., 1996; Stout & Kirley, 1994). The analysis of the amino acid 
sequences of these ecto-ATPDases has revealed a close homology with human CD39 
(cluster of differentiation), an acidic glycoprotein with a molecular mass of 70-100kDa 
with two potential transmembrane regions and six potential glycosylation sites 
(Kaczmarek et al., 1996). CD39 was originally described as a marker for B-cell 
activation and was subsequently identified on the surface of other activated 
lymphocytes and vascular endothelial cells (Maliszewski, et al., 1994). In addition, 
CD39 has been shown to act via the enhancement of cell-cell interactions. Monoclonal 
antibodies to a number of epitopes of CD39 induce homotypic adhesion, through the 
involvement of other adhesion molecules, including GDI la and CD 18 (Kansas et al.,
1991). Kaczmarek et al. (1996) isolated CD39 cDNA from human endothelial cells 
and subsequently expressed this in COS-7 cells. Using this method CD39 was found 
to have immunological identity to, and functional characteristics of vascular ATPDase, 
that is the degradation of ATP and ADP to AMP. The same study also demonstrated 
the presence of ATPDase mRNA in tissues such as human placenta, lung, kidney, 
skeletal muscle kidney and heart. Interestingly none was detected in brain tissue. 
Several bands of mRNA were detected using the CD39 cDNA probe and the authors 
concluded that this represented different splicing products.
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Recently a soluble ATPDase has been purified from potato tubers and its cDNA cloned 
(Handa & Guidotti, 1996). Sequence analysis has revealed 25% amino acid identity 
and 48% amino acid homology with human CD39 (Handa & Guidotti, 1996) a 
lymphoid cell activation antigen (Maliszewski et al., 1994) that is expressed on 
activated NK cells, B cells and certain subtypes of T cells, in addition to some 
HUVEC cell lines (Kansas etal., 1991). Studies have shown that the endothelial cell 
ecto-ATPDase and CD39 are identical and that anti-CD39 antibodies 
immunoprecipitated more than 95% of ecto-ATPDase activity on HUVEC membranes 
(Marcus gr al., 1997). The diadenosine polyphosphate, diadenosine pentaphosphate, 
5',5"-Pi,Pg-pentaphosphate (Ap^A), has activity both as a P2 receptor agonist and as 
an inhibitor of CD39/ecto-diphosphohydrolase in bovine aortic endothelial and smooth 
muscle cells (Yagi et al., 1991).
1.2.1.4. Ecto 5 '-Nucleotidase (EC 3.1.3.5.)
Ecto 5'-nucleotidase activity has been functionally characterised as being related to the 
cell surface antigen CD73. CD73 has been identified as a mature B lymphocyte cell 
marker and has been cloned from a number of species, including rat, human and 
Torpedo tissues (Zimmermann, 1992).
The development of ecto 5'-nucleotidase activity in leukocytes mirrors that previously 
outlined for ecto-ATPase and ecto-ATPDase. CD73/ecto 5'-nucleotidase enzyme 
activity and mRNA transcripts are reportedly absent in murine leukocytes and early 
lymphoid progenitors, but have been identified in mature T and B lymphocytes and the 
murine myelomonocytic cell line WEHI-3 (Resta et al., 1993).
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Other CD73/ecto 5'-nucleotidase positive tissues and/or cell types include cardiac 
pericytes and fibroblasts (Mlodzik et al., 1995), vascular endothelial cells (Gordon et 
al., 1986) and mammary gland epithelial cells (Kruger et al., 1991). Clifford et al. 
(1997) reported that expression of CD73/ecto 5'-nucleotidase in human myeloid 
leukocytes is restricted to cells pre-committed to the macrophage phenotype. 
Degradation of AMP to adenosine, by an a,p~methylene ADP-sensitive mechanism, 
and the parallel upregulation of CD73 mRNA expression in PMA-induced HL-60 cells 
suggests that the observed ecto 5'-nucleotidase activity is due to CD73.
In studies using nucleotide phosphorothioate diastereoisomers, ADP-a-S, ADP-^-S, 
ATP-p-S and ATP-y-S, the ecto-ADPase and ecto-ATPase activities on pig aortic 
smooth muscle cells were found to be similar to those on pig aortic endothelial cells. 
However, the ecto 5'-nucleotidase activity of aortic smooth muscle cells exhibited 
distinct differences from that on endothelial cells. Whereas both ecto 5'-nucleotidases 
were inhibited by ADP, only the smooth muscle enzyme degraded AMPS to adenosine 
and had a 10-fold lower affinity for AMP than that on the endothelial cells (Pearson et 
al, 1985).
Rapid catabolism of ATP, ADP and AMP to adenosine occurs on passage through 
blood vessels and vascular beds. Microvascular endothelial cells from rat heart have 
been shown to metabolise ATP to adenosine via ADP and AMP (Meghji et a l, 1995). 
The kinetics of this enzyme-catalysed reaction sequence in these cells has revealed that 
it is the depletion of the original substrate at the cell surface which dominates the 
regulation of the rate of hydrolysis of ATP.
Studies using the visceral smooth muscle preparations, the guinea-pig taenia caeci and 
urinary bladder demonstrated that only the guinea-pig bladder had the ability to 
dephosphorylate AMPS (Welford et a l, 1986; 1987). This indicates a similarity
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between the ecto 5'-nucleotidase on guinea-pig urinary blader to that on pig aortic 
smooth muscle cells (Pearson et al., 1985) and a similarity between the ecto 5'- 
nucleotidase on guinea-pig taenia caeci and that on pig aortic endothelial cells which 
are both unable to degrade AMPS (Cusack et al., 1983).
A number of compounds have been shown to have an inhibitory effect on the activity 
of ecto 5'-nucleotidase, including that prepared from the smooth muscle of the rat 
small intestine which were inhibited by thymidine 5'triphosphate (TTP) and AMPCP 
(Burger & Lowenstein, 1970).
Ischaemic preconditioning has been used to describe the phenomenon whereby brief 
periods of myocardial ischaemia and reperfusion decrease the extent«fcellular injury 
following a subsequent prolonged period of ischaemia. A number of mechanisms 
have been implicated, although it is known that the production of adenosine from AMP 
by the action of ecto 5’-nucleotidase protects the myocardium from reperfusion injury 
(Olafsson et al., 1987), and Liu et al. (1991) showed that activation of adenosine 
receptors results in ischaemic preconditioning. Adenosine receptor agonists mimic the 
infarct size-limiting effects of preconditioning in humans, rabbit and dogs (Thornton et 
ai, 1992; Kitakaze et al, 1993; Walker et al., 1995). It is also known that activation 
of protein kinase C (PKC) by ischaemic preconditioning protects rabbit heart from 
ischaemic injury (Ytrehus et al, 1994) and that this PKC activation is due to adenosine 
and catecholamines (Liu et al., 1994; Tsuchida et al., 1994). Node et al. (1997) 
demonstrated that phosphorylation and, therefore activation of ecto 5’-nucleotidase 
was induced by PKC activation and that both enzyme activities were increased by 
ischaemic preconditioning. In addition, further evidence has been obtained for PKC- 
mediated activation of ecto 5’-nucleotidase in the rat heart. The PKC activator, 
lysophosphatidylcholine (LPC) caused an increase in adenosine production from AMP
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in rat left ventricular myocardium. Furthermore the PKC inhibitor, chelerythrine 
completely abolished the increase in adenosine produced by LPC (Sato et al., 1998).
It has been shown that the ATP-sensitive K  ^(K t^p) channel antagonists, glibenclamide 
and glipizide cause a marked decrease in the production of adenosine from AMP by the 
action of ecto 5’-nucleotidase in the rat heart, with an IC^ q value for glibenclamide of 
10.5|iM. Glibenclamide was found to decrease the accumulation of adenosine in the 
extracellular matrix via inhibition of ecto 5’-nucleotidase and the reduction of 
adenosine accumulation may be due to a dual action of ecto 5’-nucleotidase and K^ -^p 
inhibition (Sato et al., 1997).
1.2.1.5. Ecto-Adenosine Deaminase (EC 3.5.4.4.)
Andy & Kronfeld (1982) first described an extracellular adenosine deaminase activity 
which was linked to an intrinsic membrane protein, which they termed adenosine 
deaminase binding protein.
Adenosine deaminase activity has been shown to be relatively high in the rat intestine 
when compared to other tissues (Centelles et al., 1987). This enzyme was originally 
considered to be exclusively intracellular. However, Franco et al. (1986) 
demonstrated a specific localisation of adenosine deaminase activity in the vicinity of 
ecto 5'-nucleotidase (EC 3.1.3.5.).
EHNA and deoxycoformycin are potent and specific inhibitors of adenosine deaminase 
(Henderson etal., 1977; Agarwal, 1982) which result in a potentiation of the relaxant 
effects of adenosine in the rat duodenum (Franco et al., 1988).
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Adenosine deaminase has been described on the surface of haematopoietic cells (Aran 
et al., 1991) and this discovery has led to the suggestion that ecto-adenosine 
deaminase has a role in regulating the extracellular levels of adenosine. Ecto- 
adenosine deaminase binds to the cell surface of T-lymphocytes through the activation 
of the marker CD26 (Kameoka et al., 1993), which has also been termed adenosine 
deaminase binding protein or dipeptidylpeptidase IV. The functional role of the ecto- 
adenosine deaminase/CD26 complex is not known. However, confocal microscopy, 
affinity chromatography and immunoprécipitation have shown that the binding of ecto- 
adenosine deaminase to A, receptors, and that this binding increases the affinity of 
binding of the ligand concerned, suggesting that ecto-adenosine deaminase is required 
for effective coupling between A, receptors and heterotrimeric G proteins (Ciruela et 
al., 1996). The authors also suggest, apart from cleavage of adenosine, a further role 
for ecto-adenosine deaminase in facilitating signal transduction via A, receptors.
1.2.1 6. Nucleoside Transporters
As yet there is no evidence for carrier-mediated cellular uptake of nucleotides, 
however, several transport processes for nucleosides and nucleobases have been 
characterised. Nucleoside transporters mediate the transfer of nucleosides across 
biological membranes and are critical to the salvage pathways for the synthesis and 
storage of purine and pyrimidine nucleotides. Nucleoside transporters are also 
important for the cellular permeabilities of antineoplastic nucleosides and for uptake of 
autocoid nucleoside adenosine. At present, three nucleoside transporter subtypes have 
been cloned (Huang et al., 1994; Che et al., 1995; Yao et al., 1996; Griffiths et al., 
1997) and functional assays have revealed at least seven subtypes distinguishable by
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nucleoside permeability selectivity, inhibitor sensitivity and requirement for Na"'’ 
(Griffith & Jarvis, 1996; Geiger et al., 1997).
Recently two cDNA sequences encoding Na'^-dependent nucleoside transporters have 
been cloned recently from the rat by expression screening in Xenopus oocytes, and 
have been termed rat concentrative nucleoside transporter 1 (rCNTl) (Huang et al., 
1994) and rat concentrative nucleoside transporter 2 (rCNT2) or sodium/purine 
nucleoside transporter (Che et al., 1995). These cDNA sequences appear to be from 
the same gene family as rCNT2 has 64% amino acid identity with rCNTl. A cDNA 
encoding an equilibrative (Na^-independent) transporter has been cloned from human 
placenta and has been called human equilibrative nucleoside transporter 1 (hENTl) 
(Griffiths et al., 1997). Interestingly, there is no significant amino acid identity 
between hENTl and rCNTl or rCNT2, indicating that hENTl belongs to a separate f 
gene family.
The physiological significance of individual nucleoside transporter subtypes has not 
been established. Both adenosine and uridine have similar affinities for each of 
rCNTl, rCNT2 and hENTl when they are expressed in Xenopus oocytes (Huang et 
al., 1994; Yao et al., 1996; Griffiths et al., 1997). However, uridine uptake was 
much higher than adenosine uptake by rCNTl, whereas it was similar to adenosine 
uptake by rCNT2 and hENTl (Yao etal., 1996; Griffiths et al., 1997). As hENTl is 
a site of action for the coronary vasodilators dilazep and dipyridamole, which inhibit 
the cellular uptake of adenosine and enhance the receptor-mediated effects of 
extracellular adenosine, hENTl is clearly important in the physiological regulation of 
adenosine receptor activation. Owing to their widespread tissue distribution, 
equilibrative nucleoside transporters, such as hENTl, are also considered to be critical
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components of nucleotide salvage pathways. In contrast, Na^-dependent transporters 
have more limited tissue distribution (for review see Jennings et al., 1998).
While adenine and uracil, nucleobases, can enter cells as low-affinity (mM) substrates 
for nucleoside transporters, a number of cell types possess transporters that exhibit 
selectivity for nucleobases. As yet there is no molecular information regarding the 
nature and identity of these transporters, however, functional assays indicate that both 
equilibrative (Na^-independent) and concentrative (Na' '^-dependent) nucleobase 
transport processes exist (Griffith & Jarvis, 1996). At present there is no evidence for 
extracellular UrdPase activity, therefore nucleobase transport is unlikely to be an 
integral component of uridine nucleotide salvage following P2 receptor activation by 
UTP and/or UDP.
The nucleoside transporter mechanism expressed by mammalian erythrocytes and 
many cultured cell lines is a non-concentrative, simple carrier with a broad substrate 
specificity. Differences in the sensitivities of uridine transport by erythrocytes and 
cultured cells to inhibition by dipyridamole, dilazep and lidoflazine are largely species- 
specific. Uridine transport in human, porcine and rabbit cells is between 2-10 fold 
more sensitive to inhibition by dipyridamole (IC5 0  approximately 50nM) and about 10- 
20 fold more sensitive to dilazep inhibition (IC5 0  approximately 5nM) than is uridine 
transport in rat and mouse cells. In addition, it has been demonstrated that uridine 
transport in human erythrocytes and HeLa cells is strongly inhibited by lidoflazine 
(IC5 0  = 10-140nM), whereas that in both rat and mouse cells was highly resistant to 
inhibition by lidoflazine (IC5 0  > lOjxM) (Plagemann & Woffendin, 1988). The same 
studies showed that superimposed on these species differences were cell-specific 
variations in the sensitivities of nucleoside transport mechanisms to these inhibitors. 
Uridine transport in Walker 256 rat carcinoma cells was more resistant to inhibition by
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dipyridamole and dilazep than rat cells of other types. Transport in human Hep-2 cells 
was more resistant to lidoflazine (IC5 0  = 2|xM) than that of human erythrocytes and 
HeLa cells, whereas it showed similar sensitivity to dilazep and dipyridamole. Uridine 
transport in Chinese hamster ovary (CHO) cells was more resistant to inhibition by 
dilazep tahn that of neonatal hamster kidney cells. In addition, HeLa cells and their 
clones have been shown to express uridine transporters with differences of 1 0 0 0  fold 
in sensitivity to inhibition by dilazep, with IC5 0  values of 5nM and 5|iM, respectively 
(Plagemann & Woffendin, 1988).
Ribavirin (l-p-D-ribofuranosyl-l,2,4-trizole-3-carboxamide) is a broad-spectrum 
antiviral agent used in the treatment of hepatitis C, influenza, respiratory syncytial 
virus and Lassa fever (Knight et ah, 1981; Hall et al., 1985; McCormick et al., 1986; 
diBisceglie et ah, 1992). The main toxic effect associated with ribavirin therapy is that 
of anaemia. Studies have shown that ribavirin undergoes saturable uptake into human 
erythrocytes and that this uptake is via nucleoside transporters of the NBTI-sensitive 
{es) subtype, the IC5 0  for NBTI being 0.99nM. In addition, the nucleosides adenosine 
and uridine inhibited the influx of ribavirin into erythrocytes, adenosine being more 
effective than uridine, although, the nucleobases adenine and hypoxanthine had no 
effect on the uptake of ribavirin. Furthermore, uridine caused the countertransport of 
ribavirin in human erythrocytes. The same study demonstrated that horse 
erythrocytes, a cell type which lacks the es transporter, accumulated ribavirin only 
slowly and by a pathway resistant to NBTI inhibition (Jarvis et ah, 1998).
The role of the adenosine transporter mechanism as a regulator of neuronal activity is 
supported by the wide distribution of adenosine receptors in the central nervous 
system (Snyder, 1985). The clearance of adenosine from the vicinity of its receptors 
is mediated by the effective nucleoside uptake system which has also been
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characterised in a number of other tissues (Jarvis & Young, 1980; Plagemann et al., 
1988). Several studies in cultured chromaffin cells have been published concerning 
the long term regulation of adenosine transport in cultured chromaffin cells. It has 
been demonstrated that nerve growth factors enhanced the capacity of the adenosine 
transport mechanism (Torres et al., 1987). Similarly, in the same cellular model, 
thyroid hormones (notably T3) not only increase adenosine transport, but also the 
number of adenosine transporters (Fideu & Miras-Portugal, 1992). Adenosine 
transport in cultured chromaffin cells, considered a model for postganglionic 
sympathetic neurones, is inhibited by antagonists of P2Y receptors. Studies in 
chromaffin cell cultures have shown that ADP-p-S, Ap^A and AMPPNP inhibited the 
uptake of adenosine, with Ap^A (a physiological P2Y receptor agonist) showing the 
greatest inhibitory effect (45%) (Sen et al., 1993). The authors noted that adenosine 
transport inhibition was due to an increase in the cytosolic Ca^  ^concentration and the 
activation of PKC.
The actions of protein kinase A (PKA) and protein kinase C (PKC) on adenosine 
transport are well documented. PKA results in an inhibitory effect on adenosine 
transport and a decrease in the number of binding sites for NBTI to the same extent 
(Sen et al., 1990). NBTI binding is used as a tool to bind specifically to adenosine 
transporters and is used to quantitatively determine the level of functional adenosine 
transporter molecules in rat and guinea-pig synaptosomes (Morgan & Marangos, 
1987; Lee & Jarvis, 1988; Torres et al., 1988). Similarly, an inhibitory effect of PKA 
on NBTI binding has been reproduced in membranes obtained from chromaffin tissue 
(Sen et al., 1990). In addition, activators of PKC, such as phorbol esters, also result 
in inhibition of adenosine transporters (Delicado et al., 1991). In chromaffin cells, 
ACh and other nicotinic agonists, induce the binding of PKC to membranes and result 
in its subsequent activation (Terbush & Holz, 1986; Terbush et al., 1988). The
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observed inhibitory effect of PKC on adenosine transport is followed by a parallel 
decrease in NBTI binding (Delicado et ah, 1991). It is noteworthy that stimulators of 
secretion from chromaffin granules also modulate adenosine uptake.
”A characteristic action of adendsine on the heart is the concentration-dependent 
slowing of the atrio-ventricular (AV) nodal transmission (Drury & Szent-Gyorgi, 
1929). Further interest in the pysiological role of adenosine in AV nodal function was 
generated by the observation that in guinea-pig perfused hearts the selective A, 
receptor antagonist, BW-A1433, increased the maximal AV conduction time but did 
not result in second or third degree AV block (Jenkins & Bellardinelli, 1988). They 
also noted that inhibition of the uptake of adenosine by dipyridamole, and that in the 
absence of dipyridamole adenosine was more potent on the AV node than the sinoatrial 
(SA) node. In guinea-pig perfused hearts and isolated right atria adenosine, but not 
NFCA, was shown to undergo saturable agonist uptake which was competitively 
inhibited by dipyridamole. The authors assumed that adenosine and NFCA acted 
extracellularly at Aj receptors and that in the AV node, but not the SA node, adenosine 
transported into cells was assumed to potentiate the effects of adenosine A, receptor 
activation (Meester et al, 1998). The authors predicted that for the AV node assay the 
potentiation of adenosine by uptake blockade is offset by a simultaneous decrease in 
potentiation due to the intracellular action of adenosine.
Hepatocytes are the primary source of nucleosides for mammalian cells which lack de 
novo nucleoside biosynthesis, therefore the existence of a salvage mechanism is 
advantageous. The presence of a Na'^-dependent, concentrative nucleoside transport 
mechanism has been demonstrated in canalicular membrane vesicles, but not 
sinusoidal membrane from rat liver. The transporter has high affinity for the 
nucleosides adenosine and uridine, with an apparent K^ for adenosine of 14)iM. In
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addition, the transport mechanism was reported to be insensitive to NBTI and 
dipyridamole. The authors also reported that the canalicular memebrane vesicles from 
rat liver possessed abundant ecto-ATPase and ecto-5'nucleotidase activities and that 
exogenous nucleotides were degraded to nucleosides and conserved by the Na'^ - 
dependent nucleoside transport system (Che et ah, 1992).
1.3. Purine Receptors
ATP, ADP, UTP, UDP and adenosine are known to act as extracellular signalling 
molecules via purine and pyrimidine nucleotide and nucleoside receptors. Adenosine 
acts at PI receptors which are sub-divided into four classes A,, - ^ 3
receptors and which are all G protein-coupled receptors (see Table 1.6.). However, 
ATP, ADP, UTP and UDP (along with a number of diadenosine polyphosphates) act 
via P2 receptors, sensitive to either purine or pyrimidine nucleotides or both (see 
Tables 1.8. and 1.9.). P2 receptors are subdivided into P2X receptors, ligand- 
gated ion channels of which at least 7 different members have been cloned, and G 
protein-coupled P2Y receptors of which at least 5 different members have been cloned. 
Several of the cloned P2Y receptors exhibit high selectivity for the uridine nucleotides, 
UTP and UDP, namely the P2Y^ and P2Y^ receptors, supporting the proposal that, 
despite the lack of evidence for the regulated release of uridine nucleotides, UTP and 
UDP may also play important physiological roles. The localisation, structure and 
function of these receptors is discussed elsewhere in this thesis (see sections 1.3.2.2. 
and 1.3.2.3.).
Purine and pyrimidine nucleotides are ubiquitous to all living cells in most biological 
systems. It was not until the effects of adenosine on heart rate and arterial pressure
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were described by Drury & Szent-Gyorgyi (1929) that extracellular effects of these 
compounds were even considered. Since then there has been an increasing acceptance 
of the extracellular role which these compounds play in both central and peripheral 
systems. The cell surface receptors which are responsible for mediating these effects 
have been identified and characterised in the intervening years and these are reviewed 
in the following sections. The first classification of these receptors arrived with 
Bumstock (1978), when he divided the receptors into two subclasses based on the 
relative potencies of adenosine and ATP and their susceptibility to antagonism by 
methylxanthines. PI (adenosine) receptors exhibited an agonist potency order of 
adenosine > AMP > ADP > ATP and their effects are blocked by methylxanthines, 
whereas at P2 receptors the agonist potency order is ATP > ADP > AMP > adenosine 
and their effects are not blocked by the methylxanthines.
1.3.1. Adenosine (PI) Receptors
Adenosine (PI) receptors have been further subdivided on the basis of whether they 
inhibit or stimulate adenylate cyclase, and therefore, lead to a decrease or increase in 
intracellular cyclic AMP (cAMP) levels. Those receptors mediating the inhibition of 
adenylate cyclase were classed A, receptors, while those mediating stimulation of 
adenylate cyclase were classed Aj receptors (Van Calker et al., 1979). These same 
receptors were also classified Rj and R^  (corresponding to inhibitory and stimulatory, 
respectively) receptors in an additional classification system proposed by Londos et al. 
(1980). However, the former classification system has become the accepted 
nomenclature system.
It has since been discovered that adenosine can bind to numerous other effector 
systems in addition to adenylate cyclase such as channels, Ca^^  channels.
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phospholipase C (PLC), phospholipase A (PLA) and guanylate cyclase (see Fredholm 
etal., 1994). The nomenclature system has therefore been amended so that the A/A^ 
classification no longer implies modulation of a specific effector system.
The A2  receptor has now been further subdivided into Aj^ and A2 B receptors (Daly et 
al., 1983; Bruns et al., 1986; Bruns et al., 1987). There has been a third addition to 
the PI receptor classification. On the basis of cloning and functional characterisation 
studies Zhou et al. (1992) proposed the A3  receptor in the rat striatum. The cloning of 
Ap A2 A and A2 B receptors has also been carried out, confirming the existence of 
separate PI receptors, showing they all form part of the G-protein coupled receptor 
class (see Collis & Hourani, 1993; Fredholm et al., 1994; Olah & Stiles, 1995). 
Table 1.6. outlines the classification of PI receptors.
Adenosine has been chemically modified in a number of ways which has produced a 
range of analogues (Jacobson, 1990). These analogues have been used to further 
classify PI receptors in functional studies, although it must be noted that rank order of 
potency of agonists cannot be relied upon in isolation to characterise receptors. For 
example, tissues may contain more than one subtype of PI receptor which may cause 
the same or opposite effects, thereby distorting the order of potency. Also, potency 
cannot be directly related to affinity and is also affected by efficacy and the receptor 
reserve present, therefore the use of selective antagonists is the preferred method of 
receptor classification. C2-substitution of the adenine moiety results in analogues such 
as 2-chloroadenosine (2CAD0), 2-phenylaminoadenosine (CV1808) and 2-p- 
((carboxyethyl)phenylethylamino)-5'-N-ethylcarboxyamidoadenosine (CGS21680); 
N^-substitutions of the adenine moiety gives analogues such as N -^ 
(phenylisopropyl)adenosine (PI A), N^-cyclohexyladenosine (CHA) andN^- 
cyclopentyladenosine (CPA) which are potent agonists at A, receptors. Structural
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alterations at the ribose moiety are rarely tolerated by PI receptors, however 5'-N- 
ethylcarboxyamidoadenosine (NECA) has been used as a non-selective PI receptor 
agonist (Bruns et al., 1986). The potency of adenosine can also be influenced by 
uptake and deamination, and these 'termination mechanisms' are discussed in detail 
elsewhere in this thesis. There is no evidence, however, for the uptake or deamination 
of analogues such as CPA or NECA. For example, in the guinea-pig trachea (Brown 
& Collis, 1982) and the guinea-pig taenia caeci (Prentice et al., 1995) uptake blockers 
do not enhance responses to NFCA, and NFCA is known not to be deaminated 
(Raberger et al., 1977). CPA is also not deaminated and the effects of N^-substituted 
analogues are also not enhanced by uptake blockers (Brown & Collis, 1982).
1.3.1.1. Al Receptors
The adenosine A, receptor is a member of the G-protein coupled receptor superfamily 
(Munshi et al., 1991), and is known to be present predominantly pre-synaptically 
playing an important role in the central and peripheral nervous systems. It has been 
shown to inhibit the release of a variety of neurotransmitters, including acetylcholine 
(ACh), dopamine, noradrenaline (NA), G ABA and 5-HT (Harms et al., 1978; Stone, 
1981; Williams et al., 1984). The A, receptor has also been demonstrated post- 
junctionally on smooth muscle preparations, including rat colon, guinea-pig aorta and 
guinea-pig trachea mediating contractions of the tissue (Farmer et a l, 1988; Stoggall & 
Shaw, 1990; Bailey et a l, 1992). A, receptors are also present in the heart, for 
example in the guinea-pig atria Aj receptors have been shown to mediate cardiac 
depression (Collis, 1983).
The second messenger system linked to A, receptors was originally considered to be 
solely the inhibition of adenylate cyclase activity (Van Calker et a i, 1979; Londos et
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al., 1980). However, more recently this receptor has been shown to be linked to 
many other effector systems in addition to adenylate cyclase (for review see Fredholm, 
1994).
The Aj receptor selective agonists have been predominantly derived from the chemical 
substitution at the position of the adenine moiety, which has been demonstrated to 
markedly increase Aj potency. These analogues include CHA, PIA and CPA, as has 
been alluded to previously (Bruns et al., 1986). PIA exists as two isomers, R-PIA 
and S-PIA, and the Aj receptor shows stereoselectivity to the R-PIA isomer, which is 
100-fold more potent at the Aj receptor than S-PIA (Collis, 1983). For example, R- 
PIA has an affinity of 1.2nM whereas S-PIA has an affinity of 0.53|iM at the Aj 
receptor. CPA is used as a potent agonist at Aj receptors with an affinity of 0.6nM. 
CPA is approximately 700-fold selective for the A, receptor over the A  ^ receptor and 
is also about 440-fold selective for the Aj receptor over the A3  receptor (Bruns et al., 
1986; Van Galen et al., 1994). NFCA has an affinity of 6.3nM at A, receptors and 
binds to both Aj and A^  ^receptors, although it is approximately 400-fold selective for 
A, over receptors, but only 10-fold selective for Aj over A3  receptors (Bruns et 
al., 1986; Van Galen et al., 1994). NFCA has been widely used as a non-selective PI 
agonist in many tissues.
The naturally occurring xanthines, caffeine and theophylline, were first proposed as 
PI receptor antagonists by Sattin & Rail (1970). Caffeine and theophylline are both 
non-selective, weak, competitive antagonists and caffeine has affinities at the A,, Aj^ 
and Ajb receptors of 44,45 and 30|iM, respectively, whereas theophylline has 
affinities of 14, 22 and 32jxM at those same subtypes (Bruns et al., 1986; Van Galen 
etal., 1994).
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Structural changes to the methyl groups of theophylline has led to the development of 
the Aj selective antagonist, l,3-dipropyl-8-cyclopentylxanthine (DPCPX) (Bruns, 
1990). DPCPX has an affinity for A, receptors of 0.9nM and is more than 500-fold 
selective for Aj receptors over A  ^ receptors, where it has micromolar affinity (see 
Collis & Hourani, 1983).
The 8 -phenyl analogues of theophylline have also been used as Aj receptor 
antagonists. 8 -phenyltheophylline (8 -PT) is a non-selective antagonist with affinities 
in the micromolar range for both Aj and A^  receptors (Bruns & Fergus, 1989). The 
addition of a sulphur group to the 8 -PT structure has produced 8 - 
(sulphophenyl)theophylline (8 -SPT) which is also a non-selective antagonist at A, and 
Aj receptors, with affinities of approximately 5|iM at both receptors.
Recently, molecular biology studies have confirmed the existence of A, receptors in 
many tissues. Libert et a l (1989) have cloned two orphan receptors, RDC7 and 
RDC8  from a canine cDNA library. They identified the RDC7 as the A, receptor and 
showed that it was expressed in a number of systems, including canine thyroid gland, 
brain, kidney, heart and testes (Libert et al., 1991; Libert et al., 1992). The canine 
receptor when expressed in Chinese hamster ovary (CHO) cells confers CPA-mediated 
inhibition of forskolin-stimulated adenylate cyclase activity. The Aj receptor has been 
cloned from a number of other species, including rat and bovine tissues (Repert et al., 
1991; Mahan et al., 1991; Tucker et al., 1992; Olah et al., 1992). The rat A, receptor 
shows 91% sequence homology with the canine receptor. The bovine A, receptor also 
has a greater than 90% sequence homology with both the canine and the rat A, 
receptor, but shows a different agonist potency order. In the canine and rat, the 
agonist potency order is R-PIA > NFCA > S-PIA, which is more similar to the 
classically recognised agonist potency order at A, receptors, whereas at the bovine A,
52
receptor the agonist potency order is R-PIA > S-PIA > NECA (Tucker et al., 1992; 
Olah et al., 1992). The human A, receptor has also been cloned and shows a 94% 
sequence homology to the bovine, canine and rat A, receptors and displays the 
classical A, receptor agonist potency order (Salvatore et al., 1992).
1.3.1.2. A 2 A and A 2 B Receptors
A 2  receptors belong to the G-protein coupled receptor superfamily and are thought to 
be mainly present postjunctionally, mediating relaxation of smooth muscle 
preparations such as in the guinea-pig taenia coli (Bumstock et al., 1984), guinea-pig 
trachea (Brown & Collis, 1982), guinea-pig aorta (Collis & Brown, 1983) and the rat 
aorta (Lewis et al., 1994; Prentice & Hourani, 1996). However, the presence of Ag 
receptors prejunctionally in the central nervous system mediating excitatory actions has 
also been suggested (Corrieadesa & Ribeiro, 1994; Fredholm, 1995). For example, 
A2 A receptors are present on cholinergic striatal nerve terminals stimulating ACh 
release (Kirk & Richardson, 1994).
The Aj receptor exists as two recognised subtypes (Daly et al., 1983), A2 A and A2 B 
receptors. A2 A receptors are high affinity and A2 B are low affinity receptors, which are 
both linked to adenylate cyclase activation. The A^ A receptor has a higher affinity for 
adenosine agonists compared to A2 B receptors.
An adenosine receptor initially classified as an A4  receptor when it was first described 
in rat brain in studies using the radioligand [^H]-CV1808 (Cornfield et al., 1992), 
was, like the adenosine A3 receptor, resistant to blockade by the xanthine antagonists 
and thought to be linked to the stimulation of K^-channels. However, subsequent
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binding studies have indicated that the A4  receptor is more likely to be a temperature- 
sensitive form of the Aj^ receptor (Luthin & Linden, 1995), and therefore it has not 
been included in the recognised adenosine receptor nomenclature.
Substitution at the C2 position of the adenine moiety has been shown to increase 
potency at the A^  ^receptor. CGS21680 has an affinity of 15nM at the Ag^  receptor 
while it is effectively inactive at the A^ g receptor up to a concentration of lOOjiM, and 
has micromolar affinity at both the A, and A3  receptors. Therefore, CGS21680 is 
considered to be the standard Aj^ receptor selective agonist used to distinguish 
between subtypes (170- and 39-fold selective for versus A, and A3  receptors, 
respectively) (Bruns et al., 1986; Hutchinson et al., 1989; Van Galen et al., 1994). 
CV1808 has also been used as a potent agonist at A^  ^ receptors, showing nanomolar 
affinity at A ^ receptors compared to micromolar affinity at Ajg receptors. However, 
CV1808 shows only 2-fold selectivity for A2 A compared to Aj receptors (Bruns et al., 
1986). There are as yet no selective A2 B receptor agonists, though the identification of 
such a molecule would prove useful in the pharmacological separation of A2 A A2 B 
receptor-mediated responses. The non-selective ligand, NECA, is also used as an A2  
receptor agonist (Bruns et al, 1986; Van Galen et al., 1994), with an affinity of lOnM 
at the A2 A receptor compared to 1.9{xM at A2 B receptors (Bruns et al., 1986).
The N^-substituted analogues, R-PIA, S-PIA and CPA have low potencies at the A2  
receptors. The affinities of R-PIA, S-PIA and CPA at the A^^ receptor are 0.12, 0.22 
and 0.46pM, respectively (Bruns et al., 1986). In addition, unlike the A, receptor, 
A2 A r^id A2 B receptors do not show stereoselectivity with respect to the R- and S- 
isomers of PIA, both having similar affinities (see Collis & Hourani et al., 1993; 
Fredholm et al., 1994). The potency orders for adenosine receptor agonists are shown 
in Table 1.6.
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Caffeine is a weak and non-selective antagonist at receptors and it is from this 
structure which the commonly used xanthine antagonists at Aj receptors have been 
developed. 8-(3-chlorostyryl)caffeine (CSC) has an affinity of 54nM at A^  ^ receptors 
but only 8.2jiiM at A^ g receptors, a selectivity greater than 100-fold for the A ^ over 
the Ajg receptor (Jacobson et al., 1993). CSC is also a weak antagonist at A, 
receptors with an affinity of approximately 28pM, a selectivity greater than 500-fold 
for Aja over A, receptors (Jacobson et al., 1993). The xanthine analogue, N-[2- 
(dimethyl-amino)ethyl]-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-IH- 
purin-8 -yl)benzenesulphonamide (PD 115,199), has been used as an antagonist to 
distinguish between Aja and A^ g receptor-mediated responses (Bruns et al., 1987). 
PD 115,199 has an affinity at Aja receptors of 15.5nM and 0.16}iM at the Ajg 
receptor, a 1 0 -fold selectivity for the A ^ receptor compared to the A^ g receptor. 
However, PDl 15,199 also has nanomolar affinity at A, receptors (13.9nM) and 
therefore cannot be used reliably to distinguish between A, and Aja receptor-mediated 
responses. DPCPX has been widely used to distinguish between Aj and A^  
receptors, since receptor-mediated effects are antagonised in the order A, > A^ g > AgA 
receptors. The affinity of DPCPX at A,, A^ A and A^ g receptors is 0.9nM, 0.36p,M 
and 0.47|iM, respectively (Bruns et al., 1987; Collis et al., 1989; see Collis & 
Hourani, 1993; see Coates et al., 1994; see Fredholm et al., 1994).
A number of non-xanthine A^  receptor antagonists have been synthesised and the 
ligand which has been demonstrated to show the highest degree of selectivity is 4-(2- 
[7-amino-2-(2-furyl)-[l,2,4]-triazolo[2,3-a]-[l,3,5]-triazin-5-yl)amino]ethyl)phenol 
(ZM 241385) (Poucher et al., 1995). This compound has nanomolar affinity at the 
Aja receptor with a pAj value of 8.57 and is between 400- and 1000-fold selective for 
Aja compared to A, receptors, 30-80-fold selective for A^ A versus Ajg receptors and 
6700-fold selective for A^ A compared to A3 receptors (Poucher et al., 1995).
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Aja and Ajb receptors have been cloned from a number of sources. The RDC8  
receptor has been cloned from the canine thyroid gland and this led to the identification 
of the A2 A receptor (Schiffman et al., 1990). The clone was expressed in African 
green monkey kidney (COS) cells exhibited characteristics of the high affinity A2 A, 
with a Kg, of 26nM for CGS21680 and an agonist potency order of NECA > 2CAD0 
> adenosine > CPA (Maenhaut et al., 1990). A rat A^ receptor has also been cloned 
from brain cDNA libraries (Chem et al., 1992; Fink et al., 1992). The rat A2 A receptor 
shows 82% sequence homology with the canine AgA receptor and CGS21680 has a Kg, 
of 37nM. The agonist potency order at this receptor is NECA > R-PIA > CPA > S- 
PIA, which is the generally accepted order of potency at A2 A receptors. A human A2 A 
receptor has also been cloned from heart and brain cDNA libraries (Salvatore et al.,
1992) and has been found to have 93% sequence homology with the canine 
receptor but only 82% sequence homology with the rat A2 A receptor. This receptor, 
expressed in COS cells also exhibits the generally accepted A2 A receptor potency order 
of agonists observed in the rat, and CGS21680 also has a K  ^ in the nanomolar range 
(17nM).
In contrast to the A2 A receptors, which are largely localised in the striatum, A2 B 
receptors are found throughout the brain (Daly et al., 1983; Bruns et al., 1986). A rat 
A2 B receptor, originally designated as RFL9, was cloned from a rat brain cDNA library 
and when expressed in COS cells, no binding of the A2 A-selective ligand CGS21680 
was detected and only binding of NECA was observed (Stehle et al., 1992). A human 
A2 B receptor has also been cloned and shows 8 6 % sequence homology with that 
cloned from the rat (Salvatore et al., 1992).
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1.3.1.3. A3  Receptors
The existence of a prejunctional adenosine receptor, classified as an A3  receptor, was 
originally proposed by Ribeiro & Sebastiao (1986), in the frog neuromuscular 
junction, due to the observation that the potency order of agonists did not follow the 
classical A/Aj receptor division. The agonist potency order was found to be CPA= 
CHA = R-PIA = NECA > 2CAD0 in atrial tissues and suggested the presence of a 
novel adenosine receptor in these tissues which was termed an A3  receptor. However, 
this receptor failed to gain wide acceptance and later studies (Kennedy et ol., 1992) 
have shown this receptor to be an Aj receptor, as the presence of both A, and A^  
receptors in a single tissue can account for discrepancies in the observed agonist 
potency orders. In the rat vas deferens the potency order of agonists mediating 
inhibition of nerve-mediated contraction is NECA = CPA > adenosine, and as there are 
known to be both inhibitory prejunctional A, and postjunctional receptors in this 
tissue, the observed agonist potency order can be explained by the fact that CPA can 
activate Aj receptors, whereas NECA and adenosine activate A^  receptors (Hourani et 
a/., 1993).
A new A3  receptor has now been identified. Unlike the A, and Aj receptors, the 
existence of this receptor has been shown by cloning studies. This A3  receptor was 
first proposed in the rat by Zhou and co-workers (1992). Selective agonists at the A3  
receptor are formed by the N-benzyl substitution of NECA, giving compounds such as 
N^-(iodobenzyl)-5'-(N-methyl-carboxamido)adenosine (IB-MECA). This compound 
has a nanomolar affinity (0.33nM) at the A3  receptor and is used as a selective A3  
receptor agonist (Gallo-Rodriguez et al, 1994). IB-MECA is also active at A, and A^ /^  
receptors with affinities of 54nM and 56nM, respectively, having 50-fold selectivity 
for A3  receptors compared to A, and Ag^  receptors (Kim et al, 1994; Van Galen et a l,
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1994). The N^-substituted ligand, N^-2-(4-amino-3-phenyl)-ethyladenosine (APNEA) 
is also used as an A3  receptor agonist, although it is considered non-selective as it has 
nanomolar affinity at both the A, and A3  receptor (Van Galen et a l, 1994). APNEA 
has been shown to induce hypotension in the pithed rat, and this has been suggested to 
be due to an action at A3  receptors present on mast cells (Fozard & Hannon, 1994).
A3 receptor selective antagonist ligands do exist but their definition is complicated by 
the fact that the A3  receptor is not highly conserved between species. Whereas some 
antagonists are active at the human and sheep A3  receptor, they may be inactive at the 
rat A3  receptor. This may be an indication of the existence of A3  receptor subtypes, 
but it has been more widely accepted that the underlying reason for these observations 
is differences between species. Antagonists at the A3  receptor include acidic 
substituted 8 -phenylxanthines such as 3-(3-iodo-4-aminobenzyl)-8-(4-oxyacetate)-l- 
propylxanthine (BW-A522, also known as I-ABOPX), where BW-A522 has 
nanomolar affinity at the human and sheep A3  receptors, 18nM and 3nM, respectively, 
(Linden et al., 1993; Salvatore etal., 1993). BW-A522 has also been shown to block 
the hypotensive responses to APNEA in the pithed rat, although the potency of BW- 
A522 was only in the micromolar range (Fozard & Hannon, 1994). BW-A522 and 
DPCPX have affinities in the micromolar range at the rat A3  receptor, 1.7|iM and 
5.3|xM respectively (Kim et al., 1994). At present the only potent and selective A3  
receptor antagonist available is MRS 1191
When expressed in COS and CHO cells the transfected rat A3 receptor bound the 
ligands R-PIA, S-PIA and APNEA, all of which are also A, receptor agonists. NECA 
was also active at this receptor with the potency order R-PIA = NECA > S-PIA > 
adenosine. The rat A3  receptor has been shown to be insensitive to the xanthine 
antagonists DPCPX and 8 -SPT (Zhou et al., 1992).
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The highest expression of the rat A3  receptor is in the testes, with lower levels of 
expression in the lung, kidney, heart, cerebral cortex, striatum and the olfactory bulbs 
(Zhou et al., 1992). However, the tissue distribution of A3  receptors appears to 
exhibit species differences. In the sheep higher levels are expressed in the lung, 
spleen, pars tuberalis and pineal gland with only moderate levels in the testes, kidney 
and brain (Linden et al., 1993). In contrast, in humans the highest levels of A3  
receptor expression are observed in lung and liver, moderate levels in the aorta and 
brain and the lowest levels in the testes and heart (Linden et al., 1993; Salvatore et al.,
1993). The human and sheep A3  receptors show 72% sequence homology with the rat 
A3  receptor, whereas they show 85% sequence homology with each other.
The agonist potency order for both the human and sheep A3  receptors is the same as 
that previously reported for the rat subtype, namely R-PIA = NECA > S-PIA > 
adenosine. However, the xanthine antagonists, DPCPX, 8 -PT and BW-A522, have 
been shown to bind to the human and sheep A3  receptors, unlike the rat A3  receptor 
(Linden et al., 1993; Salvatore et al., 1993). The rat A3  receptor mRNA has been 
shown to be present in the bentral nervous system and a number of peripheral tissues 
with a similar distribution to that of the human and sheep A3  receptors, suggesting that 
the rat A3  receptor also has a wide tissue distribution (Linden et al., 1994; Dixon et al., 
1996).
Human, rat and sheep A3  receptors are linked to the inhibition of forskolin-stimulated 
adenylate cyclase activity. In contrast, A3 receptors in cultured rat mast cells are 
positively coupled to phospholipase C (PLC) leading to the production of inositol 
triphosphate (IP3) and an increase in intracellular Ca^  ^(Ramkumar et al., 1993).
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1.3.1 A . P  Site
It has been observed that high concentrations of adenosine in vitro, in the millimolar 
range, inhibit the activity of adenylate cyclase via the "P site" (Londos & Wolff, 
1977), which is an intracellular site within the catalytic site of adenylate cyclase. This 
site binds adenosine, but not 2-CADO to inactivate the enzyme. The other adenosine 
receptor agonists, NECA, R-PIA and CHA are not active at the P site, nor is it 
sensitive to antagonism by 8 -SPT (Daly, 1982; Collis & Brown, 1983). Since a high 
concentration of adenosine is required to cause inhibition of adenylate cyclase catalytic 
site, and since intracellular adenosine is regulated by adenosine deaminase, the P site is 
not thought to play a significant physiological role.
1.3.1.5. ATP as a PI Receptor Agonist
ATP is widely thought to act at PI receptors following its extracellular metabolism by 
nucleotidase enzymes to adenosine. In the guinea-pig atrium and ileum, responses to 
ATP and the ATP analogue, AMPPCP have been shown to be antagonised by the P 1 
receptor antagonist 8 -SPT (Collis & Pettinger, 1982; Moody ef al., 1984). In these 
tissues responses to both ATP and AMPPCP are not reduced in the presence of 
adenosine deaminase, which converts adenosine to inosine, which is inactive in this 
tissue, suggesting a direct action of ATP and AMPPCP at PI receptors. Similarly a 
direct action of AMPPCP at PI receptors in the rat colon and duodenum has also been 
proposed as AMPPCP is relatively stable in these tissues and responses were not 
sensitive to antagonism by P2 receptor antagonists, such as suramin, but were 
antagonised by the PI receptor antagonist, 8 -SPT (Bailey & Hourani, 1990; Hourani 
et al., 1991). It must be noted, however, that in these same tissues other ATP
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analogues, such as AMPCPP and 2-MeSATP are known to activate P2 receptors 
(Bailey & Hourani, 1990; Hourani et al., 1991).
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Figure 1.2, Structures of PI and P2 Receptor Ligands 
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1.3.2. P2 Receptors
The receptors by which extracellular ATP and and a number of its structural analogues 
exert their effects have been termed P2 receptors. The classification of P2 has relied 
upon structure-activity relationships of a series of agonists, and using these 
characteristics several subtypes were originally identified (see Tables 1.7. and 
1.8.). ATP can be structurally modified at the purine or ribose moiety or the 
triphosphate chain to form a number of analogues which can discriminate between the 
major P2 receptor subtypes. However, particularly with data from the expression of 
cloned receptors, it became clear that caution should be exercised when interpreting 
data from pharmacological studies in whole tissues, as the agonist potency order from 
these studies does not always correspond with that observed at the cloned receptor, 
due primarily to the presence of ectonucleotidases which are present in whole tissues 
but not in the cloned receptor systems, leading to dephosphorylation of ATP and some 
of its analogues. In addition, further complicating factors are the lack of selective P2 
receptor antagonists and the presence of heterogeneous populations of P2 receptors in 
some tissues.
The initial subdivision of P2 receptors into the P2X and P2Y subtypes was made by 
Bumstock & Kennedy (1985). They proposed that the P2X receptor had an agonist 
potency order of AMPCPP = AMPPCP > ATP = 2-MeSATP and mediated contraction 
of smooth muscle preparations, whereas the P2Y receptor mediated relaxation and had 
an agonist potency order of 2-MeSATP »  ATP > AMPCPP = AMPPCP. Two 
further subtypes were proposed by Gordon (1986) for receptors on mast cells and 
macrophages which he classed P2 2  receptors and those on platelets which he classed 
Pjj receptors. This was based on the activation of these receptors by ATP"^  and ADP, 
respectively.
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Additionally, a P2 receptor at which the pyrimidine nucleotide, UTP, and ATP are 
equipotent, and at which other P2 agonists are effectively inactive was termed a P2U 
receptor (Dubyak et al., 1991; O'Connor et a l, \99\). A  P2D receptor was also 
proposed, which is sensitive to activation by the diadenosine polyphosphates (Hoyle et 
ai, 1990; Pintor & Miras-Portugal, 1993). The diadenosine polyphosphates (ApnA) 
are a class of compounds in which two adenosine molecules are linked via two or 
more phosphate groups, such as Ap^A, Ap^A and Ap^A, have been suggested to 
mediate their effects via receptors initially classified as receptors (Hoyle et a l, 
1990; Pintor & Miras-Portugal, 1993). However, the diadenosine polyphosphates 
have been shown to activate other P2 receptors, including P2X receptors in the guinea- 
pig vas deferens and human bladder (Mackenzie et al., 1988; Hoyle et al., 1989; 
Westfall et al., 1996). Also, Ap^A is known to be degraded extracellularly in the 
guinea-pig bladder and vas deferens (Westfall et ah, 1996), and for this reason the P^ ^^  
receptor never gained widespread acceptance.
The differing degree of metabolism of ATP and its structural analogues and the 
varying levels of activity of ectonucleotidases in whole tissues and cultured cells has 
led workers in the area of P2 receptor classification to constantly search for a more 
suitable nomenclature system for the P2 receptors. For example, the different rank 
order of potencies of agonists used to define a particular receptor subtype in an isolated 
tissue may also reflect the structure activity relationship and activity of the 
ectonucleotidase enzymes present ÇWéifoïd et al, 1986; 1987).
Recently molecular information concerning P2 receptors has increased to an enormous 
extent with the cloning of some of the cDNAs of this family of receptors and their 
subsequent expression in a number of isolated cells. Several cDNAs encoding 
receptors with structural features characteristic of the G-protein coupled receptor
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superfamily at which adenine and/or uracil nucleotides are active have been cloned. 
They have seven transmembrane, hydrophobic domains, a consensus N-linked 
glycosylation sequence near to the amino terminus, potential phosphorylation sites in 
intracellular and carboxy terminal domains and, in addition, contain a number of amino 
acid residues which are highly conserved among other G-protein coupled receptors. 
On expression in isolated cells, these receptors have been shown to have structure- 
activity relationships characteristic of P2Y receptors.
The more recent cloning of a number of P2 receptors prompted a comprehensive 
revision of P2 receptor nomenclature by the International Union of Pharmacology 
(lUPHAR) Committee on Receptor Nomenclature (Barnard et al., 1998; Humphrey et 
al., 1998). The details of this revised system of nomenclature is outlined in the 
following sections of this thesis.
1.3.2.1. P2X Receptors
The first genes for P2X receptor subunits were cloned in 1994 and since then 
numerous genes that encode P2X receptors have been cloned from a number of 
sources, both mammalian and non-mammalian. At present, seven distinct P2X 
receptor subunits are known to exist and these have been named P2Xj - P2 X7  (North 
& Barnard, 1997; Bumstock, 1997).
P2X receptors are known to be ligand-gated cation channels for extracellular ATP. 
Each subtype is capable of forming homomeric channels, but it is believed more likely 
that they exist as heteromeric structures. P2X subunits belong to a family of ion 
channels that contain two hydrophobic transmembrane domains within each subunit, 
intracellular N- and C-termini and a large cysteine-rich extracellular loop (North,
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1996). More recent structure-function studies indicate that the channel pore is lined by 
residues that include, at least to some degree, the second transmembrane domain 
(Rassendren et al., 1997). There is evidence from antagonist binding studies and site- 
directed mutagenesis of glycosylation sites that the region between the first and second 
transmembrane domains is an extracellular loop (Buell et al., 1996). There has been 
progress determining the molecular basis underlying the profound desensitisation of 
the P2Xi receptor subunit upon prolonged exposure to agonists (Werner et al., 1996). 
However, there are a number of questions still remaining unanswered. Namely, the 
stoichiometry of native P2X receptors (which subunit phenotypes dominate in 
heteromeric channel structures) and the molecular identity of agonist binding site.
Each of the P2X receptor subunits forms a functional cation channel when they are 
expressed as single entities in heterologous expression systems, especially Xenopus 
oocytes, HEK cells and CHO cells. There are certain patterns which appear to be 
repeated between the properties of these presumed homomeric receptors and P2X 
receptors in native cell types, which has led to the suggestion that certain native cell 
types may also express homomeric P2X receptors. The evidence for this being the 
case for the P2X,, P2 X2  and P2 X3  subunits appears to be the strongest (Rae et al., 
1988). It should be noted, however, that although the functional characteristics of 
P2Xj receptors in smooth muscle cells and homomeric P2X, subunits have been 
shown to correspond, there is still a lack of evidence for the endogenous receptor 
being homomeric P2X, subunits. For example, it is known that a number of native 
cell types express multiple P2X receptor subunit mRNA transcripts. In addition, the 
expression of these multiple transcripts has been detected at the protein level using 
immunocytochemistry (Kidd et al., 1995; Collo et al, 1996; Vulchanova et al, 1996). 
In this respect it has been suggested that P2 X2  and P2 X3  subuntis form heterotrimeric 
ion channels which resemble closely properties of native P2X receptors in sensory 
neurones (Lewis e ta l, 1995). Since this initial suggestion of heterotrimeric channels
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formed from P2 X2  and P2 X^  receptor subunits, co-immunoprecipitation studies have 
confirmed the presence of these two P2X receptor subtypes as heterotrimeric channels 
and functional studies have shown the existence of P2 X2 -P2 X3  heteromers on 
nociceptive afferent neurones from the trigeminal ganglia (Cook et al., 1997; Radford 
et al., 1997). There are problems in determining the heteropolymerisation of P2X 
receptor subunits in native cell types by functional studies since subunit-selective 
antagonists have not yet been identified.
The seven as yet identified and cloned P2X receptor subtypes have been described as 
belonging to four groups by their functional characteristics. Group 1 P2X receptors 
have been identified as P2X, and P2 X3  receptors and are AMPCPP-sensitive, rapidly 
desensitising to AMPCPP and sensitive to blockade by suramin. P 2 X 2  and P2Xg 
receptors are said to belong to the Group 2 P2X receptors, which are AMPCPP- 
insensitive, non-desensitising and suramin-sensitive. Group 3 P2X receptors are 
AMPCPP-insensitive, non-desensitising and suramin-insensitive and include the P2X^ 
and P2 Xg subtypes, although the human P2 X  ^receptor is less suramin-insensitive and 
PPADS-insensitive than the rat homologue, where these antagonists have been shown 
to be ineffective or weak antagonists (Buell et al., 1996; Soto et al., 1996; Michel et 
al., 1997). As yet the Group 4 P2X receptors only include the P2X^ subunit, which 
has been described as AMPCPP-insensitive, non-desensitising, pore-forming and only 
weakly suramin-sensitive (see Humphrey et al., 1998).
Recently it is thought that whilst the problems of the lack of selective agonist and 
antagonist ligands at P2X, and indeed P2Y receptors, remains, the limitations imposed 
by agonist breakdown has been largely circumvented under strictly controlled 
conditions. It is believed now to be possible to quote reliable potency order estimates 
for agonists using isolated cells and concentration-clamp techniques, presumably in the 
absence of agonist uptake and/or breakdown, since the agonists are applied rapidly and
6 8
continually to single cell preparations, under which conditions ecto-ATPases are 
thought not to operate (Zimmermann, 1994; Humphrey e ta l, 1995; Kennedy & Leff, 
1995; Zimmermann & Braun, 1996).
In light of the new classification of P2X (and P2Y) receptors a number of points need 
clarification. For instance, the previously assumed P2X selective agonist, AMPCPP, 
has been shown not to be effective at all P2X subunits. It is also apparent that the 
classically used P2 receptor antagonist, suramin has only low affinity for the P2X^, 
P2 Xg and P2 X^  subunits, although it is more effective at the human P 2 X  ^ than at the 
rat P2 X4  (Garcia-Guzman et a l, 1997).
The observations from these studies has raised a number of questions as regards the 
characteristics of native P2X receptors. Firstly, it is possible that responses mediated 
by those receptor subunits which are insensitive to AMPCPP and suramin may 
previously have been overlooked and even classified as other types of ATP receptor. 
Secondly, novel responses mediated by P2X receptors remain to be discovered. 
Thirdly, in native cell types, the ability of suramin to antagonise P2X receptor- 
mediated responses at low concentrations would indicate that P2X subunits that are 
insensitive to suramin are not involved. P2X receptor subunits may also be 
distinguished from each other by the biophysical properties of the channel, such as 
single channel properties, rectification and permeability to different ions.
The cDNAs encoding P2 receptors with the structural features characteristic of ligand- 
gated ion channels (e.g. two hydrophobic transmembrane domains and a pore-forming 
motif) were originally cloned from the rat vas deferens (Valera et a l, 1994), rat 
phaeochromocytomaPC 12 cells (Brake eta l, 1994) and rat dorsal root ganglia (Chen 
et al, 1995). These cloned receptors have been designated as P2X receptors under the
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recent amendments to the nomenclature system for P2 receptors, however, as there is 
only 40-45% sequence homology between these receptors they appear to represent 
different subtypes of the P2X receptor family, i.e. P2X, and P2X^ (Chen et al., 1995; 
Surprenant et al., 1995). In addition, pharmacological differences have been identified 
between these P2X receptors when they are expressed in isolated cells, such as 
differences in agonist potency orders and sensitivities to desensitisation, although 
suramin was found to be an antagonist at each of these receptors (Brake et al., 1994; 
Valera et al., 1994; Chen et al., 1995).
The P2X receptor cloned from human urinary bladder is the human homologue of the 
P2X receptor cloned from the rat vas deferens (Evans et al., 1995). It was suggested 
that the cloned receptor from the rat vas deferens represents the P2X receptor found on 
tissues such as visceral and vascular smooth muscle, whereas the cloned receptor from 
rat PC 12 cells represents the P2X receptor found in a number of neuronal tissues 
(Surprenant et al., 1995), which was in agreement with the tissue distribution of the 
mRNA for these cloned receptors (Brake et al., 1994; Valera et al., 1994). In 
addition, the tissue distribution of the mRNA for the cloned receptor from rat dorsal 
root ganglia indicates it represents a P2X receptor found in sensory neurones (Chen et 
al., 1995). It has also been shown that the P2X receptor cloned from the rat dorsal 
root ganglia not only forms a functional ion channel when expressed in isolation, but 
may also form a heteromultimer when coexpressed with the P2X receptor cloned from 
the rat PC 12 cell line, but not with P2X receptors cloned from the rat vas deferens or 
human urinary bladder and, therefore, displays characteristics of both receptors, that 
is, AMPCPP-sensitive, non-desensitising (Lewis et al., 1995). The P2X receptors 
cloned from rat vas deferens, rat PC 12 cells and rat dorsal root ganglia were assigned 
the P2Xp P2Xj and P2X^ receptor subtypes, with the P2X receptor cloned from 
human urinary bladder appearing to belong to the P2X, subtype.
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The classification and properties of the P2X receptor subunits discussed here are 
outlined in Table 1.7. over the following pages.
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1 .3 .2 3 . P 2Y  R eceptors
P2Y receptors are G-protein coupled receptors, of which five mammalian subunits 
have been cloned and shown in functional studies to be activated by both adenine and 
uridine nucleotides (Lustig et a l, 1993; Webb et a l, 1993; Chang et al., 1995; 
Communi et al., 1995; Nguyen et al., 1995; Communi et al., 1997). The five 
receptors have been termed P2Yj, P2Y ,^ P2Y ,^ P2Y^ and the recently cloned receptor 
which has been tentatively designated as the P2Yj, receptor (Communi et al., 1997). 
It is thought that other P2Y receptors may exist. For instance, an adenylate cyclase 
inhibiting receptor for ADP has been studied in platelets (Hourani & Hall, 1994) and 
specific cell surface receptors for the diadenosine polyphosphates have been proposed 
but not yet identified unequivocally (Pintor & Miras-Portugal, 1993).
In addition, two avian P2Y receptors (Webb et al., 1996; Boyer et al., 1997) and a 
P2Y receptor from Xenopus neural plate (Bogdanov et al., 1997) have been cloned 
and shown in functional studies to be activated by nucleotides. These non-mammalian 
receptors exhibit 50-60% sequence homology with other established mammalian P2Y 
subunits. However, it has not yet been determined whether these receptors have 
homologues in mammals, or whether they correspond to previously defined 
mammalian receptors.
Two additional G protein-coupled receptors have been suggested to be P2Y receptors 
(Akbar gr al., 1996; Webb et al., 1996), namely the proposed P2Y^ and p2y5 (6H1) 
receptors. However, the receptor originally proposed as the human P2Y^ receptor has 
been removed from the current nomenclature for P2Y receptors. Although it has 30% 
sequence identity with the human P2 Y^  receptor, it appears to bind nucleotides in a 
specific series and has a nucleotide-binding consensus sequence, its primary response 
has been shown to be to leukotriene B4 (Yokomizo et al., 1997). The p2y5 receptor
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was identified from the chicken (Webb et a l, 1996), by a specific nucleotide binding 
series. With the most recent update to the P2 receptor nomenclature system this 
receptor, and a possible sequence homologue in the human genome, has been 
designated in lower case since, as yet, no functional response to nucleotides has been 
described.
Cloned mammalian P2Y receptors, when expressed in a null cell line, have all been 
shown to activate phospholipase C (PLC). The P2Yu receptor also activates adenylate 
cyclase in addition to PLC (Communi et al., 1997), although whether both these 
responses are observed when the receptor is expressed in native cells at physiological 
levels has not yet been clearly established.
The identification of P2Y receptor subunits in pharmacological studies has been 
problematic due to the lack of subtype-specific agonists and antagonists. Further, the 
agonist selectivity and potency orders at molecularly defined P2Y receptors has been 
difficult to establish due to the presence of ectonucleotidases on tissues containing P2 
receptors (Zimmermann, 1996).
The human P2Y, (hP2YJ receptor is activated by adenine nucleotides but not by 
uridine nucleotides. ADP is the most potent physiological agonist at the P2Y, 
receptor, although the importance of ATP as an agonist at this receptor has not been 
clearly defined (Leon et al., 1997). The human P2 Y2  (hP2 Y2 ) receptor is activated 
equipotently by ATP and UTP, but is activated at most only partially by diphosphate 
nucleotides (Lustig et al., 1993; Nicholas gr al., 1996). The human P2 Y4  (hP2 Y4 ) 
receptor is activated by UTP but only weakly, if at all, by ATP, UDP and ADP, 
whereas ATP and UTP are equipotent at the rat P2 Y4  (rP2 Y4 ) (Communi et al., 1995; 
Nguyen etal., 1995; Communi et al., 1996 (a); Nicholas et al., 1996).
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By contrast, the rat and human P2Yg receptors (rP2Y^ and hP2Yg, respectively) have 
been cloned and are both UDP-selective receptors and are activated weakly, if at all, by 
UTP, ATP and ADP (Chang et al., 1995; Communi et al., 1996 (b); Nicholas et al., 
1996).
The recently cloned human P2Yj, (hP2Yji) receptor has been shown to be activated by 
ATP and ADP, but not UTP and UDP (Communi et al., 1997).
The P2Yi receptor is the only receptor for which significant progress has been made in 
developing synthetic agonists and antagonists that are of high affinity and 
demonstrable selectivity. For instance, 2-MeSADP is an agonist with low nM affinity 
at the P2 Yi receptor that does not activate P2 Y2 , P2 Y4  or P2 Y^  receptor subunits. 
However, 2-MeSADP has high affinity for the yet to be cloned G/adenylate cyclase- 
linked P2Y receptor, and its activity at the P2Y^ receptor, which is also activated by 
adenine nucleotides, has not been established.
Suramin and reactive blue 2 have been utilised as P2 receptor antagonists, but they 
exhibit only low selectivity between all the P2X and P2Y receptor subtypes. Suramin 
has previously been shown to be an antagonist at both P2Y, and P2 Y2  receptors 
(Charlton et al., 1996). PPADS competitively antagonises the P2Y, and P2 Y4  
receptors but is inactive at the P2 Y2  receptor (Charlton gr al., 1996; Communi et al., 
1996 (a)).
A cDNA encoding a P2 receptor of the P2Y subtype was originally cloned from the 
whole brains of chicks. The agonist potency order at this receptor was identified as 
being 2-MeSATP > ATP > ADP »  AMPCPP = UTP, and for which suramin and 
reactive blue 2 were antagonists. The mRNA for this receptor was detected in chick
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brain, spinal cord, gastrointestinal tract, spleen and leg muscle, but not in the heart, 
liver, stomach, lung or kidney (Webb et al., 1993). A wide distribution of this mRNA 
was subsequently shown in the cerebellum and telencephalon and in specific nuclei of 
the mesencephalon and diencephalon of one day old post-hatched chicks, suggesting a 
neuronal localisation of this P2Y receptor which is believed to be the P2Y^ receptor 
(Webb et al., 1994).
A cDNA has also been isolated from turkey whole brains, which shows >98% 
sequence homology to the cDNA from chick whole brains and encodes a receptor 
which when expressed in isolated cells has a structure-activity relationship 
characteristic of a P2Y receptor. The distribution of turkey mRNA differed slightly 
from that of the chick, as it was widely distributed in brain, lung, blood and, to a 
lesser extent, in the entire gastrointestinal tract and skeletal muscle (Filtz et at., 1994). 
P2Y receptors have also been cloned from bovine aortic endothelial cells (Henderson 
et al., 1995) and from rat and mouse insulinoma cells (Tokuyama et al., 1995), which 
all exhibit approximately 8 6 % sequence homology with the P2Y receptor cloned from 
chick whole brain. As all of these cloned P2Y receptors show a high homology with 
each other they were originally grouped as a single P2Y receptor subtype (namely the 
P2 Y; receptor).
A cDNA encoding a further G-protein coupled receptor, which was initially not 
classed as a P2Y receptor but, rather, a P2U receptor since ATP and UTP were found 
to be equipotent, was originally cloned from mouse neuroblastoma-glioma hybrid 
(NG108-15) cells. At this receptor only ATP, UTP and ATP-y-S were potent 
agonists, whilst 2-MeSATP, AMPCPP, AMPPCP, ADP and adenosine showed little 
or no activity. The mRNA of this receptor is also widely distributed, being found in 
the spleen, testes, liver, kidney, lung, heart, brain and neuroblastoma cells and is
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believed to be the receptor (Lustig et al., 1993). However, this receptor, 
although in the same family of the G-protein coupled receptors as the P2Y, receptor 
previously cloned, shares only approximately 40% sequence homology with them 
(Barnard gf aZ., 1994).
Other cDNAs encoding receptors of the P2Y receptor subtype, which were originally 
classified as P^  ^ receptors, have also been cloned and show widespread but slightly 
different distribution from the P2Y receptor previously cloned from the mouse. A 
P2Y receptor has been cloned from rat alveolar type II cells (Rice et al., 1995) which 
show >97% sequence homology with the mouse P2Y receptor, and from human 
airway epithelial (CF/T43) cells and colonic epithelial (HT29) cells (Parr et al., 1994) 
which shows 89% sequence homology with the mouse P2Y receptor. In addition, 
these P2Y receptors show only 35-40% sequence homology to the previously cloned 
P2Y receptors (Parr etal., 1994; Rice et al., 1995). Since all these cloned P2Y, and 
those initially termed 'P^ '^, receptors are G-protein coupled receptors and show a high 
sequence homology to each other, but not to the previously cloned P2Y receptors, they 
were assigned the original classification of the P2 Yj receptor subtype.
A further P2Y receptor has been cloned from chick whole brain which is also a G- 
protein coupled receptor and when expressed in isolated cells has a strong preference 
for ADP, with ATP having a similar potency and so is thought noit to be the 
homologue of the P2Y (formerly P^ )^ receptor cloned from human platelets. This 
receptor shows only 39% sequence homology to the P2Y receptor previously cloned 
from chick whole brain, and its mRNA has been reported to be present within a 
number of peripheral tissues in addition to the brain (Barnard et al., 1995; Harden et 
al, 1995). Initially this receptor was termed the P2 Y3  receptor.
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In addition to the original classification of P2X, P2Y and P2U receptor clones a 
further receptor subtype with preference for binding pyrimidine nucleotides was 
isolated from human genomic DNA libraries . It was found to be a G-protein coupled 
receptor with a molecular weight of 36.5kDa, but which has no N-glycosylation 
consensus sequence. UTP and UDP have both been shown to be potent and full 
agonists at this receptor, whereas ATP has been shown to be less potent and a partial 
agonist, ADP of low activity and 2-MeSATP to be inactive. However, this P2 
receptor which shows only 35% sequence homology to the cloned chick P2Y receptor 
and 51% sequence homology to the cloned human colonic and airway epithelial P2Y 
(formerly classed the P^ )^ receptor, appears to be a member of the same family of G- 
protein coupled receptors and is suggested to be the P2 Y4  receptor (Communi et a l,
1995).
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1.4. Pharmacological Actions of Adenosine, ATP, UTP and Analogues 
in Smooth Muscle
In a number of tissues the pharmacological actions of adenosine, ATP, UTP and a 
number of structural analogues of these have been investigated and have been shown 
to be mediated via PI and P2 receptors. These tissues include visceral smooth muscle 
of the gastrointestinal tract, vas deferens, urinary bladder, vascular smooth muscle and 
endothelial cells. In most of these tissues there is a heterogeneous population of both 
PI and P2 receptors, as well as ectonucleotidases which rapidly dephosphorylate 
ATP, and some, but not all, of its structural analogues to adenosine. For this reason, 
a short discussion of the action of PI receptors these tissues has been included in each 
case.
1.4.1. Cardiovascular System
Adenosine regulates coronary blood flow and has negative dromotropic, chronotropic 
and inotropic effects on the heart (Fredholm & Sollevi, 1986). These effects of 
adenosine can be mediated directly via PI receptors. Adenosine acts on A, receptors 
on the atrioventricular node resulting in bradycardia and the observed agonist potency 
order is CPA > R-PIA > NECA > 2-CADO (see Olsson & Pearson, 1990). Aj 
receptors have also been shown on atria producing negative inotropic effects causing a 
decrease in the force of contraction of the heart (Collis, 1983), where a decrease in the 
action potential and an increase in the potassium conductance is observed (Jahnel & 
Nawarth, 1989). Adenosine has little direct effect on the ventricular myocardium, 
however, it has been shown to have an inhibitory effect on the positive inotropic effect 
of catecholamines (Bellardinelli & Isenberg, 1983).
82
Adenosine mediates the vasodilation of a number of blood vessels. The order of 
potency of adenosine and its structural analogues for the relaxation of coronary blood 
vessels is NECA > R-PIA > 2-CADO and the antagonist DPCPX has micromolar 
affinity, suggesting that adenosine mediates vasodilation via A^  receptors (Ramogopal 
et a i, 1988). In the guinea-pig coronary artery the presence of A^^^  receptors and in 
the rat coronary artery the presence of Aj^  ^ and A^ g receptors and a further undefined 
xanthine resistant receptor has been shown (Otley et a i, 1996). In the rat aorta, 
adenosine has been proposed to relax the tissue via Aj^ receptors due to the high 
potency of CGS21680 compared to NECA (Lewis et al., 1994). However, in this 
tissue relaxant responses to stimulation of other, non-A^^ receptors has also been 
observed. An A^ g receptor present on the smooth muscle of the rat aorta which is 
activated by R-PIA and CPA, and also an additional site has been shown (Prentice & 
Hourani, 1996).
The location of A2  receptors in blood vessels was suggested originally to be on the 
vascular smooth muscle cells (Collis & Brown, 1983). However, it was subsequently 
observed that removal of the endothelium resulted in a reduction of the relaxant 
response to adenosine in the guinea-pig aorta (Rose'Meyer & Hope, 1990). It was 
suggested that an endothelium-dependent mechanism may also be involved in the 
response of this tissue to adenosine. In the rat aorta responses to adenosine are 
abolished in endothelium denuded preparations and by the nitric oxide synthase 
inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), showing an endothelium- 
dependent mechanism via the nitric oxide pathway (Lewis et al, 1994). The presence 
of Aj receptors was also shown in the guinea-pig aorta, where they mediate 
vasoconstriction. The physiological importance of this is not known however, since
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the A, receptor mediated response is only revealed when the Aj receptor mediated 
effect is blocked (Stoggall & Shaw, 1990).
In contrast to adenosine, ATP is not thought to have an important effect on the heart. 
Although ATP has been shown to induce negative inotropic effects by an action on 
P2X receptors (Froldi et al., 1994).
ATP is known to modulate the vascular tone of blood vessels by an action on P2 
receptors which are located both on the endothelial cells and the vascular smooth 
muscle cells. In general, vasoconstriction is mediated via P2X receptors located on the 
vascular smooth muscle cells, whereas vasodilation is mediated via P2Y receptors 
located on the endothelium, although there have been a few notable exceptions 
(Burnstock & Kennedy, 1985; 1986; Pearson & Gordon, 1989; Ralevic & Burnstock,
1991).
ATP produces vasodilation of blood vessels via P2Y receptors which have been 
shown to be located on endothelial cells, since removal of the endothelium from a 
number of blood vessels including the canine femoral artery (De Mey & Vanhoutte, 
1981), rat femoral artery (Kennedy et al., 1985), canine coronary artery (Houston et 
al., 1987), rat pulmonary vessels (Liu et al., 1989) and rat mesenteric arterial bed 
(Ralevic & Burnstock, 1988) has been shown to abolish the relaxations induced by 
ATP. Stimulation of the P2Y receptors on the endothelium by ATP results in the 
release of endothelium-derived relaxing factor (EDRF) (Pearson & Gordon, 1989; 
Boeynaems & Gordon, 1990), since identified as nitric oxide (NO) (Palmer et al., 
1987; 1988), which relaxes the adjacent layers of smooth muscle. ATP has also been 
shown to release prostaglandins, such as prostacyclin (PGI2), from endothelial cells 
(Pearson & Gordon, 1989; Boeynaems & Pearson, 1990), which contributes to
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endothelium-dependent vasodilation in some blood vessels. There are, however, 
differences in the formation of the two effector molecules, PGI2 and NO, in response 
to ATP acting at P2Y receptors. Whereas PGI2 release is rapid and transient, NO 
release is rapid and sustained. Furthermore, the release of PGI2 is subject to P2Y 
agonist-specific desensitisation whereas NO release is not (Boeynaems & Pearson, 
1990).
The suggestion that P2Y and P2U receptors existed on vascular endothelial cells was 
first proposed by O'Connor et al. (1991), although the relative contributions of these 
receptors to the response to ATP varies between vascular tissues. In endothelial cells 
derived from the micro vasculature of bovine adrenal medulla (Allsup & Boarder, 
1990; Wilkinson et al., 1993), rabbit microvessels from cardiac muscle (Mannix et al.,
1993) and rat brain (Frelin et al., 1993), hydrolysis of inositol phosphate in response 
to ATP was initially proposed to be mediated by P2U receptors. In contrast, the cell 
line AG4762 derived from bovine aortic endothelial cells have been shown to contain 
only P2Y receptors (Allsup & Boarder, 1990), whereas both P2Y and P2U receptors 
were originally proposed to coexist on bovine aortic endothelial cells (Motte et al., 
1993; Purkiss etal., 1994; Wilkinson et al., 1993; 1994; Communi et al., 1995) and 
bovine aortic collateral artery rings (Wilkinson et al., 1994).
In the canine basilar artery it has been demonstrated that whilst vasoconstriction 
elicited by AMPCPP and AMPPCP occurs in the presence and absence of 
endothelium, that elicited by 2-MeSATP is effectively abolished by removal of the 
endothelium. Further, both reactive blue 2 and aspirin attenuate the vasoconstriction 
induced by 2-MeSATP but not AMPCPP. It was suggested that in addition to a 
vasoconstriction-mediating P2X receptor on the smooth muscle, there is an additional
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endothelium-dependent, vasoconstriction-mediating P2 receptor for which 
thromboxane (TXA^) was proposed to be the mediator (Shirahase et al., 1991).
P2X receptors have been shown to mediate vasoconstriction in a number of blood 
vessels, including the rabbit ear artery (Leff gf al., 1990; O'Connor et al., 1990), rat 
portal vein (Reilly & Burnstock, 1987), rat and human pulmonary vessels (Liu et al., 
1989a, b), rabbit and rat mesenteric artery (Burnstock & Warkand, 1987; Ralevic & 
Burnstock, 1988; Windscheif et al., 1994), dog coronary artery (Houston et al., 
1987), rat femoral artery (Kennedy et al., 1985) and rat coronary blood vessels 
(Hopwood & Burnstock, 1987). In addition, to a higher potency of AMPCPP than 
ATP in eliciting vasoconstriction, desensitisation to AMPCPP (Houston et al., 1987; 
Ralevic & Burnstock, 1988; Leff et al., 1990; O'Connor et al., 1990), as well as 
antagonism by suramin (Leff et al., 1990) and PPADS (Windscheif et al., 1994; 
Ziganshin et al, 1994) have also been demonstrated. The location of the P2X receptor 
is on the vascular smooth muscle as removal of the endothelium has been shown not to 
abolish vasoconstriction in response to nucleotides, but often to enhance them 
(Kennedy et al., 1985; Ralevic & Burnstock, 1988; Liu et al., 1989; Ralevic & 
Burnstock, 1991; Shirahase 1991).
In the smooth muscle of the rat tail and femoral arteries and canine saphenous vein it 
has been proposed that ATP and UTP elicit vasoconstriction via a P2X receptor and a 
P2Y receptor (initially classified as a P2U pyrimidinoceptor), respectively. This was 
based on the observations that ATP but not UTP induced contractions are desensitised 
by AMPCPP, and that ATP and UTP desensitised responses to themselves hot no 
cross-desensitisation was observed (Saiag et al., 1987; 1990). It has also been 
proposed that in the rabbit basilar artery that UTP induced contractions are mediated 
via a P2Y receptor, whereas ATP induced contractions are mediated via a P2 receptor
8 6
distinct from a P2X receptor. This was based on the observations that while ATP-y- 
S, ATP and UTP were shown to elicit marked contractions, unlike AMPCPP, 
AMPPCP and 2-MeSATP which were effectively inactive, subsequent responses to 
ATP were reduced following prolonged exposure to ATP-y-S, whilst subsequent 
responses to UTP were slightly enhanced. In addition, ATP was found to elicit 
marked additional vasoconstriction following precontraction with UTP, whereas UTP 
elicited only a slight additional response following precontraction with htself (Von 
Kugelgen & Starke, 1990).
Vasonconstriction-mediating receptors at which UTP is equipotent with ATP, 
originally classified as P2U receptors for this reason, have been identified in a number 
of blood vessels including the rat mesenteric vascular bed (Ralevic & Burnstock, 
1991; Windscheif et al., 1994), rabbit aorta (Pavestadt et al., 1991; Chinellato et al.,
1992), bovine aortic smooth muscle cells (Demolle et al., 1988) and rat pulmonary 
artery (Rubino & Burnstock, 1995).
Although P2Y receptors have classically been described as existing on endothelial 
cells, it has been shown in some blood vessels, such as the rabbit portal vein 
(Kennedy & Burnstock, 1985), rabbit mesenteric artery (Mathieson & Burnstock, 
1985), rabbit hepatic artery (Brizzolara & Burnstock, 1991) and human pulmonary 
arteries (Liu etal., 1989), that P2Y receptors mediating vasodilation are located on the 
vascular smooth muscle. This has been largely based on the observations that removal 
of the endothelium does not affect relaxations induced by ATP, and that these are not 
mediated directly via its degradation to adenosine, as while adenosine also elicits 
endothelium-dependent relaxations, PI receptor antagonists such as 8 -PT antagonise 
responses to adenosine but not those to ATP.
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1.4.2. Gastrointestinal Tract
The gastrointestinal tract is composed of a number of tissues including stomach, 
duodenum, ileum, colon and taenia caeci. In the case of the duodenum, ileum and 
colon the outer section of the smooth muscle layer is comprised of the longitudinal 
muscle, whilst the thicker, more muscular inner layer is the muscularis mucosae. In 
many cases there have been different populations of receptors and receptor subtypes in 
each of the two layers and where it is known that differences exist between the two 
layers the results are reviewed here.
1.4.2.1. Stomach
The longitudinal muscle of the rat gastric fundus relaxes in response to both nerve 
stimulation and exogenously added purines with an agonist potency order of 2 - 
MeSATP »  AMPCPP > ATP »  adenosine. Further, relaxations induced by ATP 
and 2-MeSATP, but not AMPCPP or adenosine are biphasic in nature and exhibit 
rebound contractions (Hunt et al., 1983; Lefebvre & Burnstock, 1990; Matharu & 
Hollingsworth, 1992). Also, the relaxant response to ATP and a number of analogues 
has been shown to be related to the critical tone of the tissue. When the tone was 
raised by an initial submaximal dose of carbachol, ATP induced a larger relaxation 
followed by a smaller contraction. The contractile response to ATP was reduced by 
indomethacin and the P2 receptor antagonist, while reactive blue 2 inhibited the 
relaxant responses (Lefebvre & Burnstock, 1990).
The observation that contractions are antagonised by indomethacin (Lefebvre & 
Burnstock, 1990) and that rebound contractions are seen in a number of other 
gastrointestinal tissues has led to the suggestion that they may play a role in peristalsis 
and have been shown to result from prostaglandin synthesis via activation of relaxant 
P2 receptors (Burnstock gr aZ., 1975; Brown & Burnstock, 1981). However, whereas 
in the presence of indomethacin initial desensitisation with AMPCPP was shown to 
completely abolish relaxations to ATP, contractions induced by ATP were increased, 
which implies that contractions are not a completely secondary response to relaxation 
and, therefore, not true rebound contractions (Matham & Hollingsworth, 1992). It 
has therefore been proposed that in the rat gastric fundus longitudinal muscle there are 
separate receptors which mediate relaxation and contraction. As 2-MeSATP is more 
potent than ATP, and AMPCPP is inactive in inducing contractions in the presence and 
absence of indomethacin, contractile responses are thought to be mediated via a P2Y 
receptor. In contrast, AMPCPP is more potent than ATP in inducing relaxation and 
complete desensitisation is seen to AMPCPP, which has led to the proposal of the 
existence of a relaxant P2X receptor. However, in the presence of AMPCPP only 
partial desensitisation is observed to 2-MeSATP and it has been suggested that 2- 
MeS ATP-induced relaxant responses are mediated by a second mechanism in addition 
to a P2X receptor, at which ATP and AMPCPP act.
Despite the evidence that responses to exogenous ATP are similar to those elicited by 
NANC nerve stimulation in a number of stomach preparations, and quinacrine-positive 
fibres have been observed in rat stomach (Crowe & Burnstock, 1981), the suggestion 
that ATP is the NANC neurotransmitter in the stomach has not been widely accepted 
mainly due to the fact that desensitisation to ATP has been shown not to reduce 
relaxations evoked by nerve stimulation (Baer & Frew, 1979). However, the use of 
ATP as a desensitising agent has produced mixed results (Ambache & Zar, 1970).
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Adenosine can also induce relaxations of stomach preparations, such as the rat gastric 
fundus longitudinal muscle, via relaxant PI receptors which are blocked by 8 -SPT and 
potentiated by NBTI (Matharu & Hollingsworth, 1992) and has also been shown to 
inhibit gastric acid secretion via A, receptors present on parietal cells (Okwusaba et a l, 
1977; Westerberg & Geiger, 1989). There is also evidence that increased mucosal 
blood flow associated with increased gastric acid secretion is also mediated by 
adenosine since it is sensitive to blockade by the PI receptor antagonist 8 -PT (Gerber 
& Smith, 1989).
1.4.2.2. Duodenum
NANC nerve stimulation of the duodenum results in a transient relaxation which is 
followed by a contraction. Both components of the response to nerve stimulation are 
mimicked by ATP, however, the contractile response is thought to be due to 
prostaglandin synthesis, since the response is abolished by indomethacin (Manzini et 
al., 1985). Responses to ATP are antagonised by the enzymatic degradation of ATP 
to AMP, reactive blue 2 and prior desensitisation of P2 receptors by AMPCPP 
(Manzini et al., 1985; 1986). However, there have been conflicting reports of the 
antagonist action of reactive blue 2 on NANC nerve stimulated responses, and there is 
therefore not total acceptance that ATP is the sole NANC neurotransmitter in the 
duodenum (Serio et al., 1990). Further evidence against ATP being the only 
transmitter of NANC innervation to the duodenum is that desensitisation caused by 
AMPCPP does not significantly affect nerve-mediated responses. Histological 
studies have provided evidence for the presence of vasoactive intestinal polypeptide 
(VIP) in the gastrointestinal tract and it has been proposed as a putative transmitter. 
However, VIP produces a sustained relaxation which does not exhibit the same
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characteristics as nerve stimulation and chymotrypsin reduces responses to VIP but 
has no effect on nerve-mediated or ATP-induced responses (Manzini et al, 1985).
Adenosine also has an inhibitory effect on the duodenum and is thought to act via PI 
receptors since 8 -SPT and theophylline antagonise responses to adenosine but not 
those to ATP (Gaion et al, 1988; Furukawa & Nomoto, 1989; Hourani gr al., 1991). 
However, relaxations to AMPPCP, unlike responses to ATP, 2-MeSATP and 
AMPCPP, are antagonised by 8 -SPT. As AMPPCP is resistant to degradation by 
ectonucleotidases, unlike ATP, AMPPCP-induced relaxant responses appear to be due 
to a direct action at PI receptors (Hourani etal., 1991). It has been shown that there is 
a heterogeneous population of PI receptors in rat duodenum, as the agonist potency 
order for PI agonist in this tissue is NECA > CPA > AMPPCP = adenosine > 
CGS21680, which is not characteristic of any known PI receptor subtype. 
Furthermore, DPCPX (InM) antagonises relaxations to CPA and AMPPCP, and only 
at micromolar concentrations those induced by NECA and adenosine. This has led to 
the proposal that the PI receptors present in the rat duodenum are a mixture of A, and 
Aj subtypes and, given the low potency of CGS21680 in the rat duodenum, the Aj 
subtypes were proposed to be of the Ajg subclass (Nicholls et al., 1992). Binding 
studies using pHJDPCPX in whole rat duodenum have provided evidence for the 
existence of a high affinity single site with a for DPCPX in the nanomolar range, 
confirming the presence of A, receptors in this tissue (Peachey et al, 1994).
The agonist potency order in mediating relaxations of the rat duodenum has been 
shown to be 2-MeSATP > ATP > AMPCPP > AMPPCP, which is characteristic of a 
P2Y receptor (Nicholls et al., 1990; Hourani et al., 1991). Both suramin and PPADS 
(10-lOOp.M) cause a rightward shift in the relaxation concentration-response curves to 
2-MeSATP, a response characteristic of P2Y receptors. This evidence also supports a
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direct action of AMPPCP at the A, subtype, and not an indirect action via its 
degradation to adenosine, since the micromolar concentration of DPCPX required to 
antagonise relaxations to adenosine indicates its action at the Aj receptor subtype, 
unlike AMPPCP. The low potency of CGS21680 indicates that the Aj subtype is an 
Ajg receptor (Nicholls et al., 1992). It has since been demonstrated in studies using 
the separated layers of the rat duodenum that the muscularis mucosae contains a 
contractile-mediating Ajg receptor and the longitudinal muscle contains both Aj and 
Ajg receptors which both mediate relaxation, as is the case in the whole tissue 
(Nicholls graZ., 1995).
Furthermore the rat duodenum has been shown to degrade ATP rapidly and 
sequentially to ADP, AMP, adenosine and inosine, with approximately 90% of ATP 
degraded after a 20 minute incubation period. However, whilst inosine is the end 
product of ATP degradation in the presence of the duodenum, the end product in the 
incubation buffer where the tissue had previously been incubated and then removed 
was AMP, evidence that the enzymes responsible are not purely membrane-bound 
ectoenzymes but also soluble enzymes which leaked into the incubation medium. 
However, degradation of AMP to adenosine appears to be solely due to an ecto 5’- 
nucleotidase (Nicholls graZ., 1992).
ATP is much more potent than adenosine in relaxing the rat duodenum and responses 
to ATP and electrical stimulation are resistant to blockade by 8 -PT, indicating that 
relaxant responses are not mediated by PI receptors (Manzini et al., 1995; 1996). 
Contractions to UTP and to ATP-y-S have also been shown and this was thought to 
be evidence for the existence of a Pj^, now the P2Yj receptor (Johnson & Hourani, 
1994).
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More recently, studies in the separated layers of the rat duodenum have demonstrated 
the presence of P2 receptors (Johnson etal., 1996). Relaxations via P2Y receptors in 
the longitudinal muscle have an agonist potency order of 2-MeS ATP > ATP = ATP-y- 
S > AMPCPP (Johnson et al., 1996). Contractions in the muscularis mucosae via a 
mixed population of Pju and P2X receptors were also shown to have the agonist 
potency order ATP-y-S > AMPCPP = ATP = UTP »  2-MeSATP (Johnson et al.,
1996), and responses were insensitive to blockade by suramin, indicative of a P2Yj- 
or P2 Y4 -mediated component (previously classified as a Pj^-mediated response). The 
potency of ATP-y-S in both the longitudinal muscle and the muscularis mucosae of the 
rat duodenum is further evidence for the existence of both P2X- and P2Yj-mediated 
components of the relaxant response to this agonist (Johnson et al., 1996). In 
addition, the rat duodenum muscularis mucosae also exhibits responses to AMPCPP 
via P2X receptors with an agonist potency order AMPCPP > 2-MeS ATP and 
responses were antagonised by suramin, whereas those to ATP and UTP were 
equipotent in this tissue and were insensitive to blockade by suramin, suggesting that 
responses to ATP and UTP in this tissue are mediated via Pj^ receptors (Johnson et 
al., 1996). ATP-y-S has been suggested to activate both P2X and Pju receptors in 
this tissue (Johnson 1996).
1.4.2.3. Ileum
There is much less evidence that ATP is the NANC transmitter in the ileum than for the 
duodenum (Bauer & Kuriyama, 1982). Adenosine and adenine nucleotides can relax 
rabbit and guinea-pig ileum and it is believed they act by inhibiting ACh release 
(Wiklund et al., 1985). ATP appears to act via PI as opposed to P2 receptors and 
some workers have suggested that ATP can act following degradation to AMP (Moody 
et al., 1984), whilst others have shown that ATP can have a direct action on PI
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receptors (Wiklund & Gustafsson, 1986). In addition, as previously mentioned, 
NANC nerve stimulation in the rat duodenum is sensitive to ATP desensitisation and 
to ATP degradation by ectonucleotidases, whereas in the rat ileum responses to NANC 
nerve stimulation are insensitive to either ATP desensitisation and ATP degradation, 
suggesting that ATP is not the neurotransmitter in the ileum (Manzini et a l, 1986). 
ATP and adenosine act on the guinea-pig ileum to inhibit the nerve-mediated release of 
ACh. The site of action of adenosine and ATP is via a prejunctional A, receptor and 
further, the action of ATP has been demonstrated to be due to its subsequent sequential 
dephosphorylation to adenosine since nanomolar concentrations of DPCPX antagonise 
the ATP response (Moody & Burnstock, 1982; Coates et al., 1984; Wiklund et al., 
1985). It would appear, therefore, that ATP is not the neurotransmitter released 
following NANC nerve stimulation in the ileum
Adenosine has been shown to have an inhibitory action on ACh release in the 
gastrointestinal tract and on peptidergic transmission in guinea-pig ileum. The potency 
order of PI agonists for inhibiting tachykinin release was CPA > NECA > CV1808. 
Concentrations of DPCPX in the nanomolar range caused inhibition of responses to 
receptor agonists, suggesting the existence of an A, subtype (Christofi et al., 1990). 
Studies on epithelial cells in the mucosa of the ileum have shown that adenosine 
lowers intracellular cyclic AMP (cAMP) levels, and that this is an receptor-mediated 
event (Raymann & Gneiss, 1988).
ATP may also have excitatory effects in the ileum. In the guinea-pig ileum 
longitudinal muscle ATP resulted in contractile responses (Kennedy & Humphrey, 
1994). In the same tissue, AMPCPP activates prejunctional P2X receptors, as 
responses were abolished by atropine and tetrodotoxin (Kennedy & Humphrey,
1994). A postjunctional receptor has also been identified with a potency order of 2-
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MeSATP > ATP, suggesting a P2Y receptor mediating contraction of the guinea-pig 
ileum. Wiklund & Gustafsson (1988) had earlier suggested a novel purinoceptor 
subtype, a Pjg receptor, since responses were insensitive to desensitisation with 
AMPCPP or antagonism by reactive blue 2. However these observations can also be 
explained in terms of activation of prejunctional P2X receptors by ATP and P2Y 
receptors on the smooth muscle by 2-MeSATP (Kennedy & Humphrey, 1994). UTP 
is inactive in the guinea-pig ileum longitudinal muscle, suggesting an absence of Pju 
receptors in this tissue (Kennedy & Humphrey, 1994).
The inclusion of 5’-nucleotidase and adenosine deaminase reduced the responses to 
ATP, whereas responses were potentiated by the adenosine uptake inhibitor 
dipyridamole (Moody & Burnstock, 1982; Moody et al, 1984). In contrast, a direct, 
inhibitory action of ATP on ACh release has been proposed, since the inhibitory action 
of ATP is enhanced in the presence of inosine 5’-triphosphate (ITP) and inosine 5’- 
diphosphate (IDP) (Wiklund & Gustafsson, 1986), which have been shown to inhibit 
the degradation of ATP and ADP in porcine aortic endothelial and smooth muscle cells 
(Pearson effl/., 1980).
ATP and a number of its structural analogues have also been shown to contract the 
whole guinea-pig ileum and longitudinal muscle (Moody & Burnstock, 1982; Wiklund 
e ta l, 1985; Wiklund & Gustafsson, 1988a, 1988b; Kennedy & Humphrey, 1994) 
whereas AMP and adenosine exhibit no such response, indicating the presence of P2 
receptors. The agonist potency order for contractile responses of the guinea-pig ileum 
longitudinal muscle is 2-MeSATP > ATP = ADP, and that ATP-mediated contractile 
responses are not antagonised by the P2Y receptor antagonist reactive blue 2, nor do 
they exhibit desensitisation by AMPCPP (Wiklund & Gustafsson, 1988b). Since the 
characteristics of this receptor did not fit the classical P2X and P2Y receptor
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classification of the time as proposed by Burnstock & Kennedy (1985), the authors 
designated a novel subtype of P2 receptor, a Pjg receptor. However, it was 
subsequently found that reactive blue 2 shows only partial selectivity for the P2Y 
receptor within a narrow micromolar concentration range (Kennedy, 1990), and 
cannot therefore be considered selective for the P2Y subtype when used at the 
millimolar concentrations as used by Wiklund & Gustafsson (1988b). In addition, 
whilst desensitisation of responses to ATP by AMPCPP exposure has been used 
classically as evidence for the presence of the P2X subtype, recent data from cloned 
P2X receptors has shown that although desensitisation occurs rapidly at the P2X 
subtype cloned from rat vas deferens (Valera et al., 1994) and rat dorsal root ganglia 
(Chen et al., 1995), at the P2X subtype cloned from rat PC 12 cells desensitisation 
occurs only slowly and not to AMPCPP at all, which is inactive at this cloned P2X 
receptor (Brake et al., 1994). The suggestion of a Fjs receptor was therefore not 
widely accepted.
I.4.2.4. Colon
The smooth muscle of the rat colon has been shown to contain a heterogeneous 
population of PI and P2 receptors which mediate both contraction and relaxation. As 
in the duodenum and the ileum studies have revealed a differential location of
these receptors in the muscularis mucosae and longitudinal muscle of the colon.
The rat colon longitudinal muscle relaxes in response to purines with an agonist 
potency order of NECA > CPA = AMPCPP > adenosine = AMPPCP = ATP, and the 
PI antagonist DPCPX (3|iM) antagonises responses induced by each of the agonists 
with the exception of AMPCPP. The potency order for adenosine and its analogues 
and the high concentration of DPCPX required for inhibition of responses indicates the
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presence of a PI receptor of the Aj subtype. Since adenosine deaminase abolishes 
relaxations induced by adenosine and inhibits those responses to ATP and AMPPCP, 
it appears that both ATP and AMPPCP are acting indirectly at this receptor following 
their breakdown to adenosine. The evidence is that ATP and AMPPCP are degraded 
to adenosine in the rat colon longitudinal muscle (Bailey & Hourani, 1992).
In contrast, relaxations induced by AMPCPP, which is degraded to AMPCP, are 
antagonised by suramin, whereas those induced by the other agonists are resistant to 
antagonism. Since the potent P2X selective agonist L-AMPPCP is inactive, it has 
been suggested that there is also a relaxant P2Y receptor present, at which AMPCPP is 
acting (Bailey & Hourani, 1992). However, 2-MeSATP is only a weak agonist in this 
tissue and this is believed to be due to its degradation to 2 -methylthioadenosine, which 
is known to be much less active than adenosine in the guinea-pig taenia caeci (Satchell 
& Maguire, 1975). This has been used to explain the relative lack of activity of 2- 
MeSATP in the rat colon longitudinal muscle (Bailey & Hourani, 1992).
The rat colon muscularis mucosae has been shown to contract in response to purines. 
The agonist potency order for adenosine and its analogues in inducing contractile 
responses is CPA > NECA > adenosine, and DPCPX at nanomolar concentrations 
inhibits these contractions. This is indicative of the presence of A, receptors (Bailey et 
al., 1992). The rat colon muscularis mucosae also contracts in response to AMPPCP 
with a potency order of AMPPCP > adenosine, and AMPPCP-mediated contractions 
are inhibited by DPCPX (InM). Since AMPPCP is not significantly degraded by the 
rat colon muscularis mucosae (Bailey & Hourani, 1990), it has been suggested that 
responses are due to a direct action of AMPPCP on A, receptors (Bailey et al., 1992). 
In addition, while suramin had no effect on responses to adenosine or AMPPCP, 
those induced by AMPCPP were completely abolished which suggests the
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involvement of a P2 receptor. Contractions to ATP were not significantly decreased 
by DPCPX, only partially inhibited by suramin and effectively abolished by a 
combination of both DPCPX and suramin, indicating both an A, and a P2 component 
to its action (Bailey eta l, 1992).
As the order of potency of nucleotides inducing contraction of the rat colon muscularis 
mucosae is 2-MeSATP > ATP > AMPCPP, it has been proposed that they are acting at 
a P2Y receptor (Bailey & Hourani, 1990). However, a lower maximal response is 
seen for 2-MeSATP than to ATP (Bailey & Hourani, 1990), similar in nature to that 
seen in tissues previously described as containing a heterogeneous population of Pj^ 
and P2Y receptors (O’Connor et a l, 1991). As the responses to UTP have not been 
investigated in the rat colon muscularis mucosae, the presence of an additional Pj^ 
contraction-mediating receptor was not discounted at that time.
1.4.2.5. Taenia Caeci
The guinea-pig taenia caeci has been a central tissue in the development of the 
hypothesis for the existence of purinergic nerves since it was shown by Bennett et a l 
(1966) that stimulation of intramural nerves resulted in a relaxant response which was 
followed by a rebound contraction resistant to sympathetic blockade. It was not until 
1973, however, that Tomita & Watanabe showed that ATP mimicked the nerve- 
mediated response.
Studies using the luciferin-luciferase assay (Burnstock et al, 1978) have demonstrated 
the release of ATP from intramural nerves, although it is believed the degradation of 
ATP by this tissue requires a superfusion assay to be used in order to observe ATP 
release from nerve endings (White et a l, 1981). The enzyme nucleotide
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ipyrophosphatase has also been shown to antagonise the responses of the taenia caeci 
to both ATP and field stimulation of intramural nerves (Satchell, 1981).
The agonist potency order in this tissue for P2 receptor agonists is 2-MeSATP > ATP 
>= AMPCPP > AMPPCP (Satchell & Maguire, 1975; Burnstock & Kennedy, 1985). 
ATP is thought to relax the taenia by Ca^  ^ mobilisation which activates apamin- 
sensitive K  ^channels, resulting in hyperpolarisation, a mechanism which is consistent 
with a PLC-coupled receptor (Den Hertog, 1982). The P2Y receptor present on the 
guinea-pig taenia caeci is thought to be of the P2Y, subtype based on the potency of 2- 
MeSATP. The P2Y receptors present on the guinea-pig taenia caeci are unlikely to be 
of the P2Yj or P2Y^ subtypes since UTP is much less potent than ATP in this tissue 
(Piper & Hollingsworth, 1995; Brown & Burnstock, 1981).
However, AMPCPP activates apamin-sensitive K  ^channels directly as well as via the 
mobilisation of intracellular Ca^  ^ (Den Hertog et al., 1985). This would suggest the 
existence of a relaxant P2Y receptor and an additional P2 receptor. The additional 
receptor is known not to be a P2X receptor since the potent P2X agonist, L-AMPPCP 
is inactive in this tissue (Hourani et al., 1985).
In addition, responses to AMPCPP showed higher sensitivity to the P2 receptor 
antagonist PPADS than those induced by ATP and 2-MeSATP, suggesting both 
PPADS-sensitive and PPADS-insensitive P2 receptors are present in the guinea-pig 
taenia caeci (Windscheif et al., 1995), whereas responses to ATP were found to be 
inhibited by suramin (Den Hertog et al., 1989; Hoyle et al., 1990). However, a 
further complication is that both suramin and PPADS are known to possess 
ectonucleotidase inhibitory properties (Windscheif et al., 1995).
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Adenosine has also been shown to relax the guinea-pig taenia caeci, although the 
observed response is much slower than that to ATP or to field stimulation (Cusack & 
Planker, 1979). The response to adenosine is also antagonised by theophylline, 
whereas that to ATP is unaffected (Brown & Burnstock, 1981). The potency order of 
adenosine agonists in the guinea-pig taenia caeci is NECA > 2-CADO > R-PIA > CHA 
> S-PIA > adenosine. A micromolar concentration of DPCPX was required to 
antagonise responses to those agonists, which suggests the activation of Aj receptors 
(Burnstock etal., 1984; Prentice et al., 1995). More recently the Aj receptors on the 
guinea-pig taenia caeci have been identified as the Ajg subclass (Prentice et al., 1997), 
due to the absence of relaxant responses to the Aj^ receptor-selective agonist, 
CGS21680, and the pKg value of 7.80 for ZM241385 against NECA, which is more 
consistent with the reported adenosine Ajg receptor affinity for this compound (pAj = 
7.06 against adenosine in guinea-pig aorta) than with its reported adenosine Aj^ 
receptor affinity (pAj = 9.02 against CGS21680 in the guinea-pig Langendorff heart 
preparation) (Poucher et al., 1995). This is consistent with a report of high levels of 
adenosine Ajg receptor mRNA expressed in the intestine, caecum and urinary bladder 
of the rat (Stehle et al., 1992).
A component of the relaxant response to AMPPCP was shown to be attributable to its 
breakdown to adenosine, which then acts via A2 receptors (Hourani et al., 1991). In 
addition to this the relaxant response to adenosine of the 5-methylfurmethide pre­
contracted guinea-pig taenia caecum was found to be resistant to blockade by 8 -PT or 
micromolar concentrations of DPCPX and also biphasic in the presence of the 
adenosine uptake blocker dipyridamole (Prentice et al., 1995). The potent Aj receptor 
agonist NECA, which is not significantly removed from the extracellular compartment 
by uptake processes (Collis et al., 1983; Burnstock et al., 1984) was also shown to 
exhibit a biphasic relaxant response in guinea-pig taenia caecum. The first phase of the
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concentration-effect curves to NECA were right-shifted in a concentration-dependent 
manner by both 8 -PT and DPCPX (0.3-10jLiM) and became monophasic in the 
presence of higher concentrations of DPCPX (30jiM) (Prentice et a l, 1995). The 
authors concluded that both adenosine and its analogue NECA elicited both Aj and 
non-Aj-receptor mediated relaxant responses in the guinea-pig taenia caecum and, 
under conditions where adenosine uptake processes were optimal, non-Aj-receptor 
mediated responses predominate.
The P2 antagonist and ectonucleotidase inhibitor, DIDS, which has been shown to 
block responses mediated via the P2 Xj (formerly Pj^) receptor in rat parotid acinar 
cells (Soltoff et al., 1993) and the P2X receptor in rat vas deferens (Biiltmann & 
Starke, 1994), was found to block responses to AMPCPP but not to ATP, 2- 
MeSATP, ADP-p-S or adenosine in the guinea-pig taenia caeci (Dudeck et al., 1995). 
However, the lack of potency of L-AMPPCP indicates an absence of P2X receptors in 
this tissue (Hourani et al., 1985). There is evidence that DIDS inhibits the 
extracellular breakdown of ATP and 2-MeSATP in the taenia caeci, but this is unlikely 
to explain the differential antagonism of AMPCPP, 2-MeSATP and ATP-induced 
relaxations, as responses to the P2Y selective agonist ADP-p-S (resistant to 
breakdown to ectonucleotidases) were not antagonised by DIDS. It has therefore been 
proposed that there is a heterogeneous population of relaxation-mediating P2Y 
receptors in the taenia caeci, comprising a P2Y receptor which is insensitive to DIDS 
(for which the agonist potency order in the presence of DIDS is 2-MeSATP »  ATP 
»  AMPCPP) and an additional relaxant DIDS-insensitive P2 receptor at which 
AMPCPP can act (Dudeck et al., 1995).
ATP and 2-MeSATP have been shown to be rapidly degraded by ectonucleotidases 
present on the guinea-pig taenia caeci to their corresponding nucleosides, whereas
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AMPCPP and AMPPCP were shown to be much more resistant to degradation. As 2- 
MeSATP is more potent and the methylene phosphonates less potent than ATP in 
inducing relaxation, this suggests that there is no distinct relationship between the 
relative potency of an analogue at the P2Y receptor subtype and its degradation 
(Welford er fl/., 1986).
1.4.3. Vas Deferens
The smooth muscle of the vas deferens is innervated by the sympathetic nerve fibres of 
the hypogastric nerve. Stimulation of this nerve results in a biphasic contraction where 
the initial twitch-like contraction has been demonstrated to be due to the release of 
ATP, and referred to as the 'purinergic component', and the second, slower 
contraction is due to the release of noradrenaline (Meldrum & Burnstock, 1983; Fedan 
et al., 1986; Burnstock, 1990; Von Kugelgen & Starke, 1991). As contractions for 
the initial phase are blocked by ANAPP3 (Fedan et a l, 1982; Sneddon et al., 1982), 
suramin (Von Kugelgen et al., 1989; Mallard et al., 1992; Sneddon et al., 1992) and 
by desensitisation with AMPCPP (Meldrum & Burnstock, 1983) it is thought that they 
are mediated by ATP activating P2X receptors. In contrast, the second phase is 
antagonised by a-adrenoceptor blockers such as prazosin, indicating that this is 
mediated via oc^-adrenoceptors (Sneddon et al., 1982; Von Kugelgen et al., 1989). 
ATP has a co-transmitter role with noradrenaline in this tissue (Sneddon & Burnstock, 
1984; White, 1988). Released ATP causes a contraction of the smooth muscle via 
P2X receptors with the agonist potency order AMPCPP = AMPPCP > ATP = 2- 
MeSATP, which is characteristic of P2X receptors (Burnstock & Kennedy, 1985). 
However, this agonist potency order is not reflected at the cloned P2X receptor from 
the rat vas deferens (Valera et al., 1994) and this discrepancy was thought to be due to 
the presnce of ectonucleotidases present in this tissue which degraded some but not all
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of the agonists (Kennedy & Leff, 1995). In experiments in the guinea-pig vas 
deferens where the divalent cation concentration was altered, the active form of ATP 
was suggested to be ATP"*', as the presence of Mg^ '^  in the buffer solution increases the 
concentration of ATP required to initiate contraction (Morishita & Furukawa, 1989; 
Fedan et al., 1990). However, this could also be explained in terms of the 
ectonucleotidase activity as these enzymes are also affec ted by divalent cation 
concentrations, therefore if the divalent cations are altered in the buffer solution this 
may influence the activity of these enzymes thereby increasing or decreasing the rate of 
breakdown of ATP to adenosine, which has its own effects at PI receptors in this 
tissue. In the guinea-pig vas deferens ARL 67156 significantly enhanced the 
purinergic component of the neurogenic contraction to a greater extent than in the 
guinea-pig urinary bladder, thus showing that ecto-ATPase activity may have a greater 
role in modulating neurotransmission in this tissue (Bailey & Hourani, 1994; Westfall 
et al., 1996).
Although the vas deferens is another tissue which has been instrumental in the original 
classification of the P2X receptor, recent studies have shown the possible presence of 
more than one type of P2 receptor mediating contraction in this tissue. For example, 
in the guinea-pig vas deferens the contractions induced by high concentrations of ATP 
are biphasic, where the first phase of the contraction is mediated via P2X receptors and 
the second phase of the contraction is associated with the transfer of a phosphate group 
from ATP to the tissue, following cleavage of the phosphate chain by an ecto-kinase 
enzyme (Fedan & Lamport, 1990; Lamport-Vrana et al, 1991). It has also beenshown 
in this tissue that suramin at low concentrations has little effect, whereas at 
concentrations in excess of lOOpM the effects of ATP are enhanced (Bailey & 
Hourani, 1994). Although this may be explained in terms of suramin acting as an 
ectonucleotidase inhibitor, desensitisation of the P2X receptor by AMPCPP abolishes
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responses to ATP, while in the presence of suramin the response to ATP is unaffected. 
It was, therefore, suggested that there is a contractile receptor in addition to a P2X 
receptor in the guinea-pig vas deferens at which ATP acts (Bailey & Hourani, 1994). 
Similarly in the mouse vas deferens it was suggested that there is
also more than one site of action for ATP. Suramin was found to antagonise 
responses to AMPCPP, whereas only low concentrations of ATP-induced contractions 
were inhibited by suramin (Von Kugelgen & Starke, 1990). In addition, in the rat vas 
deferens a contraction-mediating receptor of the P2X subtype which is sensitive to 
suramin and reactive blue 2, and a non-P2X receptor which is insensitive to suramin 
and reactive blue 2 was proposed (Biiltmann & Starke, 1994). This differential 
antagonism of the effects of ATP and AMPCPP could be explained in terms of the 
ectonucleotidase activity of the tissue and therefore result from the activation of a 
single class of receptor, or a heterogeneous population of P2 receptors. However, 
studies with the ectonucleotidase inhibitor, ARL 67156, has also revealed differential 
effects of suramin, and this would appear to suggest that the differential antagonism of 
suramin cannot be simply explained in terms of the inhibition of ectonucleotidase 
activity (Westfall gf aZ., 1996).
A biphasic response to ATP is observed in the mouse vas deferens where a contractile 
réponse is preceded by a marked relaxation. The relaxation has been attributed to a 
P2Y receptor mediated event, with the agonist potency order 2-MeSATP > ATP > 
AMPCPP and the response was antagonised by reactive blue 2, but not by the PI 
receptor antagonist 8 -PT (Boland et al, 1992).
The pyrimidine nucleotide, UTP, is also active on the guinea-pig and mouse vas 
deferens, where it is less potent than ATP in causing contraction. However, like ATP, 
responses to UTP are antagonised by suramin and were susceptible to cross­
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desensitisation by ATP, suggesting the activation of P2X receptors in these tissues 
(Von Kugelgen et al., 1990; Bailey & Hourani, 1994). In contrast, at the cloned P2X 
receptor, UTP appears to be inactive (Valera et al., 1994).
In the DDTl MF-2 cell line derived from the Syrian hamster vas deferens it was 
shown that ATP increases IP3 levels and intracellular calcium via activation of a G- 
protein coupled receptor as opposed to a ligand-gated ion channel (P2X receptor) 
(Hoiting et al., 1990; Gerwins & Fredholm, 1992). It has been shown that an 
outward K  ^current is induced by nucleotides with a potency order of ATP > UTP > 
TTP > CTP = GTP, whcih is blocked by suramin, and at which adenosine, ADP, 
AMPCPP and 2-MeSATP are inactive. Since UTP is also active in this cell line, the 
receptor was suggested to be of the P^  ^ subtype, now classified as a P2Y2  or P2 Y^  
receptor (Van der Zee et al., 1992). The presence of adenosine Aj receptors in the 
DDTl MF-2 cell line which are negatively coupled to adenylate cyclase has also been 
demonstrated (Dickenson & Hill, 1993a). In addition, an Aj receptor-mediated 
inositol phospholipid hydrolysis and mobilisation of calcium in these cells has also 
been established and has been shown to be due to G-protein coupling to PLC 
(Gerwins & Fredholm, 1992; Dickenson & Hill, 1993b).
The presence of PI receptors has also been demonstrated on the rat vas deferens. 
Adenosine is inhibitory in the vas deferens and the presence of A, receptors on the 
sympathetic nerves mediating the inhibition of neurotransmitter release (noradrenaline 
and ATP) has been shown (Paton et al., 1981). Neuronally released ATP can also 
activate prejunctional Aj receptors as an indirect result of its degradation by 
ectonucleotidases, but a direct action of ATP on prejunctional adeosine receptors in the 
rat vas deferens has also been proposed, although an indirect role for ATP in this 
tissue appears more probable (Forsyth et al, 1991; Kurz et al., 1993). Noradrenaline,
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which is the other co-transmitter in the vas deferens, has also been shown to have a 
feedback mechanism acting via prejunctional U 2  adrenoceptors to cause inhibition of 
transmitter release, whereas the postjunctional contractile effect of noradrenaline is 
mediated via OC; adrenoceptors (Mallard et ah, 1992; Biiltmann & Starke, 1993). The 
potency order of adenosine agonists in causing inhibition of nerve-medaited 
contraction has been shown to be NECA = CPA > adenosine (Hourani et al., 1993). 
Though this agonist potency order does not fall into the classical separation of the A, 
and A2  adenosine receptors, the antagonist DPCPX has been shown to be effective in 
inhibiting the effects of CPA at nanomolar concentrations, whereas the effects of 
NECA and adenosine are inhibited only by micromolar concentrations of DPCPX. 
This suggests the presence of both inhibitory A, and A2  receptors (Hourani et al., 
1993). Indeed, a postjunctional inhibitory effect of adenosine causing inhibition of 
smooth muscle contraction has been demonstrated. The agonist potency order in 
causing inhibition of ATP or noradrenaline induced contractions was NECA »  
adenosine, with CPA being inactive, suggesting activation of receptors in the vas 
deferens (Hourani et al., 1993). In addition, CV 1808, an A2 A selective ligand, is 
inactive in this tissue (Major et al., 1989), suggesting the A2  receptor is of the A2 B 
subtype. Excitatory postjunctional effects of CPA and R-PIA, but not by NECA, 
causing potentiation of ATP induced contractions have also been shown in the rat vas 
deferens,with DPCPX having nanomolar affinity as an antagonist, suggesting this 
effect is mediated by a postjunctional Aj receptor (Hourani & Jones, 1994). Binding 
studies using [^HjDPCPX in the rat vas deferens have also identified a high affinity 
single site with a for DPCPX in the nanomolar range confirming the presence A, 
receptors (Peachey et al., 1994).
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1.4.4. Urinary B ladder
The original classification of the P2X receptor subtype (Burnstock & Kennedy, 1985) 
was based partly on the observations in the guinea-pig and rat urinary bladder that 
contractile responses are observed with an agonist potency order of AMPCPP = 
AMPPCP > ATP = 2-MeSATP (Brown et al., 1979; Burnstock et al., 1983; Kasakov 
& Burnstock, 1983) and that marked desensitisation rapidly occurred following the 
administration of AMPCPP or AMPPCP (Lukacsko & Krell, 1982; Hourani, 1984).
Binding studies with [^H]AMPCPP in the rat urinary bladder have shown that a 
potency order of AMPCPP > AMPPCP > suramin > ATP > ADP > 2-MeSATP »  
adenosine exists in displacing [^H]AMPCPP from its binding site. This is widely 
accepted to indicate binding to a P2X receptor (Bo & Burnstock, 1990). Species 
differences have been noted in that the density of binding of pH] AMPCPP is higher in 
rat urinary bladder than in either the rabbit or guinea-pig (Bo & Burnstock, 1992). 
However, with the cloning of the cDNA encoding the P2X receptor from the human 
urinary bladder smooth muscle and its subsequent expression in isolated cells, it 
became apparent that while the above agonist potency order is seen in pharmacological 
studies with whole tissues, it does not reflect the true potency order at this P2X 
receptor in the human urinary bladder, which has been demonstrated as 2-MeS ATP > 
ATP > AMPCPP »  ADP (Evans et al., 1995). As has been alluded to previously, 
the presence of ectonucleotidases on whole tissues but not on isolated cell preparations 
in which the cloned receptor has been expressed may account for these differences in 
observed potency orders (Kennedy & Leff, 1995).
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ATP and several structural analogues which have substitutions on the purine moiety, 
such as 2-MeSATP, have been shown to be rapidly and sequentially dephosphorylated 
to their corresponding nucleosides by ectonucleotidases on the guinea-pig urinary 
bladder, whereas methylene phosphonate analogues, such as AMPCPP and 
AMPPCP, are resistant to degradation which would suggest that susceptibilty to 
degradation does indeed limit the potency of ATP and certain of its structural 
analogues (Welford et al., 1987). The development of more sensitive high 
performance liquid chromatography (h.p.l.c.) methods have shown that ATP is 
actually degraded beyond its nucleoside, adensoine to inosine, indicating the presence 
of an ecto-adenosine deaminase on this tissue (Bailey & Hourani, 1994).
The contractile effects of AMPCPP in the urinary bladder have been shown to be 
antagonised by PPADS and suramin, which led to the suggestion of a P2X receptor 
mediated effect (Hoyle et al., 1990; Ziganshin et al., 1993). However, 
ectonucleotidase inhibition by suramin in the guinea-pig urinary bladder results in a 
decrease in the rate and extent of degradation of ATP by this tissue in the presence of 
suramin (Hourani & Chown, 1988; Bailey & Hourani, 1994), and this complicates its 
use as an antagonist. PPADS has also been indicated as an inhibitor of 
ectonucleotidases in the guinea-pig taenia caeci (Windscheif et al., 1995).
In contrast, UTP has been shown to be a weak agonist in contracting the guinea-pig 
urinary bladder and contractile responses were found to be abolished in the presence of 
suramin (Bailey & Hourani, 1994). In addition, at the P2X receptor cloned from the 
human urinary bladder smooth muscle UTP is effectively inactive (Evans et al, 1995). 
However, it has also been suggested that there is a heterogeneous population of P2 
receptors in the urinary bladder. It has been observed in the rat urinary bladder that 
contractions induced by ATP and AMPCPP are rapid and transient, whereas those to
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ADP-P-S and UTP are slower and sustained, with biphasic contractile responses in the 
presence of ATP plus UTP. In addition, following desensitisation with AMPCPP 
subsequent responses to ADP-P-S were only partially reduced while those to UTP 
were unaffected. It has therefore been proposed that in addition to a P2X receptor, 
there is an additional contractile P2 receptor at which ADP-p-S and UTP act (Bolego et 
al, 1995a) There is also the suggestion that there is an additional P2 receptor which 
mediates contraction in the rat urinary bladder, at which ADP-p-S but not AMPCPP is 
active, as both ADP-p-S and AMPCP were found to induce contractions following 
desensitisation of P2X receptors by AMPCPP (Suzuki & Kokubun, 1994). In 
contrast, following desensitisation of the P2X receptor in the canine urinary bladder 
with AMPCPP, contractions were not induced by AMPCP, which was taken as 
evidence for a single contraction-mediating P2X receptor (Suzuki & Kokubun, 1994). 
However, a contraction-mediating receptor at which ADP-p-S but not AMPCPP is 
active has been proposed in the human urinary bladder (Palea et al., 1994). In the 
mouse urinary bladder, in addition to contractions, relaxations have been 
derrionstrated, and the agonist potency order or eliciting relaxations is 2-MeSATP > 
ATP > AMPPCP. Since 8 -SPT did not antagonise responses to ATP, it was proposed 
that in addition to a contractile P2X receptor, there is a relaxant P2Y receptor (Boland 
et al., 1993). Similarly, a relaxant P2Y receptor has also been suggested in the rat 
urinary bladder (Bolego gf a/., 1995b).
Adenosine and AMP have been shown to relax the urinary bladder and responses are 
antagonised by theophylline, suggesting the presence of relaxation-mediating PI 
receptors (Burnstock et al., 1972; Brown et al., 1979; Lukacsko et al., 1982). The 
agonist potency order in inducing relaxation is NECA »  adenosine > CPA = 
CGS21680, and as DPCPX at a concentration of lp.M is required to antagonise 
relaxations induced by adenosine and NECA, it is proposed that they are acting via an
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Ajb receptor (Nicholls et al., 1992). As contractions induced by ATP and AMPPCP 
are not affected by theophylline (Brown et al., 1979) or DPCPX (Nicholls et al., 
1992) it appears that they are not acting at the PI receptor in the urinary bladder either 
directly or indirectly.
1.4.5. Anococcygeus
ATP has been shown to induce contraction of the rat anococcygeus muscle (Gillespie, 
1972; Burnstock e ta l, 1978; Carpenter & Joshi, 1980; Stone, 1983). Burnstock and 
co-workers found that contractions induced by ATP were converted to relaxant 
responses in the presence of indomethacin and have, therefore, been suggested to be 
mediated via prostaglandin synthesis (Burnstock et al., 1978), although other groups 
have reported a lack of effect for indomethacin and suggested that the contractions are 
not therefore due to prostaglandin synthesis (Carpenter & Joshi, 1980). It has been 
suggested that this discrepancy is a result of contractions to ATP becoming 
progressively smaller as muscle tone declines in some, but not all, preparations in the 
presence of indomethacin (Stone, 1983). The agonist potency order in inducing 
contractions is L-AMPPCP > AMPPCP > ATP (Hourani et al., 1996), and it has been 
reported that desensitisation of this contractile response on repeated administration of 
ATP or AMPPCP is observed, from which the presence of a contraction-mediating 
P2X receptor has been proposed (Kulkami & Sharma, 1994). In contrast, in the 
rabbit anococcygeus muscle ATP induces relaxation rather than contraction (Creed et 
al., 1977; Burnstock et al., 1978; Sneddon et al., 1982), although occasional dose- 
related contractions do occur (Creed et al., 1977). It has been shown that ATP- 
induced relaxations of the rabbit anococcygeus muscle are reduced in the presence of 
8 -SPT, indicating that part of the response is due to its degradation to adenosine. In 
addition, suramin does not antagonise relaxations induced by ATP, suggesting that a
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component of the P2 receptor action of ATP in this tissue is suramin-insensitive 
(Graham & Sneddon, 1993).
Contractions in response to field stimulation of adrenergic nerves in the rat 
anococcygeus muscle are inhibited by adenosine, resulting in an observed relaxation. 
The agonist potency order for this inhibition, and antagonism by DPCPX has led to 
the proposal that this inhibition is mediated via a prejunctional PI receptor of the A, 
subtype (Stone, 1983; Coates etal., 1994). ATP also inhibits contractions induced by 
adrenergic nerve stimulation, and like adenosine these inhibitory effects are blocked by 
theophylline, suggesting an action of ATP at PI receptors. This action of ATP 
appears to be an indirect action via its degradation to adenosine, as ecto-adenosine 
deaminase has been shown to reduce inhibitory responses to ATP and adenosine to a 
similar extent (Stone, 1983).
1.5. Aims of the Thesis
The aims of this thesis were to determine the rate and extent of extracellular 
metabolism of ATP by ectonucleotidases and the simultaneous accumulation of the 
products of this degradation by a number of smooth muscle tissues which have 
previously been shown to contain receptors for purine and/or pyrimidine nucleotides 
and/or nucleosides using high performance liquid chromatography. The extent to 
which soluble ectonucleotidases are released into the buffer by each of these tissues 
was also investigated.
In addition, the effects of :- (1) the P2 receptor and ectonucleotidase inhibitor, 
suramin, (2) known co-transmitters with ATP (such as NA), (3) modulators of K^ T^P
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channel function, (4) ecto-adenosine deaminase inhibition, (5) nucleoside transport 
inhibition, (6 ) PI receptor blockade by 8 -SPT on the rates of ATP degradation have 
been investigated in either the rat colon muscularis mucosae or the rat vas deferens.
A further aim was to investigate the functional effects of the ADP analogue, adenosine 
3’, 5’-phosphosulphate (A3’P5’PS), in the rat whole duodenum and the stability and 
extent of extracellular degradation of this compound in the presence of this smooth 
muscle preparation.
The rate of breakdown of ATP, Ap^A and Ap^A by the guinea-pig vas deferens in the  ^
absence and presence of suramin was also investigated. Further, the relationship 
between tissue wet weight and the rate of extracellular ATP metabolism was studied in 
the whole and bisected portions of the prostatic and epididymal portions of the guinea- 
pig vas deferens. . ■
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Chapter 2 
GENERAL METHODS
113
of incubation buffer
2.1. Animals
Male Wistar albino rats (200-300g) were obtained from Bantin and Kingman Ltd (Hull) 
and housed in the University of Surrey Experimental Biology Unit for at least 48 hours 
until use in either degradation or pharmacological studies. Animals were housed in 
groups not exceeding 8  animals and were allowed free access to standard rat chow and 
water. Animal groups were kept under controlled conditions of temperature (22 ± 1°C), 
humidity (45-55%) and a 12 hour light-dark cycle (0700-1900h).
Male Dunkin-Hartley guinea-pigs were obtained from Bantin and Kingman Ltd (Hull) 
and housed in the University of Surrey Experimental Biology Unit for at least 48 hours 
until use in degradation studies. Animals were housed in groups not exceeding 4 
animals and were allowed free access to standard guinea-pig chow and water. Animal 
groups were kept under controlled conditions of temperature (22 ± 1°C), humidity (45- 
55%) and a 12 hour light-dark cycle (0700-1900h).
Adult male Wistar albino rats (2G0-300g) and adult male Dunkin-Hartley guinea-pigs 
(300-350g) were killed by cervical dislocation. The abdomen was opened up and the 
colon, duodenum or vas deferens were removed. A detailed description of dissection 
and preparative techniques for individual tissues are included in the relevant sections in 
this thesis (rat colon muscularis mucosae, section 3.2.; rat vas deferens, section 4.2.; 
guinea-pig vas deferens, section 5.2.; rat whole duodenum, section 6.2.).
2.2. HPLC Methods
Frozen 50pl aliquots were removed from the freezer and thawed prior to dispensing 
into 2ml glass h.p.l.c. vials containing 250pl conical inserts, making injection of
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smaller samples easier and more accurate. The samples were then placed immediately 
into a cooled autosampler maintained at 1°C (Shimadzu,. SIL-1 OAx J  ready for injection. 
To avoid injecting air into the sytem and thereby causing damage to the h.p.l.c. column, 
only 40)11 of each 50|il sample was injected.
Reverse phase h.p.l.c. analysis of the samples was performed using a Shimadzu 
LC1ÜAT system with a Techsphere 5|im ODS Cjg column (25cm x 4.6mm) eluted with 
O.IM KH^PO/SmM tetrabutylammonium hydrogen sulphate (adjusted to pH 6.0 with 
9M KOH) (solvent A) and a 60:40 mixture of solvent A and acetonitrile (pH 6.73) 
(solvent B). A non-linear gradient of the following type was employed at a flow rate of 
1.3ml min'  ^ :- 0-2.5min 0% B; 2.5-5min 0-20% B; 5-lOmin 20-40% B; 10-13min 
40-100% B; 13-18min 100% B; 18-25min 0% B.
Nucleotides, nucleosides, diadenosine polyphosphates and their metabolites were 
detected by ultraviolet absorbance (u.v.) at their optimum wavelengths (see Table 2.1.) 
using a Shimadzu SPD-IOa u.v./visible detector, and were quantified by the area of 
their individual absorbance peaks, which was linearly related to their concentration (see 
section 2.3.). The results were displayed graphically as the mean and standard error of 
the mean (s.e.mean).
2.2.7. Materials
Acetonitrile (h.p.l.c. grade), potassium hydroxide and all buffer salts (analytical grade) 
were obtained from Fischer Scientific, Loughborough, U.K. ATP, ADP, AMP, 
adenosine, inosine, UTP, UDP, UMP, uridine, AP ,^ Ap^A, Ap^A, Ap^A, Ap^A and 
ApgA were obtained from Sigma Chemical Company, Poole, U.K.
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2.3. HPLC Results
ATP, ADP, AMP, adenosine, inosine, UTP, UDP, UMP, uridine, AP4 , Ap^A, Ap^A, 
Ap^A, ApgA and Ap^A were injected at a volume of 40pl for a range of concentrations 
(lOjiM-lmM) and at varying volumes (lO-lOOjil) at a fixed concentration of lOOjiM. 
The results are presented for each nucleotide, nucleoside and diadenosine 
polyphosphate as peak area, given in relative absorbance units against concentraion 
(Figures 2 .1 . - 2.3.) and as peak area against injection volume (Figures 2 .4 . - 
2 . 6 . ).
For each of the compounds tested there was a linear relationship between the peak area 
of the u.v. chromatogram and both the concentration of the compound and the injection 
volume throughout the range of concentrations and injection volumes tested. The 
gradient did not significantly differ from unity for any of the nucleotides, nucleosides or 
diadenosine polyphosphates tested. For this reason it was justifiable to choose a 
starting concentration for subsequent experiments for each of these compounds which 
lay within this concentration range. Since a concentration of lOOp-M ATP has been 
shown to produce reliable and reproducible responses in the tissues investigated in the 
following chapters of this thesis, that is, the rat colon muscularis mucosae, the rat vas 
deferens, the guinea-pig vas deferens and the rat whole duodenum this was chosen as 
the starting concentration for each of the compounds subsequently investigated in order 
that results for each nucleotide, nucleoside and diadenosine polyphosphate were 
comparable.
Representative chromatograms for the separation of purine and pyrimidine nucleotides 
and nucleosides are shown in Figures 2.7. and 2.8., respectively.
116
Figure 2.1. U .v. Absorbance Peak Area and Concentration o f Purine Nucleotides and
Nucleosides
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Figure 2.2. U .v. Absorbance Peak Area and Concentration o f Pyrimidine Nucleotides
and N ucleosides
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Each point is the mean of at least 20 determinations and the error bars were smaller 
than the symbol size in each case.
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Figure 2.3. U .v. Absorbance Peak Area and Concentration o f Purine Nucleotides and
Diadenosine Polyphosphates
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(f) AP^ as determined by h.p.l.c. Each point is the mean of at least 20 determinations 
and the error bars were smaller than the symbol size in each case.
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Figure 2.4. Relationship Between U.v. Absorbance Peak Area and Injection Volum es
of Purine Nucleotides and Nucleosides
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symbol size in each case.
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Figure 2.5. Relationship Between U.v. Absorbance Peak Area and Injection Volum es
o f Pyrimidine Nucleotides and Nucleosides
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Figure 2.6. Relationship Between U.v. Absorbance Peak Area and Injection Volum e of
Purine Nucleotides and Diadenosine Polyphosphates
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122
Figure 2.7. Representative Chromatogram for the Separation o f ATP, ADP, AMP,
Adenosine and Inosine
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Separation of ATP (■), ADP (•), AMP (A), adenosine (□) and inosine (♦) by
h.p.l.c.
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Figure 2.8. Representative Chromatogram for the Separation o f UTP, UDP, UMP,
and Uridine
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Separation of UTP (■), UDP (•) , UMP (À) and uridine (♦) by h.p.l.c.
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Table 2.1. Optimum W avelengths and Extinction Coefficients for Purines,
Pyrimidines and Diadenosine Polyphosphates.
Purine, pyrimidine or 
dinucleotide 
polyphosphate
Extinction 
coefficient (lO'"^  M)
Optimum wavelength 
(nm)
ATP 1.54 259
ADP 1.54 259
AMP 1.54 259
adenosine 1.51 260
inosine 1 . 2 2 248.5
UTP 1 . 0 0 262
UDP 1 . 0 0 262
UMP 1 . 0 0 262
uridine 1 . 0 1 261
AP, 1.54 259
ApjA 3.08 259
ApgA 3.08 259
AP4 A 3.08 259
Ap,A 3.08 259
APsA 3.08 259
For abbreviations see main body of text.
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Table 2.2. H .p.l.c. Retention Times for Purines, Pyrimidines and Diadenosine
Polyphosphates.
Purine, pyrimidine or 
dinucleotide 
polyphosphate
Retention time 
(minutes)
ATP 16.3
ADP 13.1
AMP 1 0 . 6
adenosine 9.0
inosine 6.4
UTP 14.7
UDP 11.3
UMP 9.2
uridine 4.8
A?4 17.9
AP2 A 16.1
ApjA 17.1
AP4 A 17.6
AP5 A 18.7
APôA 19.4
The retention times detailed in the above table were obtained using a flow rate of 
l.Smlmin'^ and a Techsphere 5jxm ODS C^ g column (25cm x 4.6mm). Under these 
conditions suramin had a retention time of between 23-26 minutes and had no effect on 
the retention times of any of the nucleotides, nucleosides or diadenosine polyphosphates 
tested. For abbreviations see main body of text.
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Chapter 3
RAT COLON MUSCULARIS 
MUCOSAE
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3.1. Introduction
The rat colon muscularis mucosae is a tissue which has previously been shown to 
exhibit contractile responses to both adenosine and ATP, acting via A, and P2 receptors 
which appear to be of the P2Y, subtype, respectively. In addition, this tissue has also 
been shown to degrade ATP via the sequential dephosphorylation catalysed by 
ectonucleotidases to ADP, AMP and by ecto-5'nucleotidase to adenosine, which may 
then undergo further degradation via deamination by adenosine deaminase to inosine or 
undergo uptake into cells via membrane-bound transporters (Bailey & Hourani, 1990; 
Bailey etal., 1992; Hourani et al., 1998). Inosine may then be further metabolised to 
hypoxanthine, xanthine and uric acid, the latter two steps being catalysed by xanthine 
oxidase. This enzyme has been shown to be inhibited by allopurinol, a structural 
analogue of xanthine, with a IQ in the nM range (Elion, 1978). This is of interest since 
inosine was initially thought to be the inactive product of adenosine metabolism, but 
there are recent reports which make it clear that inosine is indeed active at adenosine A3  
receptors, resulting in mast cell degranulation, and in certain circumstances may even 
represent the major endogenous agonist at these receptors (Jin et al, 1997).
As a tissue which has previously been shown to contract to both adenosine and ATP, 
and also a tissue which has been used to demonstrate the existence of extracellular 
nucleotidase enzymes which rapidly degrade ATP (Bailey & Hourani, 1990; Bailey et 
al., 1992; Hourani etal., 1998), the rat colon muscularis mucosae was chosen to study 
the effects of the ectonucleotidase and P2 antagonist suramin on the rate of 
dephosphorylation of a variety of nucleotides and any accompanying changes in the 
pattern of metabolites detected. In addition the effects of modulators of different 
aspects of adenosine metabolism, namely deamination, cellular uptake and the further 
degradation of the adenosine metabolite, inosine, were investigated with respect to their
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possible effects on the various stages of the extracellular metabolic pathway of ATP 
degradation. The aim was to determine the existence of any feedback mechanisms in 
operation in this tissue which may be triggered by the modulation of downstream 
extracellular metabolite levels.
In addition to ATP, UTP, ADP and UDP the diadenosine polyphosphates (ApnAs) are 
believed to be another group of potential endogenous ligands at P2 receptors. The most 
studied of these are Ap^A, Ap^A and Ap^A, which have a variety of pharmacological 
effects and have been proposed to act as neurotransmitters by a number of authors 
(Hoyle, 1990; Ogilvie, 1992; Pintor & Miras-Portugal, 1993; Baxi & Vishwanatha, 
1995). Whilst there has been the suggestion that these compounds act via a separate 
class of receptors (see Pintor & Miras-Portugal, 1995), it is evident that they act at the 
known P2 receptors already classified and if specific receptors do indeed exist they are 
likely to belong to one of the P2 families, P2X and/or P2Y (Fredholm et al., 1997). In 
certain smooth muscle preparations the ApnAs have been shown to act at P2X receptors 
to cause contraction of the smooth muscle. The potency of the agonists in causing 
contraction of the guinea-pig vas deferens and urinary bladder has been shown to 
increase with increasing length of the phosphate chain, that is they increase in potency 
from Ap^A, Ap^A to Ap^A and are also more potent than ATP at inducing contraction of 
these tissues (Stone, 1981; Mackenzie et al., 1988; Pohl et al., 1991; Bailey & 
Hourani, 1995; Hoyle gf aZ., 1995a; 1995b; Usuuq e tal., 1996; Westfall etal., 1997).
The diadenosine polyphosphates have also been shown to possess vasoconstrictor 
properties in a variety of vascular preparations, including human umbilical vein (Davies 
et al., 1995), rat isolated perfused kidney vessels (Van der Geit et al., 1997) and rat 
mesenteric arteries (Ralevic et al., 1995). All of the above effects are inhibited by 
typical P2 receptor antagonists, such as suramin and PPADS, a compound which has
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reported selectivity for P2X receptors (Bailey & Hourani, 1995; Hoyle et al., 5a; 
1995b; Ralevic et al., 1995; Usune et al., 1996; Van der Geit et al., 1997; Westfall et 
al., 1997). At the cloned P2X, receptor, Ap^A has been reported to be an agonist, 
although with lower potency than ATP and evoking a lower maximal response, 
whereas at the cloned P2 X2  receptor only Ap^A of the diadenosine polyphosphates is an 
agonist, again with lower potency than ATP, with Ap^A and Ap^A and the other 
diadenosine polyphosphates being either inactive or of much lower potency (Evans et 
al., 1995; Pintor etal., 1996a). In contrast, they have been demonstrated to be potent 
and full agonists at the cloned P2 Yj receptor, with an agonist potency order of ATP > 
Ap^A > ApgA > ApgA (Lazarowski gr al., 1995), whereas at the cloned chick P2YQ 
receptor only Ap^A was a full agonist, equipotent with ATP, while Ap^A is only a weak 
partial agonist and the other diadenosine polyphosphates are inactive (Pintor et al., 
1996a).
In contrast to cloned P2 receptors, the effects of diadenosine polyphosphates in isolated 
smooth muscle preparations have not been thoroughly investigated to date, although 
they are reported to relax guinea-pig taenia caeci with an agonist potency order of Ap^A 
> Ap^A > ApgA (Hoyle et al., 1995b) and in vascular preparations those with the 
shortest phosphate chain length (such as Ap^A) are known vasodilators (Pohl et al., 
1991; Ralevic et al., 1995; Van der Geit et al., 1997). The source of a potential 
problem with the characterisation of the pharmacological responses to these compounds 
is that in the tissues so far studied adenosine has also been shown to induce relaxant 
responses, and the effects of the diadenosine polyphosphates may be directly or 
indirectly via PI receptor activation rather than P2 receptors. Indeed, in a number of 
tissues effects of diadenosine polyphosphates have been shown to be mediated via PI 
receptors, including the guinea-pig vas deferens, taenia caeci and urinary bladder 
(Stone, 1981; Hoyle etal., 1995a), guinea-pig left atrium (Hoyle et al., 1996), inward
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and outward ionic currents in follicular oocytes of Xenopus laevis (Pintor et a l, 1996b) 
and negative chronotropic and inotropic effects in guinea-pig and human cardiac 
preparations (Vahlensieck etal., 1996).
It has been previously demonstrated that ectonucleotidase enzymes are capable of 
breaking the phosphate chain linking the two adenine moieties asymmetrically, giving 
rise to AMP and the appropriate adenine nucleotide, that is Ap^A is degraded to AMP 
and AP4 . In addition, these compounds are reported to be more resistant to degradation 
than ATP (Pohl etal., 1991; Ogilvie etal., 1992; Rodriguez-Pascal, et al., 1992; Pintor 
etal., 1996b). As is the case with ATP (Hourani & Chown, 1989; Bailey & Hourani, 
1994; Crack et al., 1994), the ectoenzymes which break down the diadenosine 
polyphosphates are inhibited by the P2 receptor antagonist, suramin (Mateo et al., 
1996; Pintor et al., 1997).
The trypanocidal drug, suramin, acts as an antagonist at both P2X and P2Y receptors 
(Hoyle et al., 1990) in smooth muscle preparations and, in addition, has been shown to 
possess inhibitory effects on ectonucleotidase activity (Hourani & Chown, 1989). This 
ectonucleotidase inhibition has been suggested to be responsible for an apparent lack of 
inhibition of the pharmacological responses to rapidly-degraded agonists, such as ATP 
(Crack et al., 1994; Bailey & Hourani, 1994; 1995). As described previously, suramin 
acts as an antagonist at cloned P2Xj, P2Yj and P2Y^ receptors, but not at rat or human 
P2 Y4  receptors (Valera et al., 1994; Charlton et al., 1996a; 1996b; Bogdanov et al., 
1998). Suramin has also been shown to be a potent inhibitor of the diadenosine 
polyphosphate hydrolase present in the Torpedo electric organ (Pintor et al., 1997) and 
the effects of suramin on the degradation of the diadenosine polyphosphates by the rat 
colon muscularis mucosae were studied here.
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The enzyme adenosine deaminase is specifically inhibited by EHNA with a K; value in 
the low nanomolar range (Ijzerman & Van Der Wenden, 1998). Since initial studies in 
this tissue (see Results section of this chapter) failed to detect the presence of 
adenosine in the incubation buffer following the dephosphorylation of ATP, the 
mechanism(s) of removal of adenosine from the extracellular compartment were thought 
to be highly efficient, namely removal by membrane-bound nucleoside transporters 
and/or deamination to inosine via adenosine deaminase. The effect of the adenosine 
deaminase inhibitor, EHNA, was therefore investigated on the rate of production of 
adenosine observed in the incubation medium, whilst simultaneously identifying the 
existence of any feedback mechanisms regulating the breakdown of ATP via ADP and 
AMP.
As mentioned previously, the uptake of nucleosides, such as adenosine and uridine, is 
mediated via membrane-bound nucleoside transporters. Initially, two types of 
transporter were identified and classified by their sensitivity or insensitivity to inhibition 
by NBTI. NBTI-insensitive transporters require micromolar concentrations of NBTI to 
inhibit the transport of nucleosides, whereas nanomolar concentrations are required to 
block the membranal transport of nucleosides by NBTI-sensitive carriers (Thom & 
Jarvis, 1996). However, a further method of classification has resulted from the 
observation that the cloning of several members of the two families has identified that 
there exist equilibrative nucleoside transporters (ENT) (Griffiths et al., 1997a; Griffiths 
et al., 1997b; Crawford et al., 199S) and sodium-dependent concentrative nucleoside 
transporters (CNT) (Ritzel etal., 1997; Wang et al., 1997; Ritzel et al., 1998). It has 
been determined that the CNT-mediated processes are insensitive to inhibition by the 
commonly used adenosine uptake inhibitor NBTI, whereas the sensitivity of ENT- 
mediated processes varies. For instance, NBTI-insensitive transporters (ENT2 
transporters, which are sometimes referred to in the literature as ei transporters) require
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micromolar concentrations of NBTI to block the transport of nucleosides, however, 
uptake processes mediated via NBTI-sensitive (ENTl or es transporters) are commonly 
inhibited by nanomolar concentrations (Thom & Jarvis, 1996; Jennings et al., 1998). 
The existence, in smooth muscle tissues which possess adenosine receptors, of both 
uptake and enzymatic removal mechanisms for adenosine generated by the extracellular 
dephosphorylation of ATP, ADP and AMP has been demonstrated by the reported 
effect of EHNA on the rat duodenum and of NBTI on the rat mesenteric artery. In the 
rat duodenum a concentration of 0.5p.M EHNA potentiated the observed relaxant 
responses to adenosine (Franco et al., 1988), whereas in the rat mesenteric artery 
vasodilatory responses to adenosine were enhanced by the uptake inhibitor NBTI at a 
concentration of l|iM (Prentice et al., 1997). Therefore, adenosine uptake and 
deamination can result in the reduction of the observed potency of adenosine in tissues 
which contain PI receptors.
The rat colon muscularis mucosae is a tissue which has been extensively used in the 
study of PI and P2 receptor populations of smooth muscle preparations and, as such, 
was thought a particularly relevant tissue in which to study the effects of inhibitors of 
nucleotide and diadenosine polyphosphate metabolism in conjunction with the effects of 
adenosine uptake and ecto-adenosine deaminase inhibitors. The advantages of using 
the hplc method employed in this study are that, not only can the direct effects on the 
actual levels of the substrate and breakdown product be observed simultaneously, but 
also the existence of any feedback mechanisms within the extracellular metabolic 
pathways can be elucidated.
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3.2. Methods
The distal colon, cut as far towards the rectum as possible and 4cm from this point, was 
removed and placed in warmed (32°C) Tyrodes buffer. The tissues were cleared of any 
connective tissue, and washed thoroughly to remove any faecal matter by passing 
Tyrode buffer through the lumen using a plastic pasteur pipette (1ml). A glass rod of 
external diameter 5mm was placed inside the colon. The outer longitudinal muscle layer 
was then removed by gentle rubbing with cotton wool moistened with warmed Tyrode 
buffer and discarded. The remaining thick-walled tube of mucosal tissue, containing 
the muscularis mucosae, was then cut to lengths of 2 cm and each section placed in 
separate 1.5ml tubes. This was to allow experiments in the absence and presence of 
suramin to be performed on tissues from the same animal, with one of the two lengths 
of colon (alternated between distal and proximal tissues from different animals) 
preincubated with suramin and one preincubated with water.
The degradation of ATP, UTP, AP ,^ Ap^A, Ap^A, Ap^A, Ap^A and Ap^A (lOOpM) by 
the rat colon muscularis mucosae was investigated in the absence and presence of 
suramin (ImM). The muscularis mucosae was dissected as previously described and 
placed in tubes containing 1.5ml Tyrode solution, gassed with 95% OJ‘S% COj and 
maintained at 32°C. The Tyrode solution had the following composition (mM): NaCl 
136.9, KCl 2.8, CaCQ 1.8, MgCl^ 2.1, NaHCO^ 11.9, NaH^PO^ 0.3 and glucose 5.6. 
Tissues were then allowed to equilibrate for 45 minutes with regular washings at 10 
minute intervals prior to the addition of drugs.
Following equilibration, water (15|xl) or suramin (ImM) was added to the tubes and 
tissues were incubated for a further 60 minutes, with regular washes and 
readministration of suramin or water as appropriate. Individual tissues were then added
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to solutions of nucleotides or diadenosine polyphosphates (lOOpM) in the presence and 
absence of suramin (ImM) and aliquots (SOpl) of incubation buffer were removed at 0, 
2, 5, 10, 20 and 30 minute time points, placed immediately on ice, stored at -20°C and 
analysed by high performance liquid chromatography (h.p.l.c.) at a later date.
To check for leakage of enzymes, tissues which had been washed and incubated with 
suramin (ImM) or water (ISpl) as above, were then incubated for a further 60 minutes 
with no washes, the tissues were then removed, the nucleotides or diadenosine 
polyphosphates added to the buffer which had previously contained the tissue, and 
samples taken for analysis at 0 and 30 minutes.
Samples were then thawed and injected onto the h.p.l.c. system as described in section
2 .2 . of this thesis.
Nucleotides, nucleosides, diadenosine polyphosphates and their metabolites were 
detected by ultraviolet (u.v.) absorbance at their optimum wavelengths (see Table
2.1.) using a Shimadzu SPD-lOA u.v./visible detector, and were quantified by the area 
of their individual absorbance peaks, which was linearly related to their concentration 
(see section 2.3.). The results were displayed graphically as the mean and standard 
error of the mean (s.e.mean).
3.2.1. Materials
ATP, Ap^A, ApjA, Ap^A, Ap^A, Ap^A, AP  ^ and tetrabutylammonium hydrogen 
sulphate (h.p.l.c. grade) were obtained from Sigma Chemical Company, Poole, UK. 
Acetonitrile (h.p.l.c. grade), potassium hydroxide and all buffer salts (analytical grade) 
were obtained from Fischer Scientific, Loughborough, UK. Suramin (hexasodium
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salt) was obtained either as a generous gift from Bayer, UK, or from Research 
Biochemicals International, Natick, USA.
3.2,2. Statistics and Data Analysis
Concentration-time curves were constructed from the non-transformed data. Semi-log 
plots of the log concentration versus time data were constructed. From these the half- 
life (ti/2 ) of the substrate was determined from the straight line fit and determining the 
time in minutes for the concentration of the substrate to decrease by 50%, that is the 
point on the abscissa which corresponds to log (Cq/2), where Cq is the intercept on the 
ordinate. The rate constant (k^ g^) for each individual reaction was calculated from the 
half-life using the equation k^ g^ = 0.693/ti/2.
The absolute levels of all the substrates and degradation products were compared at all 
time points sampled between control and treated samples using 2-way ANOVA. The 
tj/ 2  for each substrate and the k^ g^ for each reaction were compared using Student t-test.
3.3. Results
ATP, UTP, AP4 , AP2 A, ApgA, AP4 A, Ap^A and Ap^A were all degraded by the rat 
colon muscularis mucosae. In the case of ATP the major initial breakdown products 
were ADP and AMP, with a lower build-up of inosine and no detectable levels of 
adenosine found in the bathing solution (Figure 3.1.). The half-life of ATP was 6 .1 
±1.1 minutes (Figure 3.9. ; Table 3.1.). In the presence of ImM suramin the 
degradation of ATP appeared to be slower, with the half-life increasing to 9.7 ± 2.3 
minutes, although the difference between this and the control value did not achieve
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statistical significance. The presence of suramin did not significantly affect the pattern 
of observed metabolites (P <0.01) (Figure 3.1.).
In the absence of suramin, the degradation of UTP proved to be extremely rapid. The 
primary products of metabolism were firstly UDP, followed by UMP and, finally 
uridine (Figure 3.2.). In the presence of suramin the pattern of metabolites remained 
unchanged, although there was a significant effect of suramin on the half-life of UTP in 
the presence of the rat colon muscularis mucosae. Whereas the control value for the 
half-life of UTP was 4.2 ± 0.6 minutes, in the presence of suramin (ImM) the half-life 
increased to 9.0 ±1.5 minutes (P < 0.05) (Table 3.1.).
AP4  and the diadenosine polyphosphates were all degraded by the rat colon muscularis 
mucosae. Although the pattern of nucleotides produced was not so clear as for the 
breakdown of ATP and UTP, in each case it appeared as though inosine was the 
primary nucleoside product as opposed to adenosine. The products detected from the 
breakdown of the diadenosine polyphosphates were consistent with an asymmetrical 
cleavage of the phosphate chain. AP2 A gave rise to AMP which in turn gave rise to 
inosine; Ap^A gave rise to ADP, AMP and inosine; AP4 A, Ap^A, Ap^A and AP4  all 
gave rise to ATP, ADP, AMP and inosine. In the presence of ImM suramin the pattern 
of metabolites produced by the degradation of each of the nucleotides was unaffected 
(Figures 3.3. - 3.8.).
The half-lives for the degradation of Ap2 A, Ap^A, AP4 A, Ap^A and Ap^A were all 
significantly slower than that for either ATP or UTP (*P < 0.05; **P < 0.01) (Table
3.1.). The control half-lives for these nucleotides ranged from 17.55 ±4.07 minutes 
for AP2 A (P < 0.05) to 30.1 ± 4.0 minutes for Ap^A (P < 0.01). In each case, for AP4  
and the diadenosine polyphosphates, the half-lives were increased markedly in the
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presence of ImM suramin, with a 2-fold increase for most of the ligands (P < 0.05) and 
for Ap^A the half-life was increased from 30.15 ± 4.01 to 61.83 ± 6.96 (P < 0.01) 
(Table 3.1.).
The rate constants (k^ g^) for the degradation of these ligands followed a similar pattern 
as for the half-lives, with the rate of degradation for ATP being unaffected by 
preincubation with ImM suramin whereas those for UTP, AP ,^ ApjA, Ap^A, Ap^A and 
ApgA (P < 0.05) and ApjA (P < 0.05) being significantly decreased (Table 3.2.).
Following the removal of tissues, the dephosphorylation of all the nucleotides and 
dinucleotides tested by the incubation buffer which had previously contained the tissue 
was noticeably slower over a 30 minute time period than those studies performed in the 
presence of tissue (P < 0.05) (Figures 3 .17 .;3 .18 .;3 .19 .). In addition, the 
presence of suramin (ImM) resulted in a significant reduction in the extent of removal 
of ATP from the incubation buffer which had previously contained the tissue over the 
same time period (P < 0.001). This inhibitory effect of suramin was more marked in 
the case of ATP and UTP (P < 0.001) than for AP4  and the diadenosine polyphosphates 
(P < 0.05).
In a separate series of studies, the degradation of ATP (100p.M) by the rat colon 
muscularis mucosae in the absence and presence of the adenosine receptor antagonist, 
8 -SPT (lp.M); the adenosine deaminase inhibitor, EHNA (IpM and lOpM); the 
xanthine oxidase inhibitor, allopurinol (Ip-M) and the adenosine transporter antagonist, 
NBTI (lp.M and lOpM) was investigated. The results are presented as the degradation 
of ATP and the subsequent appearance and accumulation of the products of metabolism 
(Figures 3 .20 .-3 .23 .), the half-life of ATP and the rate constants for the
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extracellular breakdown of ATP under these experimental conditions (Figures 3.24.- 
3.27. and Tables 3.3.; 3.4.).
ATP was rapidly degraded by the rat colon muscularis mucosae via ADP and AMP with 
the major breakdown product detectable in the incubation buffer being inosine. Little or 
no adenosine was detectable in any of the control tissues, or in any of those tissues 
preincubated with 8-SPT, allopurinol or NBTI. The half-life and rate constants for the 
extracellular dephosphorylation of ATP was not significantly affected by the presence 
of 8-SPT, allopurinol, NBTI or EHNA (Figures 3.24. - 3.27.; Tables 3.3. and
3 .4 .).
However, preincubation with the adenosine deaminase inhibitor EHNA (1 and lOpM), 
resulted in a dose-dependent increase in the appearance and accumulation of adenosine 
in the incubation buffer (Figure 3.21.). In the presence of Ip-M EHNA the 
concentration of adenosine ranged from 2.0 to 8.5pM between 2 and 30 minutes after 
introduction of the tissue, whereas in the presence of lOpM EHNA the concentration 
and accumulation of adenosine increased from undetectable levels at time 0 minutes to 
31.1 ± 1.7p.M at time 30 minutes. In addition, the rate and extent of production of 
inosine via the deamination of adenosine was significantly reduced in the presence of 
lp,M EHNA and was effectively abolished following preincubation with lOjxM EHNA 
as compared with controls and IpM EHNA treated tissues (P < 0.01).
The effects of extracellular pH on the degradation of ATP (lOOpM) by the rat colon 
muscularis mucosae were studied. ATP was rapidly degraded at all the pH levels 
investigated (5.5, 6.5, 7.4 and 8.0) (Figure 3.28.). The rapid degradation of ATP at 
these pH levels did not allow an accurate calculation for the half-life of ATP removal 
from the incubation buffer by this h.p.l.c. method. However, it does seem from the
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initial studies that there was an increase in the rate of removal of ATP from the 
extracellular compartment following a reduction and an increase in the extracellular pH. 
In addition, the level of AMP observed in the incubation buffer following the 
degradation of ATP appears to be decreased at pH 5.5 and 6.5, i.e. in an acidified 
extracellular environment, when compared to those levels observed at pH 7.4 and 8.0 
(Figure 3.28.) (P < 0.05). Further, in these tissues the levels of inosine produced 
following the breakdown of ATP showed a significant increase in those tissues 
incubated at pH 5.5 and 6.5 when compared to those at pH 7.4 and 8.0 (P < 0.05), 
indicating that the lower levels of AMP seen in these tissues is due to an increased rate 
of production of inosine from AMP, presumably indirectly via the rapid deamination of 
adenosine, as opposed to a decrease in the rate of production of AMP from ATP via 
ADP.
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Figure 3.1. Effect o f Suramin on the Degradation o f ATP
by the Rat Colon Muscularis Mucosae.
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Degradation of ATP (lOOpM) (■) by the rat colon muscularis mucosae and the 
appearance of its metabolites ADP (•) , AMP (À) and inosine (♦) in the absence
(a) and presence (b) of suramin (ImM). Each point represents the mean of at 
least 3 determinations and the vertical bars show s.e.mean. For abbreviations 
see main body of text. Statistical analysis was performed on control and suramin- 
treated tissues using repeated measures 2-way ANOVA.
No significant difference was ob^rved between control and suramin-treated tissues (P 
< 0.05). : ^41
Figure 3.2. Effect o f Suramin on the Degradation o f UTP by
the Rat Colon Muscularis M ucosae
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Degradation of UTP (lOOjiM) (■) by the rat colon muscularis mucosae and the 
appearance of its metabolites UDP (•) , UMP (À) and uridine (♦) in the absence
(a) and presence (b) of suramin (ImM). Each point represents the mean of at 
least 3 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed on control and suramin-treated tissues using repeated measures 2- 
way ANOVA. For abbreviations see main body of text.
The rate of breakdown of UTP in control tissues was significantly different from 
suramin-treated tissues (P < 0.05).
Figure 3.3. Effect o f Suramin on the Degradation o f Ap^A
by the Rat Colon Muscularis M ucosae.
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Degradation of Ap2 A (lOOjiM) (^ 4) by the rat colon muscularis mucosae and 
the appearance of its metabolites ADP (•) , AMP (À) and inosine (♦) in the 
absence (a) and presence (b) of suramin (ImM). Each point represents the 
mean of at least 3 determinations and the vertical bars show s.e.mean. For 
abbreviations see main body of text. Statistical analysis was performed on
control and suramin-treated tissues using repeated measures 2-way ANOVA. __
The rate of breakdown of Ap^A in control tissues was significantly different from
suramin-treated tissues (P < 0.05). i
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Figure 3.4. Effect o f Suramin on the Degradation o f Ap^A by the
Rat Colon Muscularis M ucosae
(a)
120-,
80-
g
1 60-
I
§ 40- 
U
20-
5 15 250 10 20 30
(b)
Time (minutes)
120-,
80-
S 40-
20-
155 20 250 10 30
Time (minutes)
Degradation of ApgA (lOOpM) (O) by the rat colon muscularis mucosae and the
appearance of its metabolites ADP (•) , AMP (À) and inosine (♦) in the absence
(a) and presence (b) of suramin (ImM). Each point represents the mean of at 
least 3 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed on control and suramin-treated tissues using repeated measures 2-
wav ANOVA. Eor abbreviations see main body of text__________________________ -
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05). , ,144
Figure 3.5. Effect o f Suramin on the Degradation o f Ap^A by the
Rat Colon Muscularis M ucosae
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Degradation of Ap^A (lOOpM) (A) by the rat colon muscularis mucosae and the
appearance of its metabolites ATP (■), ADP (•) , AMP (A) and inosine (♦) in 
the absence (a) and presence (b) of suramin (ImM). Each point represents the 
mean of at least 3 determinations and the vertical bars show s.e.mean. 
Statistical analysis was performed on control and suramin-treated tissues using
repeated measures 2-way ANOVA. For abbreviations see main body of text._____
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05). 1 4 5
Figure 3.6. Effect o f Suramin on the Degradation o f Ap^A by the
Rat Colon Muscularis M ucosae
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Degradation of Ap^A (lOOjiM) (T) by the rat colon muscularis mucosae and the 
appearance of its metabolites AP4 (O), ATP (■), ADP (•) , AMP (A) and 
inosine (♦) in the absence (a) and presence (b) of suramin (ImM). Each point 
represents the mean of at least 3 determinations and the vertical bars show 
s.e.mean. Statistical analysis was performed on control and suramin-treated 
tissues using repeated measures 2-way ANOVA. For abbreviations see main
Jbody of text. _  _____  ______  _____________
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.01). 146
Figure 3.7. Effect o f Suramin on the Degradation o f Ap^A by the
Rat Colon Muscularis M ucosae
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Degradation of Ap^A (lOOpM) (►) by the rat colon muscularis mucosae and the 
appearance of its metabolites AP^ (%), AP^ (O), ATP (■), ADP (• ) , AMP (A)
and inosine (♦) in the absence (a) and presence (b) of suramin (ImM). Each 
point represents the mean of at least 3 determinations and the vertical bars show 
s.e.mean. For abbreviations see main body of text. Statistical analysis was 
performed on control and suramin-treated tissues using repeated measures 2-way
ANOVA. -----------------—        -  _ — 1 j-ip— . p
The rate of breakdown of Ap^A in control tissues was significantly ditterent trom
suramin-treated tissues (P < 0.05). 147
Figure 3.8. Effect o f Suramin on the Degradation o f AP^ by the
Rat Colon Muscularis M ucosae
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Degradation of AP^ (lOOjiM) (O) by the rat colon muscularis mucosae and the
appearance of its metabolites ADP (•) , AMP (À), adenosine (□) and inosine (♦) in 
the absence (a) and presence (b) of suramin (ImM). Each point represents the mean 
of at least 3 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed on control and suramin-treated tissues using repeated measures 2-way
ANOVA. For abbreviations see main body of text.  ^ ________
The rate of breakdown of AP  ^ in control tissues was significantly different from 
suramin-treated tissues (P < 0.05). 148
F igure 3.9. Effect o f Suramin on the Half-life for the Degradation of
ATP from an Initial Concentration o f lOOjiM by the Rat Colon
Muscularis M ucosae
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Half-life for the degradation of ATP from an initial concentration of 100|iM 
by the rat colon muscularis mucosae in the absence (a) and presence (b) of 
ImM suramin. Each point is the mean of at least 3 determinations and the 
error bars were smaller than the symbol size in each case. For abbreviations 
see main body of text._______  _______ _ _________ __________________
No significant difference was observed between control and suramin-treated tissues (P <
0.05). ' /  -
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Figure 3.10. Effect o f Suramin on the Half-life for the Degradation o f
UTP from an Initial Concentration o f 100|liM  by the Rat Colon
Muscularis M ucosae
(a)
§
1
I
-0.5
Time (minutes)
(b)
2.5
2
1.5
1
0.5
0
5 150 10 20 25 30
Time (minutes)
Half-life for the degradation of UTP from an initial concentration of 
100|iM by the rat colon muscularis mucosae in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinations and the error bars were smaller than the symbol size in 
each case. For abbreviations see main body of text.
The rate of breakdown of UTP in control tissues was significantly different from 
suramin-treated tissues (P < 0.05).
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Figure 3.11. Effect o f Suramin on the H alf-life for the Degradation
o f Ap^A by the Rat Colon Muscularis M ucosae
(a)
2.5-,
.2 1.5-
155 10 20 250 30
(b)
Time (minutes)
2.5-,
.2 1.5-
.2 0.5-
5 15 2510 20 300
Time (minutes)
Half-life for the degradation of AP2 A from an initial concentration of
lOOpM by the rat colon muscularis mucosae in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinations and in each case the error bars were smaller than the symbol 
size. For abbreviations see main body of text.
The rate of breakdown of AP2 A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05). ;
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Figure 3.12. Effect o f Suramin on the Half-life for the Degradation of
A pgA from an Initial Concentration o f lOOpM by the Rat Colon
Muscularis M ucosae
(a)
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Time (minutes)
(b) 
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.1 1.5i
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1 -
0
10 15 20
Time (minutes)
25 30
Half-life for the degradation of ApgA from an initial concentration of 
lOOpM by the rat colon muscularis mucosae in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinations and the error bars were smaller than the symbol size in 
each case. For abbreviations see main body of text.
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05). "
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Figure 3.13. Effect on the Half-life for the Degradation o f Ap^A from
an Initial Concentration o f lOOpM by the Rat Colon Muscularis
M ucosae
(a)
2.5
2
1.5
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S 0 . 5
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15 255 10 20 300
Time (minutes)
(b)
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15 255 10 20 300
Time (minutes)
Half-life for the degradation of Ap^A from an initial concentration of 
lOOpM by the rat colon muscularis mucosae in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinations and in each case the error bars were smaller than the 
 symbol size. For abbreviations see main body of text.
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05).
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Figure 3.14. Effect o f Suramin on the Half-life for the Degradation of
Ap^A from an Initial Concentration o f lOOpM by the Rat Colon
Muscularis M ucosae
(a)
2.5
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0
5 15 20 2510 300
(b)
Time (minutes)
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2
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1
a  0.5
0
5 15 2510 20 300
Time (minutes)
Half-life for the degradation of Ap^A from an initial concentration of 
lOOpM by the rat colon muscularis mucosae in the absence (a) and presence
(b) of ImM suramin. Each point is the mean of at least 3 determinations and 
theerror bars were smaller than the symbol size in each case. For
abbreviations see main body of text. ___  ____
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.01).
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Figure 3.15. Effect o f Suramin on the Half-life for the Degradation of
Ap^A from an Initial Concentration o f lOOpM by the Rat Colon
Muscularis M ucosae
(a)
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1o
bOO
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(b)
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15 255 10 200 30
Time (minutes)
Half-life for the degradation of Ap^A from an initial concentration of 
lOOpM by the rat colon muscularis mucosae in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinations and in each case the error bars were smaller than the 
symbol size. For abbreviations see main body of text.
The rate of breakdown of Ap^A in control tissues was significantly different from 
suramin-treated tissues (P < 0.05).
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Figure 3.16. Effect o f Suramin on the Half-life for the Degradation o f
AP^ from an Initial Concentration o f lOOpM by the Rat Colon
Muscularis M ucosae
(a)
2.5
0.5
Time (minutes)
(b)
2.5
Time (minutes)
Half-life for the degradation of AP^ from an initial concentration of lOOpM 
by the rat colon muscularis mucosae in the absence (a) and presence (b) of 
ImM suramin. Each point is the mean of at least 3 determinations and in each 
case the error bars were smaller than the symbol size. For abbreviations see 
main body of text.
The rate of breakdown of AP  ^ in control tissues was significantly different from 
suramin-treated tissues (P < 0.05).
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Figure 3.17. Effect o f Suramin on the M etabolism o f (a) ATP, (b) UTP and (c) AP^
by Enzymes Released into the Buffer by the Rat Colon Muscularis M ucosae
(a) 100-|
S 80-
g 60-
1
s 40-
8
u 20-
0
(b) 100-|
S 80-d.
g 60-
1
40-(D
G
U 20-
0
(c) 100-1
s 80-
g 60-
1
a 40-D
COu 20-
ATP ADP AMP INOSINE
UTP UDP UMP URIDINE
AP. ATP ADP AMP INOSINE
Concentration of (a) ATP, (b) UTP and (c) AP^ and the appearance of their 
metabolites following a 30 minute incubation period with Tyrode buffer which had 
previously contained the rat colon muscularis mucosae for 1 hour in the absence 
(open columns) and presence (closed columns) of suramin (ImM). Each column is 
the mean of at least 3 determinations and the vertical bars show s.e.mean. For 
abbreviations see main body of text. Statistical analysis for control versus suramin- 
treated tissues was performed using Students unpaired t-test (* P < 0.05; ** P < 
0.05; ***P < 0.001).
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Figure 3.18. Effect o f Suramin on the M etabolism o f (a) Ap2A, (b) Ap^A and (c)
Ap^A by Enzymes Released into the Buffer by the Rat Colon Muscularis M ucosae
(a) 100-
U 20
(b) 100
(c) 1 0 0 - 1
ApgA ADP AMP INOSINE
U 20
ApgA ADP AMP INOSINE
U 20
j m
Ap.A ATP ADP AMP INOSINE
Concentration of (a) AP2 A, (b) Ap^A and (c) Ap^A and the appearance of their 
metabolites following a 30 minute incubation period with Tyrode buffer which had 
previously contained the rat colon muscularis mucosae for 1 hour in the absence 
(open columns) and presence (closed columns) of suramin (ImM). Each column is 
the mean of at least 3 determinations and the vertical bars show s.e.mean. For 
abbreviations see main body of text. Statistical analysis for control versus suramin- 
treated tissues was performed using Students unpaired t-test (* P < 0.05).
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Figure 3.19. Effect o f Suramin on the M etabolism o f (a) Ap^A and (b) Ap^A by
Enzymes Released into the Buffer by the Rat Colon Muscularis M ucosae
(a) 100-,
80-
60-
S 40
20-
0
(b) 100^
80
60-
§ 40
20-
0
n m
Ap.A AP. ATP ADP AMP INOSINE
Ap.A AP. AMP INOSINE
Concentration of (a) Ap^A and (b) Ap^A and the appearance of their metabolites 
following a 30 minute incubation period with Tyrode buffer which had previously 
contained the rat colon muscularis mucosae for 1 hour in the absence (open 
columns) and presence (closed columns) of suramin (ImM). Each column is the 
mean of at least 3 determinations and the vertical bars show s.e.mean. For 
abbreviations see main body of text. Statistical analysis for control versus suramin- 
treated tissues was performed using Students unpaired t-test (* P < 0.05; ** P < 
0.05).
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Figure 3.20. Effect o f 8-SPT on the Degradation o f ATP by the Rat
Colon Muscularis M ucosae
(a)
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20 -
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(b)
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%  80- i
60- 
Ic 40- 
U
20-
5 10 15 20 25 300
Time (minutes)
Degradation of ATP (■) (lOOjLiM) by the rat colon muscularis mucosae in the 
absence (a) and presence (b) of 8-SPT (l|iiM) and the appearance of its 
metabolites ADP (•) , AMP (A) and inosine (♦). Each point is the mean of at 
least 3 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed on control and suramin-treated tissues using repeated measures 
2-way ANOVA. For abbreviations see main body of text.
No significant differences were observed between control and treated tissues.
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The level of adenosine observed in 10|iM EHNA-treated tissues was significantly 
different than in control and IjiM EHNA-treated tissues (P < 0.01).
Figure 3.21. Effect o f EH NA on the Degradation o f ATP by the Rat
Colon Muscularis M ucosae
(a) 120
U 20
10 15 20 25
Time (minutes)
80-
40-
0 5 10 15 20 25 30
Time (minutes)
(c) 120
8 40
U 20
10 15 20
Time (minutes)
Degradation of ATP (■) (lOOjiM) by the rat colon muscularis mucosae in the 
absence (a) and presence of (b) 1|liM EHNA or (c) lOpM EHNA and the 
appearance of its metabolites ADP (#), AMP (À), adenosine (□) and inosine 
(♦). Each point is the mean of at least 3 determinations and the vertical bars 
show s.e.mean. Statistical analysis was performed using 2-way repeated 
measures ANOVA. For abbreviations see main body of text.
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Figure 3.22. Effect o f Allopurinol on the Degradation o f ATP by
the Rat Colon Muscularis M ucosae
(a)
120-,
lOOi
§
3  80-
g
' 60- 
g
g 40- 
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20-
10 15 20 25 3050
Time (minutes)
80
20
Time (minutes)
Degradation of ATP (■) (lOOjxM) by the rat colon muscularis mucosae in 
the absence (a) and presence (b) of allopurinol (1|liM) and the appearance of 
its metabolites ADP (•) , AMP (À) and inosine (♦). Each point is the mean 
of at least 3 determinations and the vertical bars show s.e.mean. Statistical 
analysis was performed between control and allopurinol-treated tissues using 
2-way repeated measures ANOVA. For abbreviations see main body of text.
N o significant differences were observed between control and treated tissues.
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The level of AMP observed in 10|iM NBTI-treated tissues was significantly different
than in control and l^iM NBTI-treated tissues (P < 0.01).
Figure 3.23. Effect o f NBTI on the Degradation o f ATP by the
Rat Colon Muscularis M ucosae
80-
U  2 0 -
0 5 10 15 20 25 30
Time (minutes)
(b) 120
% 40
V 20
5 10 15 20 25
Time (minutes)
(c) 120
U 20
0 5 10 15 20 25 30
Time (minutes)
Degradation of ATP (■) (100|iM) by the rat colon muscularis mucosae in the 
absence (a) and presence of (b) IjiM NBTI or (c) lOpM NBTI and the 
appearance of its metabolites ADP (•) , AMP (A) and inosine (♦). Each 
point is the mean of at least 3 determinations and the vertical bars show 
s.e.mean. Statistical analysis was performed between control and NBTI- 
treated tissues using 2-way repeated measures ANOVA. For abbreviations 
see main body of text.
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Figure 3.24. Effect o f 8-SPT on the Half-life for the Degradation o f
ATP by the Rat Colon Muscularis M ucosae
(a)
1.5-
5  0.5-
5 15 2510 20 300
(b)
Time (minutes)
2.5-,
1.5-
bûO
0.5-
15 255 10 20 300
Time (minutes)
Half-life for the degradation of ATP (100|aM) by the rat colon muscularis 
mucosae in the absence (a) and presence (b) of 8-SPT (IpM). Each point is the 
mean of at least 3 determinations and in each case the error bars were smaller than 
the symbol size. Statistical analysis was performed using Students unpaired t-test. 
For abbreviations see main body of text.
No significant differences were observed between control and treated tissues.
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Figure 3.25. Effect o f EH NA on the H alf-life for the Degradation o f ATP
by the Rat Colon Muscularis M ucosae
1.5-
0.5-
0 5 15 20 25 3010
Time (minutes)
(b) 2m
1.5-
0.5-
5 10 15 20 25 300
Time (minutes)
2m
1.5-
0.5-
0 5 10 15 20 25 30
Time (minutes)
Half-life for the degradation of ATP (lOOpM) by the rat colon muscularis 
mucosae in the absence (a) and presence of (b) IpM EHNA or (c) lOpM 
EHNA. Each point is the mean of at least 3 determinations and in each case 
the error bars were smaller than the symbol size. Statistical analysis was 
performed between control and EHNA-treated tissues using Students unpaired 
JTest. For abbreviations see main body of text.
No significant differences were observed between control and treated tissues.
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Figure 3.26. Effect o f Allopurinol on the Half-life for the Degradation of
ATP by the Rat Colon Muscularis M ucosae
(a)
1.5-
o 0.5-
5 150 10 2520 30
(b)
Time (minutes)
1.6-
1.4-
1.2-
5 150 10 20 25 30
Time (minutes)
Half-life for the degradation of ATP (lOOpM) by the rat colon muscularis 
mucosae in the absence (a) and presence (b) of IpM allopurinol. Each point 
is the mean of at least 3 determinations and in each case the error bars were 
smaller than the symbol size. Statistical analysis was performed between 
control and allopurinol-treated tissues using Students unpaired t-test. For
abbreviations see main body of text.  '' —  - - - —   —  -  - --- - - ■
N o significant differences were observed between control and treated tissues.
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Figure 3.27. Effect o f NBTI on the Half-life for the Degradation o f ATP
by the Rat Colon Muscularis M ucosae
(a) 2-m
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0.5-
5 10 15 20 25 300
Time (minutes)
1.5-
0.5-
5 10 15 20 25 300
Time (minutes)
(c) 2 -f
1.5-
V-I
0.5-
150 5 10 2520 30
Time (minutes)
Half-life for the degradation of ATP (lOOpM) by the rat colon muscularis 
mucosae in the absence (a) and presence of (b) IpM NBTI or (c) lOpM NBTI. 
Each point is the mean of at least 3 determinations and in each case the error bars 
were smaller than the symbol size. Statistical analysis was performed between 
control and NBTI-treated tissues using Students unpaired t-test. For abbreviations 
see main body of text.
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No significant differences were observed between control and treated tissues.
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The level of AMP observed was significantly decreased and that of inosine increased at 
pH 5.5 and 6.5 when compared to pH 7.4 (P < 0.05).
Figure 3.28. Effect o f pH on the Degradation o f ATP by the Rat Colon
Muscularis M ucosae
(a) (b)
120120-1
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i  80-
c 40-
20 -20 -
¥ — ------1-------W----1------W
0 5 10 15 20 25 30 5 10 15 20 25 300
(c)
Time (minutes) Time (minutes)
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120-1 120-,
a  80- 9. 80-
60- 60-
40-
20 - 20 -
0 5 10 15 20 25 30 0 5 10 15 20 25 30
Time (minutes) Time (minutes)
Degradation of ATP (■) (100|lM) and the appearance of its metabolites ADP (•) , 
AMP (A) and inosine (♦) by the rat colon muscularis mucosae at different pH levels 
(a) pH 5.5; (b) pH 6.5; (c) pH 7.4 and (d) pH 8.0. Each point is the mean of at least 3 
determinations and the vertical bars represent s.e.mean. Statistical analysis was 
performed between control (pH 7.4) and pH adjusted tissues using 2-way repeated 
measures ANOVA. For abbreviations see main body of text.
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3.4. Discussion
The rat colon muscularis mucosae contains both PI and P2 receptors mediating the 
same response, that is contractile responses are observed to adenosine and ATP. The 
functional structure-activity relationships of the P2 receptor present in this tissue are 
typical of those observed at a P^ y receptor, in that the order of potency is 2MeS ATP > 
ATP > AMPCPP. The pyrimidine nucleotide, UTP, is also active in the rat colon 
muscularis mucosae (Hourani et al, 1993), which is presumed to indicate the presence 
of an additional P2 receptor subtype , responsive to UTP.
In addition, the structure-activity relationships in functional pharmacology experiments 
has been shown to be Ap^A = Ap^A > ATP = AP4  = Ap^A > UTP, for the purine and 
pyrimidine nucleotides and the diadenosine polyphosphates (Hourani et al., 1998). 
However, the same functional studies revealed that only those concentration-response 
curves for ATP and UTP were right shifted in the presence of lOOjiM suramin, with 
only the higher concentrations of Ap^A, Ap^A and AP4  being inhibited and no 
consistent inhibition of responses to Ap^A being observed. This has led to the 
suggestion that the effects of Ap^A and the lower concentrations of Ap^A, AP4 A and 
AP4  are not mediated by P2 receptors, and the antagonism by an A,-selective 
concentration of DPCPX (lOnM) of these agonists but not of responses to ATP and 
UTP confirms this conclusion (Hourani gr al., 1998). The higher concentration of 
suramin (ImM) has paradoxical effects in that it only inhibits those responses to UTP, 
with responses to ATP being slightly enhanced and all the other agonists being 
unaffected at concentrations lower than 300}xM. Based on the ability of suramin to 
inhibit the action of UTP in this tissue it is likely that the P2Y receptor via which UTP 
is acting is of the P2 Y2  subtype rather than the P2 Y4  receptor.
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In the light of these previous pharmacological studies the effects of nucleotides in the rat 
colon muscularis mucosae was thought likely to be influenced by their rate of 
extracellular degradation and the appearance and accumulation of their breakdown 
products in the extracellular compartment. The effect of suramin (ImM) has also been 
studied and is reported in this thesis to determine the existence of any influences on the 
observed pharmacological responses by the rate of breakdown of the various agonists. 
This thesis also represents the first report of the extracellular degradation of the 
diadenosine polyphosphates by any smooth muscle preparation and by any tissue for 
which the pharmacological profile has previously been determined.
ATP was rapidly degraded by this tissue, but no adenosine was detectable in the 
incubation buffer, presumably due to the deamination by adenosine deaminase being 
too rapid and/or the removal of adenosine via membrane-bound nucleoside transporters. 
Although this breakdown appeared to be slightly reduced in the presence suramin, this 
effect did not reach statistical significance although it may still explain the enhancement 
of pharmacological responses to ATP by this concentration (ImM) of suramin.
The fact that NBTI, at a concentration sufficient to inhibit both sensitive and insensitive 
equilibrative nucleoside transport (ENT) processes (Thom & Jarvis, 1996), did not 
affect adenosine removal and conversion to inosine in the rat colon muscularis mucosae 
suggests that here too the adenosine deaminase may be extracellular. An alternative 
explanation is that any uptake of adenosine in this tissue may be via NBTI-insensitive 
concentrative nucleoside transport (CNT) processes, which are normally associated 
with epithelia (Thom & Jarvis, 1996; Jennings et al., 1998) and could feasibly be 
present in this tissue preparation. Of those subtypes which have been cloned, mRNA 
for CNTl and CNT2 has been detected in the rat and human gastrointestinal tract (Che 
etal., 1995; Wang et al., 1997), although the activity of sodium-dependent nucleoside
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transport processes was reported to decrease down the length of the small intestine in 
the guinea-pig and the rabbit, and in rabbit descending colon such activity was absent 
(Schwenk er fl/., 1984; Roden etal., 1991).
The adenosine receptor antagonist 8 -SPT (IpM) had no effect on the extracellular 
breakdown of ATP by the rat colon muscularis mucosae. The absence of any effect of 
8 -SPT on the rate or pattern of ATP metabolism is perhaps due to the concentration 
used in the present study (Ip-M) being too low, since it has a reported pK^ value 
estimated at 5.23 ± 0.16 against NECA-mediated responses in rat isolated aorta 
(Prentice & Hourani, 1996) and an affinity of 4.8 at rat striatal receptors (Bruns et 
al., 1986). Therefore, a higher concentration of 8 -SPT should be considered in order 
to mle out any effects on ectonucleotidase activity in smooth muscle tissues at those 
levels required to cause antagonism of responses to agonists.
The lack of effect shown here on ATP metabolism by the xanthine oxidase inhibitor 
allopurinol suggests that this enzyme is not involved in the further metabolism of 
inosine. The concentration of allopurinol used here (l|iM) should have been sufficient 
to inhibit this enzyme, as it has been reported to have a K- value in the nM range, 
although the kinetics of the inhibition are not simple and indeed preincubation resulted 
in the inactivation of this enzyme (Elion, 1978).
The degradation of AP  ^and the diadenosine polyphosphates (ApjA - Ap^A) was less 
rapid than that of ATP in the presence of the rat colon muscularis mucosae which is in 
agreement with reports of their breakdown in the presence of other tissues (Pohl et al., 
1991; Ogilvie, 1992; Rodriguez-Pascual e ta l, 1992; Pintor et a l, 1996). In addition, 
unlike the situation with ATP, suramin (ImM) significantly inhibited the degradation 
and, therefore, increased the half-life of the diadenosine polyphosphates and of AP4 , as
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was the case in the Torpedo electric organ and synaptic terminals where suramin was 
reported to be a powerful inhibitor of ecto-diadenosine polyphosphate hydrolase (Mateo 
et al., 1996). This effect of suramin could explain the apparent lack of any inhibitory 
effect of suramin (ImM) on the functional responses of these agonists. As a corollary 
to this however, the rate of degradation of UTP was even more rapid than that of ATP 
and was also inhibited by suramin, whereas no enhancement of the responses to UTP 
were observed in the presence of suramin, only a dose-dependent inhibition (Hourani et 
al., 1998). The enhancement by suramin of functional responses to adenine nucleotides 
may, therefore, be due to factors other than a simple inhibition of degradation.
Recently there have been a number of reports concerning the effects of extracellular pH 
on responses of cloned and recombinant P2Xj receptors (Stoop & Quayle, 1998; 
Wildman et al., 1998). ATP responses at recombinant P2%2 receptors are known to be 
modulated by extracellular levels, which potentiate responses to ATP at these 
receptors (Brake et al., 1994; Nakazuma & Ohno, 1996; 1997). Similarly, agonist 
activity at the P2%2 receptor is also strongly affected by extracellular pH, with 
acidification (i.e. an increase in H )^ increasing and alkalinisation decreasing agonist 
potency at this ATP-gated ion channel (King etal., 1996; 1997; Wildman et al., 1997). 
Recombinant P2X receptors expressed in Xenopus oocytes exhibit increased ATP- 
activated membrane currents upon both the acidification of the bathing medium and an 
increasing Zv^^ concentration (0.3-300jiM) (Wildman et al., 1998). Further, both 
acidification and increasing Zn^  ^ levels have been shown to enhance the activity of the 
P2 receptor antagonist suramin, at the P2 X2  receptor (Wildman et al., 1998). The 
authors concluded that although Zn^  ^ and H  ^ may be acting through a common 
mechanism, these potentiating effects were unlikely to be due to an inhibitory action on 
ecto-ATPases, since the modulatory actions of Zn^  ^ and H  ^ on ATP activity differ in 
time course and defolliculated oocytes are largely devoid of surface enzymes
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responsible for the degradation of ATP (Ziganshin et al, 1995). Wildman et a l (1998) 
found that exerted a greater effect than Zn^ '^  on ATP responses at PIX^ receptors. 
At pH 5.5 the EC^ value of ATP being 547 ± 39nM and 16.2 ± 1.4pM at pH 7.5, a 30 
fold increase in ATP potency. The authors also noted that the potency of ATP 
decreased when the pH of the bathing medium was increased from pH 7.5 to pH 8.0. 
The results of the present study suggest that while there is no significant difference in 
the rate of extracellular ATP breakdown over the range of pH levels tested (5.5 - 8.0), 
although on acidification to pH 5.5 and 6.5 the level of AMP observed in the incubation 
medium is decreased when compared to that at pH 7.4 and 8.0. This decrease in AMP 
levels is accompanied by an increase in the inosine concentration in the incubation 
buffer, suggesting that acidification leads to an increase in the activity of the enzymes 
responsible for the degradation of AMP to inosine via adenosine, i.e. ecto- 
5’nucleotidase and/or adenosine deaminase. The fact that no differences were observed 
in the level of extracellular adenosine in tissues preincubated in acidified buffer indicates 
that the increased activity of both these enzymes occurs to a similar extent.
If the receptors present on the rat colon muscularis mucosae are indeed of the P2Yj 
subtype then the production of ADP from the degradation of ligands such as ATP, AP  ^
and the diadenosine polyphosphates, with the exception of Ap^A, must be an important 
consideration when assessing the pharmacological responses to these ligands in vitro. 
The production of ADP was shown to reach levels which should be carefully 
considered when evaluating functional responses to ATP, Ap^A and Ap^A.
In view of the greater stability of the diadenosine polyphosphates in comparison to 
ATP, it is surprising that their pharmacological effects in the rat colon muscularis 
mucosae should be inhibited more effectively than the actions of ATP itself by DPCPX, 
suggesting that their major effect is via A, receptors and not P2 receptors. That they
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have actions which are identified as being mediated via adenosine is not itself surprising 
since all of these agonists are capable of degradation to adenosine, although this was 
not detectable in the incubation buffer. Indeed, significantly lower total concentrations 
of the breakdown products were detected in the incubation medium than might have 
been expected, suggesting a possible role for the uptake of adenosine in the termination 
of the actions of these ligands at their extracellular receptors.
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Chapter 4
RAT VAS DEFERENS
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4.1. Introduction
The rat vas deferens has been used extensively in the study of the pharmacological 
properties of receptors for both adenosine and ATP (Hoyle, 1992; see Morris & 
Gibbins, 1992; Bumstock, 1995; Hourani et al., 1998). Stimulation of the 
sympathetic nerves of the rat vas deferens produces a biphasic response due to the 
neuronal release of the cotransmitters ATP and NA, with ATP acting primarily through 
ionotropic P2Xj receptors although there have been suggestions that other receptors 
may contribute to the response (Biiltmann & Starke, 1994; Valera et al., 1994; Khakh 
etal., 1995).
Further, adenosine has been shown to inhibit neurotransmitter release by an action at 
prejunctional Aj receptors (Muller & Paton, 1979; Paton, 1981) and the rat vas 
deferens has prevously been shown to have postjunctional A^ x receptors which inhibit 
contractions and postjunctional Aj receptors which have been shown to enhance 
contractile responses to ATP and other agonists (Hourani et al., 1993; Hourani & 
Jones, 1994; Martin & May, 1994; Brownhill et al., 1996). Therefore, the balance 
between the relative concentrations of adenosine and ATP in the incubation medium 
will have implications for the observed responses in pharmacological studies.
The rat vas deferens has previously been shown by a number of authors to degrade 
extracellular ATP via ectonucleotidases on its surface, and it has been proposed that 
this breakdown is likely to distort the observed pharmacological effects of agonists and 
antagonists (Kurz etal., 1994; Bultmann etal., 1995; 1996; Bultmann & Tuluc, 1995; 
Khakh etal., 1995; Wittenberg et al., 1996; Tuluc et al., 1998). This degradation is 
presumed to be via the sequential dephosphorylation of ATP to ADP, AMP, adenosine 
and by deamination to inosine. Alternatively, adenosine may undergo uptake into cells
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via membrane-bound transport mechanisms (see Zimmermann et al., 1995; Ijzerman & 
Van der Wenden, 1998).
Brief periods of myocardial ischaemia and reperfusion have been shown to decrease 
the extent of cellular injury resulting from a subsequent prolonged ischaemia. The 
underlying mechanism of this phenomenon, termed ischaemic preconditioning, 
remains unclear, although the effect has been demonstrated in a number of species. 
Adenosine, synthesised from AMP by ecto-5’nucleotidase, protects the heart from 
injury induced by ischaemia-reperfusion (Olafsson et al., 1987). The first 
demonstration that activation of adenosine receptors resulted in ischaemic 
preconditioning was by Liu and co-workers (1991). The use of adenosine receptor 
antagonists to inhibit the cardioprotective effects of ischaemic preconditioning and of 
adenosine receptor agonists to mimic the infarct size-limiting effect of this 
preconditioning in rabbits (Thornton et al., 1992), dogs (Kitakaze et al., 1993) and 
man (Walker etal., 1995) provided further evidence for the involvement of adenosine 
receptor systems in this preconditioning effect. Further, Ytrehus et al. (1994) showed 
that ischaemic preconditioning protects rabbit heart against ischaemic injury via 
activation of PKC, and that the underlying mechanism of PKC activation is attributable 
to either adenosine (Liu et al., 1994) and/or catecholamines (Tsuchida et al., 1994).
It has recently been shown in the rat and canine heart that the activity of ecto- 
5'nucleotidase is increased by the action of certain agents which activate PKC, 
including lysophosphatidylcholine (LPC) and that this activation with the consequent 
increase in adenosine concentration may play a role in the phenomenon of ischaemic 
preconditioning which protects against reperfusion injury (Minamino et al., 1996; 
Node etal., 1997; Sato etal., 1998). It has also demonstrated that the PKC inhibitor, 
chelerythrine completely abolishes the increase in adenosine production afforded by
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preincubation with LPC (Sato etal., 1998). The effects of activators of other protein 
kinases, such as forskolin and sodium nitroprusside, have not previously been 
studied, although, by activating adenylate cyclase and soluble guanylate cyclase, 
respectively, should stimulate cAMP-dependent and cGMP-dependent protein kinases. 
The effects of these compounds have been studied in the following experiments. The 
calcium ionophore, A23187 was also used to look at the possible effects of calcium- 
dependent protein kinases on the activity of ectonucleotidases in this tissue.
The use of the a-adrenoceptor agonist, noradrenaline, which activates both protein 
kinase C and calcium-dependent protein kinases via activation of phospholipase C 
(PLC) is of particular relevance in this tissue due to its co-release with ATP from 
sympathetic nerves in both the guinea-pig and rat vas deferens (Todorov et al., 1997).
In contrast, the channel blockers glibenclamide and glipizide have been shown to 
inhibit the activity of ecto-5'nucleotidase in the rat heart, thereby reducing adenosine 
production (Sato et al., 1997). The authors also found that the level of inosine was 
decreased in the presence of glibenclamide, making it unlikely that the decrease in the 
extracellular adenosine concentration was due to increased adenosine deaminase 
activity. The possibility that glibenclamide was increasing the activity of adenosine 
kinase and/or facilitating the uptake of adenosine via nucleoside transporters was 
eliminated since glibenclamide (30p,M) did not decrease the level of adenosine in the 
absence of AMP, that is baseline adenosine levels. The antidiabetic sulphonylureas 
such as glibenclamide and tolbutamide inhibit K\.^p channels by binding to a 
sulphonylurea receptor associated with the inwardly rectifying channel (Inagaki et 
al., 1995). Unlike glibenclamide, tolbutamide does not increase the level of 
extracellular adenosine detected in the presence of AMP. Furthermore, a distinct type 
of channel blocker, 5-hydroxydecanoate, has no effect on the level of
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extracellular adenosine duifig a constant supply of AMP (Sato et al., 1997). The 
authors have concluded from these results that the inhibitory effect of glibenclamide on 
ecto-5’nucleotidase does not result from the blockade of K\^p channels, but by a 
direct interaction with the enzyme. It was, therefore, of interest to study the effects of 
these compounds in the rat vas deferens, a tissue known to produce adenosine 
following incubation with ATP (Kurz et al., 1994; Bultmann et al., 1995; 1996; 
Bultmann & Tuluc, 1995; Khakh et al., 1995; Wittenberg et al., 1996; Tuluc et a l, 
1998).
4.2. Methods
Male Wistar Albino rats (250-250g) were killed by cervical dislocation, the abdomen 
was opened and the whole vasa deferentia were removed. The vas deferens was then 
cleared of connective tissue and 3cm lengths were removed and placed in 1.5ml of 
warmed (37°C) Krebs solution of the following composition (mM): NaCl 118.0, KCl 
4.8, MgClj 1.2, NaHCOg 25.0, KH2 PO4  1.2, CaCl2  2.5 and glucose 11.0, gassed 
with 95% O2  / 5% CO2 . Each tissue was placed in a separate tube containing 1.5ml of 
warmed (37°C) Krebs solution and equilibrated for 60 minutes.
Noradrenaline (lOpM), calcium ionophore, A23187 (10|iM), forskolin (10|iM), 
sodium nitroprusside (l|xM), glibenclamide (lOOpM) or glipizide (100p,M) were 
added as appropriate in a volume of 15p,l, or water (15|xl) or 1% dimethylsulphoxide 
(DMSO) were added as vehicle controls, and the tissues incubated for a further 60 
minutes with frequent changes of Krebs solution, with drugs or vehicles being 
readded at each change. Tissues were then transferred to tubes containing 1.5ml 
Krebs solution with ATP (lOOpM) and either noradrenaline, calcium ionophore
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A23187, forskolin, sodium nitroprusside, glibenclamide or glipizide as appropriate, or 
with water or 1% DMSO as before.
Aliquots (50p,l) of incubation buffer were taken at 0, 2, 5, 10, 20, and 30 minutes, 
placed immediately on ice prior to being frozen at -20°C for later analysis by h.p.I.e. 
See Section 2.2. for the detailed descriptions of sample preparation and h.p.l.c. 
analysis.
Nucleotides and nucleosides were detected by ultraviolet absorbance (u.v.) at their 
optimum wavelengths (see Table 2.1.) using a Shimadzu SPD-lOA u.v./visible 
detector, and were quantified by the area of their individual absorbance peaks, which 
was linearly related to their concentration (see section 2.3.). The results were 
displayed graphically as the mean and standard error of the mean (s.e.mean) of the 
concentrations.
4.2.1. Materials
ATP, noradrenaline, calcium ionophore A23187, forskolin, sodium nitroprusside and 
tetrabutylammonium hydrogen sulphate (h.p.l.c. grade) were obtained from Sigma 
Chemical Company, Poole, UK. Acetonitrile (h.p.l.c. grade), potassium hydroxide 
and all buffer salts (analytical grade) were obtained from Fischer Scientific, 
Loughborough, UK. 95% 0^/5% COj gas cylinders were supplied by British Oxygen 
Company, Guildford, UK.
4.2.2. Statistics and Data Analysis
Concentration time curves were constmcted from the non-transformed data. Semi-log 
plots of the log concentration versus time data were constructed. From these the half­
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life (tj/2 ) of the substrate was determined from the straight line fit and the time in 
minutes taken for the initial concentration of the substrate to decrease by 50% was 
determined. The rate constant for each individual reaction was calculated from the 
half-life using the equation k^ ^^  = 0.692>Hy2.
The absolute levels of all the substrates and degradation products were compared at all 
time points sampled between control and treated samples using 2-way ANOVA 
followed by Dunnetts post-hoc test. The tj, 2  for each substrate and the k^ g^ for each 
reaction were compared using an unpaired Student t-test.
4.3. Results
ATP (lOOjiM) was rapidly degraded by the rat vas deferens with a half-life of 5.83 ± 
0.4 minutes (Figure 4.7. and Table 4.1.). The major breakdown products were 
initially ADP and AMP, with the ultimate breakdown product being inosine. Little or 
no adenosine was detected in the incubation buffer (Figure 4.1.).
The half-life of ATP in the presence of the rat vas deferens was not significantly 
affected by preincubation with NA (lOjiiM), calcium ionophore A23187 (lOpM), 
forskolin (10|iM), sodium nitroprusside (IpM), glibenclamide (lOOpM) or glipizide 
(lOOpM), the half-lives in minutes being 6.90 ± 1.22, 5.86 ± 1.40, 3.92 ± 0.72, 7.22 
± 2.72, 4.03 ± 1.65 and 4.93 ± 1.14, respectively (Figures 4.7.; 4 .8 . and Table
4 .1 .).
Although no significant effects on the half-life of ATP degradation were determined in 
the presence of the named compounds, preincubation of the rat vas deferens with both 
forskolin and sodium nitroprusside resulted in significantly (P < 0.05) increased 
concentrations of AMP detected in the incubation buffer between the time points
185
measured. In the presence of forskolin the absolute level of extracellular AMP 
detected in the incubation buffer exceeded 20fxM after 5 minutes incubation, whereas 
in the control tissues the level of AMP did not exceed 9pM at any time point between 0 
and 30 minutes (P < 0.0001, after 5 minutes incubation) (Figure 4.3. (a) ; (b)). 
Preincubation with sodium nitroprusside also resulted in an increased level of 
extracellular AMP as compared with control tissues, where the level in the presence of 
sodium nitroprusside was in excess of 25jxM after 5 minutes incubation compared to 
control levels of 8.6)liM (P < 0.001) (Figure 4.4. (a); (b)). In addition,
preincubation with sodium nitroprusside also resulted in a simultaneous decrease in the 
level of inosine detected in the incubation buffer as compared with control tissues (P < 
0.0001) (Figure 4.4. (a); (b)). The level of inosine in control tissues exceeded 
40pM after 30 minutes incubation and was only 30pM in the presence of sodium 
nitroprusside. However, there was no corresponding change in the level of adenosine 
detected in the incubation buffer in sodium nitroprusside-treated tissues.
All other treatments, calcium ionophore A23187, glibenclamide or glipizide, had no 
significant effects on the level or rate of production of metabolites produced by the 
extracellular degradation of ATP by the rat vas deferens.
The rat vas deferens also degraded extracellular AMP extremely rapidly in both control 
tissues and those pretreated with forskolin (10|iM). Using this method it was not 
feasible to calculate a value for the half-life of AMP in the presence of the whole rat 
vas deferens as no AMP was detectable in the incubation medium after only 2 minutes 
in the forskolin-treated tissues and only a low level observed in the control tissues after 
2 minutes (Figure 4.9. (a); (b)).
ATP was degraded at a much slower rate by incubation buffer which had previously 
contained the whole rat vas deferens, with 55.2 ± 3.1|xM ATP remaining after 30
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minutes (Figures 4.10. ; 4.11.). Noradrenaline, calcium ionophore A23187, 
glibenclamide and glipizide had no effect on either the rate of ATP degradation or on 
the pattern and extent of metabolites detected during the 30 minute incubation period. 
However, preincubation of tissues with both forskolin and sodium nitroprusside 
resulted in a significant increase in the level of AMP detected in the buffer after 30 
minutes (P < 0.001), with no accompanying changes in the levels of ATP, ADP, 
adenosine or inosine detected or in the half-life for extracellular ATP degradation 
(Figures 4.10 (c) ;4.11. (a)).
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No significant differences were observed between control and treated tissues.
Figure 4.1. Effect o f Noradrenaline on the Degradation o f ATP by the
Rat Vas Deferens
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Degradation of ATP (100|iM) (■) by the rat vas deferens and appearance of 
the metabolites ADP (#), AMP (À), adenosine (□) and inosine (♦) in the 
absence (a) and presence (b) of noradrenaline (lOpM). Each point represents 
the mean of at least 4 determinations and the vertical bars show s.e.mean. 
Statistical analysis was performed between control and noradrenaline-treated 
tissues using repeated measures 2-way ANOVA. For abbreviations see main 
body of text.
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No significant differences were observed between control and treated tissues.
Figure 4.2. Effect o f Calcium Ionophore A 23187 on the Degradation of
ATP by the Rat Vas Deferens
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Degradation of ATP (lOOfxM) (■) by the rat vas deferens and appearance 
of the metabolites ADP (#), AMP (À), adenosine (□) and inosine (♦) in 
the absence (a) and presence (b) of A23187 (10|liM). Each point 
represents the mean of at least 4 determinations and the vertical bars show 
s.e.mean. Statistical analysis was performed between control and 
A23187-treated tissues using repeated measures 2-way ANOVA. For 
abbreviations see main body of text.
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T h e  l e v e l  o f  inosine in forskolin-treated tissues was significantly higher than in controls
(P < 0.05).
Figure 4.3. Effect o f  Forskolin on the Degradation o f ATP by the
Rat Vas Deferens
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Degradation of ATP (lOOjiM) (■) by the rat vas deferens and appearance of the 
metabolites ADP (#), AMP (À), adenosine (□) and inosine (♦) in the absence 
(a) and presence (b) of forskolin (lOpM). Each point represents the mean of at 
least 4 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed between control and forskolin-treated tissues using repeated 
measures 2-way ANOVA. For abbreviations see main body of text.
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The level of inosine in sodium nitroprusside-treated tissues was significantly higher than 
in controls (P < 0.05).
Figure 4.4. Effect o f Sodium Nitroprusside on the Degradation o f ATP
by the Rat Vas Deferens
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Degradation of ATP (lOOpM) (■) by the rat vas deferens and appearance of 
the metabolites ADP (#), AMP (A), adenosine (□) and inosine (♦) in the 
absence (a) and presence (b) of sodium nitroprusside (IpM). Each point 
represents the mean of at least 4 determinations and the vertical bars show 
s.e.mean. Statistical analysis was performed between control and sodium 
nitroprusside-treated tissues using repeated measures 2-way ANOVA. For 
abbreviations see main body of text.
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Figure 4.5. Effect o f Glibenclamide on the Degradation o f ATP by the
Rat Vas Deferens
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Degradation of ATP (100|iM) (■) by the rat vas deferens and appearance of the 
metabolites ADP (• ) , AMP (À), adenosine (□) and inosine (♦) in the absence 
(a) and presence (b) of glibenclamide (lOOpM). Each point represents the mean 
of at least 4 determinations and the vertical bars show s.e.mean. Statistical 
analysis was performed between control and glibenclamide-treated tissues using 
repeated measures 2-way ANOVA. For abbreviations see main body of text.  i _ —   —«/ -.......  ----   —-   - —'— -■ - — -.  ,
No significant differences were observed between control and treated tissues
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No significant differences were observed between control and treated tissues.
F igure 4.6. Effect o f Glipizide on the Degradation o f ATP by the
Rat Vas Deferens
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Degradation of ATP (lOOjiM) (■) by the rat vas deferens and appearance of the 
metabolites ADP (#), AMP (A), adenosine (□) and inosine (♦) in the absence
(a) and presence (b) of glipizide (100|xM). Each point represents the mean of at 
least 4 determinations and the vertical bars show s.e.mean. Statistical analysis 
was performed between control and glipizide-treated tissues using repeated 
measures 2-way ANOVA. For abbreviations see main body of text.
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No significant differences were observed between control and treated tissues
F igure 4.7. Effect o f Noradrenaline and Calcium lonophore A 23187 on the
H alf-life for the Degradation o f ATP from an Initial Concentration o f lOOpM
by the Rat Vas Deferens
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Half-life for the degradation of ATP from an initial concentration of lOOpM 
following incubation with the rat vas deferens in the absence (a) and presence of
(b) noradrenaline (lOpM) or (c) calcium ionophore, A23187 (lOpM). Each point 
is the mean of at least 4 determinations and the error bars were smaller than the 
symbol size in each case. Statistical analysis was performed between control and 
treated tissues using unpaired Student t-test.
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Figure 4.8. Effect o f Forskolin, Sodium Nitroprusside, Glibenclamide and
Glipizide on the Half-life for the Degradation o f ATP from an Initial
Concentration o f lOOpM by the Rat Vas Deferens
(a) (b)
3 3
1I I
0.10.1 0 5 10 15 20 25 3050 10 15 20 25 30
Time (minutes) Time (minutes)
(c) (d)
33
§1
I 1Io
W)o
I
bûO
0.1 0.1
5 10 15 20 25 300 50 10 15 20 25 30
Time (minutes) Time (minutes)
Half-life for the degradation of ATP from an initial concentration of lOOpM 
following incubation with the rat vas deferens in the presence of (a) forskolin 
(lOpM), (b) sodium nitroprusside (IpM), (c) glibenclamide (lOOpM) or (d) 
glipizide (lOOpM). Each point is the mean of at least 4 determinations and the 
error bars were smaller than the symbol size in each case. Statistical analysis was 
performed between control and treated tissues using unpaired Student t-test.
No significant differences were observed between control and treated tissues.,
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Figure 4.9. Effect o f Forskolin on the Degradation o f AMP by
the Rat Vas Deferens
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Degradation of AMP (À) (100|xM) by the rat vas deferens and the appearance 
of its metabolites adenosine (□) and inosine (♦) in the absence (a) and 
presence (b) of forskolin (10|liM). Each point is the mean of at least 3 
determinations and the vertical bars represent s.e.mean. Statistical analysis 
was performed between control and forskolin-treated tissues using repeated 
measures 2-way ANOVA. For abbreviations see main body of text.
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Figure 4.10. Effect o f  Noradrenaline, Calcium lonophore A 23187 or Forskolin on the
M etabolism o f ATP by Enzymes Released into the Buffer from the Rat Vas Deferens
ATP ADP AMP INOSINE
ATP ADP AMP INOSINE
80-
ATP ADP AMP INOSINE
Degradation of ATP and the appearance of its metabolites following a 30 minute 
incubation period with Tyrode buffer which had previously contained the rat vas 
deferens for 1 hour in the absence (open columns) and presence (closed columns) of (a) 
noradrenaline (lOjiM), (b) calcium ionophore, A23187 (10p,M) or (c) forskolin (10p,M). 
Each column is the mean of at least 4 determinations and the vertical bars show s.e.mean. 
For abbreviations see main body of text. Statistical analysis was performed between 
control and treated tissues using unpaired Student t-test (*** P < 0.001).
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F igure 4.11. Effect o f Sodium Nitroprusside, Glibenclamide or Glipizide on the
M etabolism o f ATP by Enzymes Released into the Buffer from the Rat Vas Deferens
100<*>
1 80-
1 60-
2
1 40-
g 20-
0
ATP ADP AMP INOSINE
ATP ADP AMP INOSINE
ATP ADP AMP INOSINE
Degradation of ATP and the appearance of its metabolites following a 30 minute 
incubation period with Tyrode buffer which had previously contained the rat vas 
deferens for 1 hour in the absence (open columns) and presence (closed columns) of 
(a) sodium nitroprusside (l|xM), (b) glibenclamide (lOOjiM) or (c) glipizide 
(100|xM). Each column is the mean of at least 4 determinations and the vertical bars 
show s.e.mean. For abbreviations see main body of text. Statistical analysis was 
performed between control and treated tissues using unpaired Student t-test (***P < 
0 .001).
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4.4. Discussion
Previous studies on the extracellular breakdown of ATP by ectonucleotidase enzymes 
in the rat vas deferens have concentrated primarily on the disappearance of ATP or on 
the release of inorganic phosphate (PJ, whereas in the present study the breakdown of 
ATP and the pattern of metabolites produced were observed simultaneously (Khakh et 
al, 1995; Bültmann et al, 1996a; b; Wittenburg et al., 1996; Tuluc et ah, 1998). The 
results presented in this thesis demonstrate that the major metabolite was inosine, with 
only very low levels of either ADP, AMP or adenosine being detected in the incubation 
buffer. This is in contrast to studies performed in this laboratory on the guinea-pig vas 
deferens, where using a comparable experimental protocol, adenosine was the major 
metabolite detected in the buffer, with lower amounts of inosine observed (Bailey & 
Hourani, 1994). This difference could relate to a species difference in the rate of 
production and removal of adenosine, via ecto-adenosine deaminase and/or nucleoside 
transporters, or it may arise as a direct consequence of using different incubation 
volumes in the two studies. For the guinea-pig vas deferens an incubation volume of 
3ml was used (Bailey & Hourani, 1994), whereas in the present study 1.5ml total 
volume was used. Since the average wet tissue weights were not markedly different 
(62mg for the guinea-pig vas deferens; 53mg for the rat vas deferens) the smaller 
volumes employed in the present study could well account for the observed increase in 
the rate of deamination of adenosine to inosine in the rat vas deferens. This is 
supported by the observation that when using bisected portions of the guinea-pig vas 
deferens, the extracellular breakdown of ATP in an incubation volume of 1.5ml results 
in essentially equal concentrations of adenosine and inosine (see Chapter 5 of this 
thesis).
In contrast to the reported inhibition of ecto-5’nucleotidase activity by the ATP- 
sensitive potassium channel (K’^ atp) inhibitor, glibenclamide, in the rat heart (Sato et
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a l, 1997), no effect of glibenclamide on either the rate of extracellular ATP 
degradation or on the pattern of metabolites produced was found in the rat vas 
deferens. In addition, another channel antagonist, glipizide, was also found to 
be without effect in this tissue. In the study on rat heart, Sato et a l (1997) reported an 
IC5 0  value for the inhibition of adenosine production from AMP by glibenclamide of 
10.5p.M, and lOOjiM inhibited adenosine production by approximately 85%. The lack 
of effect of both these inhibitors in the rat vas deferens is possibly due to tissue 
differences in the enzymes and uptake systems present within the two tissues and in 
the mechanisms by which their activities are regulated. Furthermore, it provides an 
indication that this effect of glibenclamide is not universal.
Contractile responses of the isolated rat vas deferens to noradrenaline, but not to ATP, 
have been shown to be mediated by protein kinase C (PKC) (Abraham & Rice, 1992), 
in addition to which PKC activation was reported to increase ecto-5’nucleotidase 
activity in rat and canine hearts (Minamino eta l, 1996; Node et a l, 1997; Sato et a l, 
1998), an effect shown to play a role in cardioprotection afforded by ischaemic 
preconditioning in these studies. Ischaemic preconditioning is the phenomenon 
whereby a cardioprotective effect against a prolonged ischaemic episode results 
following brief periods of ischaemia (Murry et a l, 1987). In contrast to the situation 
in the rat and canine hearts, the activation of PKC by noradrenaline in the rat vas 
deferens has no effect on the rate of extracellular ATP degradation or on the profile of 
breakdown products observed in the incubation buffer. Again this may be due to 
different regulatory mechanisms underlying the control of ectonucleotidase enzymes in 
these tissues.
The calcium ionophore A23187, was also shown to have no effect on the 
ectonucleotidase activity of the rat vas deferens, presumably demonstrating that 
calcium-dependent protein kinase activation does not influence the enzymes involved
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in extracellular ATP degradation in this tissue. However, both forskolin and sodium 
nitroprusside increased the levels of AMP detected following ATP breakdown, with 
no corresponding changes in the half-life of ATP degradation. This suggests that both 
forskolin and sodium nitroprusside, rather than increasing the rate of ATP conversion 
to AMP via ADP, cause an inhibition of the extracellular breakdown of AMP to 
adenosine and finally to inosine. Additionally, pretreatment of tissues with sodium 
nitroprusside resulted in an accompanying decrease in the production of inosine, 
possibly reflecting inhibition of ecto-5’nucleotidase or ecto-adenosine deaminase, 
although inhibition of the latter enzyme would be expected to result in a build-up of 
adenosine in the incubation buffer, which does not occur. That forskolin 
preincubation does not result in a decrease in the levels of inosine observed, suggests 
that the mechanism by which AMP levels are increased is by ecto-5 ’ nucleotidase 
inhibition. As forskolin and sodium nitroprusside have been shown to increase cyclic 
AMP (cAMP) and cyclic GMP (cGMP) levels, respectively, in the rat vas deferens at 
the concentrations used in the present study (Schultz et al., 1977; Diamond & Janis, 
1978; Haggblad & Fredholm, 1987), these effects may be due to increased cyclic 
nucleotide levels. Interestingly, however, the effects of sodium nitroprusside reported 
here are in contrast to a recent report that increases in intracellular cGMP levels 
enhanced ecto-5’nucleotidase activity in the rat ventricular myocardium in vivo (Obata 
et al., 1998). Overall, however, these effects of forskolin and sodium nitroprusside 
may reflect a degree of physiological control of extracellular ATP degradation and 
adenosine production, since both forskolin and sodium nitroprusside, like adenosine 
itself, act via increasing levels of cyclic nucleotides within cells.
The fact that ATP is degraded to a much lesser extent by incubation buffer which had 
previously contained the rat vas deferens suggests that the extent to which soluble 
ectonucleotidases are released from this tissue is small and significantly less than the 
degree to which extracellular ATP is metabolised by enzymes released into the buffer
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from gastrointestinal tissues such as the rat colon muscularis mucosae, 56|XM ATP 
remaining as compared to 27.3pM, respectively (P < 0.001, Students unpaired t-test) 
(see Chapter 3 of this thesis). This could be simply due the smaller tisue size of the 
vas deferens as compared to the colon muscularis mucosae, or may be a result of the 
preparation of the rat colon muscularis mucosae involving the removal of the outer 
layer of longitudinal muscle by a physically rubbing the tissue, resulting in the release 
of enzymes into the incubation buffer.
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Chapter 5
GUINEA-PIG VAS DEFERENS
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5.1. Introduction
The vas deferens has been extensively used in the pharmacological study of ATP 
receptors and their role in neurotransmission, especially as a cotransmitter with 
noradrenaline when released from sympathetic nerves to cause contraction of the 
guinea-pig vas deferens (Hoyle, 1992; Morris & Gibbins, 1992; Bumstock, 1995; 
Hourani etal., 1998). ATP causes a rapid transient contractile response by acting at 
ionotropic P2Xj receptors, whereas noradrenaline causes a slower, more sustained 
contraction via an action mediated by adrenoceptors (Morris & Gibbins, 1992; 
Valera et al., 1994). The non-adrenergic (purinergic) component of this response to 
sympathetic nerve stimulation is more pronounced at the prostatic end of the bisected 
vas deferens, while the adrenergic component is more marked at the epididymal end 
(McGrath, 1978). The difference, rather than reflecting different proportions of the 
two cotransmitters being released at the two ends, is believed to reflect the fact that 
noradrenaline is more potent at the epididymal end, whereas ATP is more potent at the 
prostatic end, and that the responses at the prostatic end are faster and more transient 
than those at the epididymal end (Sneddon & Machaly, 1992).
In addition, responses to adenosine have also been shown to vary between the two 
ends of the rat vas deferens. Although prejunctional inhibitory adenosine Aj receptors 
and postjunctional stimulatory adenosine A^  receptors are present at both ends, 
postjunctional inhibitory A^  receptors are only present at the prostatic end of the rat vas 
deferens (Brownhill etal., 1996).
Previous studies have shown that the guinea-pig and rat vas deferens rapidly degrade 
ATP via ectonucleotidase activity, resulting in sequential dephosphorylation of the 
phosphate chain to give rise to ADP, AMP and adenosine (Bailey & Hourani, 1994; 
see Plesner 1994; Ziganshin et al., 1994; Ziganshin et al., 1995 for reviews). The
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adenosine produced is then available to act at its own receptors, undergo deamination 
by ecto-adenosine deaminase to inosine or be taken up into cells by membrane-bound 
nucleoside transporters (Bailey & Hourani, 1994; see Plesner, 1994; Ziganshin et al., 
1994; Zimmermann et al., 1995 for reviews).
There is also evidence in the guinea-pig vas deferens that soluble ectonucleotidases are 
released from nerves on electrical stimulation in conjunction with the release of ATP 
from their storage granules, identifying a novel release system for the termination of 
action of a neurotransmitter substance (Todorov et ah, 1997). This study reported that 
the major breakdown product by the action of these soluble ectonucleotidases on 
released ATP was adenosine. The extracellular breakdown of ATP is the primary 
mechanism underlying its removal from the neuromuscular junction and, along with 
its hydrolysable analogues, this may reduce the observed potency of such ligands at 
P2 receptors, in addition to generating an extracellular pool of adenosine which overall 
has inhibitory effects, and certainly does in the guinea-pig vas deferens. Indeed, 
inhibition of ecto-ATPases by the novel ecto-ATPase inhibitor ARL 67156 has 
previously been shown to enhance responses to both exogenously added ATP and the 
purinergic component of nerve stimulation in the guinea-pig vas deferens (Westfall et 
al, 1996).
There has been a report that has suggested that tissue weight plays an important role in 
the extent to which ATP is metabolised extracellularly by the rat mesenteric artery 
(Plesner, 1997). To determine the effect of tissue weight and, more importantly, to 
determine the extent to which the influence of tissue weight might differ along the 
length of the bisected guinea-pig vas deferens (i.e. what contribution tissue weight 
makes to the extracellular degradation of ATP at the prostatic and epididymal ends of 
the vas deferens), studies on the extracellular breakdown of ATP were carried out on 
the whole and bisected guinea-pig vas deferens. In addition, degradation studies were
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performed on sections of varying weights from both the prostatic and epididymal ends 
of the tissue and regression analysis performed to determine the relationship between 
tissue weight and the rate of extracellular ATP metabolism.
The group of compounds known as the diadenosine polyphosphates (ApnAs) are 
believed to be another group of potential endogenous ligands at P2 receptors. These 
are compounds which consist of two adenine moieties linked by varying lengths of 
phosphate bridges (n = 2-6), the most widely studied of which are Ap^A, Ap^A and 
ApgA. Ap^A and Ap^A have a variety of pharmacological effects and have been 
proposed to act as neurotransmitters by a number of authors (Hoyle, 1990; Ogilvie, 
1992; Pintor & Miras-Portugal, 1993; Baxi & Vishwanatha, 1995). Whilst there has 
been the suggestion that these compounds act via a separate class of receptors (see 
Pintor & Miras-Portugal, 1995), it is evident that they act at the known P2 receptors 
already classified and if specific receptors do indeed exist they are likely to belong to 
one of the P2 families, P2X and/or P2Y (Fredholm et al., 1997). In certain smooth 
muscle preparations the ApnAs have been shown to act at P2X receptors to cause 
contraction of the smooth muscle. The potency of the agonists in causing contraction 
of the guinea-pig vas deferens and urinary bladder has been shown to increase with 
increasing length of the phosphate chain, that is they increase in potency from Ap^A, 
Ap^A to ApgA and are also more potent than ATP at inducing contraction of these 
tissues, a possible indication that resistance to extracellular breakdown may underpin 
their greater potency which led to the following studies (Stone, 1981; Mackenzie et 
al., 1988; Pohl et al., 1991; Bailey & Hourani, 1995; Hoyle et al., 1995a; 1995b; 
Usune etal., 1996; Westfall etal., 1997).
The diadenosine polyphosphates have also been shown to possess vasoconstrictor 
properties in a variety of vascular preparations, including human umbilical vein
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(Davies e ta l, 1995), rat isolated perfused kidney vessels (Van der Geit et al., 1997) 
and rat mesenteric arteries (Ralevic et al, 1995). All of the above effects are inhibited 
by typical P2 receptor antagonists, such as suramin and PPADS, a compound which 
has reported selectivity for P2X receptors (Bailey & Hourani, 1995; Hoyle et al., 
1995a; 1995b; Ralevic et al., 1995; Usune et al., 1996; Van der Geit et al., 1997; 
Westfall et al., 1997). At the cloned P2Xj receptor, Ap^A has been reported to be an 
agonist, although with lower potency than ATP and evoking a lower maximal 
response, whereas at the cloned P2 X  ^ receptor only Ap^A of the diadenosine 
polyphosphates is an agonist, again with lower potency than ATP, with Ap^A and 
ApgA and the other diadenosine polyphosphates being either inactive or of much lower 
potency (Evans et al., 1995; Pintor et al., 1996a). In contrast, they have been 
demonstrated to be potent and full agonists at the cloned P2 ^^ receptor, with an 
agonist potency order of ATP > Ap^A > Ap^A > Ap^A (Lazarowski et al., 1995), 
whereas at the cloned chick P2Yj receptor only Ap^A was a full agonist, equipotent 
with ATP, while Ap^A is only a weak partial agonist and the other diadenosine 
polyphosphates are inactive (Pintor etal., 1996a).
In contrast to cloned P2 receptors, the effects of the diadenosine polyphosphates in 
isolated smooth muscle preparations have not been thoroughly investigated to date, 
although they are reported to relax guinea-pig taenia caeci with an agonist potency 
order of Ap^A > Ap^A > Ap^A (Hoyle et al., 1995b) and in vascular preparations 
those with the shortest phosphate chain length (such as Ap^A) are known vasodilators 
(Pohl et al., 1991; Ralevic et al., 1995; Van der Geit et al., 1997). The source of a 
potential problem with the characterisation of the pharmacological responses to these 
compounds is that in the tissues so far studied adenosine has also been shown to 
induce relaxant responses, and the effects of the diadenosine polyphosphates may be 
directly or indirectly via PI receptor activation rather than P2 receptors. Indeed, in a
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number of tissues the effects of diadenosine polyphosphates have been shown to be 
mediated, at least in part, via PI receptors, including the guinea-pig vas deferens, 
taenia caeci and urinary bladder (Stone, 1981; Hoyle et a l, 1995a), guinea-pig left 
atrium (Hoyle et al., 1996), inward and outward ionic currents in follicular oocytes of 
Xenopus laevis (Pintor et al., 1996b) and negative chronotropic and inotropic effects 
in guinea-pig and human cardiac preparations (Vahlensieck et al., 1996).
It has been previously demonstrated that ectonucleotidase enzymes are capable of 
cleaving the phosphate chain linking the two adenine moieties asymmetrically, giving 
rise to AMP and the appropriate adenine nucleotide, that is Ap^A is degraded to AMP 
and AP4 . In addition, these compounds are reported to be more resistant to 
degradation than ATP (Pohl et ah, 1991; Ogilvie et al, 1992; Rodriguez-Pascal, et al, 
1992; Pintor et al., 1996b). As is the case with ATP (Hourani & Chown, 1989; 
Bailey & Hourani, 1994; Crack etal., 1994), the ectoenzymes which break down the 
diadenosine polyphosphates are inhibited by the P2 receptor antagonist, suramin 
(Mateo et al., 1996; Pintor et al., 1997).
The trypanocidal drug, suramin, acts as an antagonist at both P2X and P2Y receptors 
(Hoyle et al., 1990) in smooth muscle preparations and, in addition, has been shown 
to possess inhibitory effects on ectonucleotidase activity (Hourani & Chown, 1989). 
This ectonucleotidase inhibition has been suggested to be responsible for an apparent 
lack of inhibition of the pharmacological responses to rapidly-degraded agonists, such 
as ATP (Crack et al., 1994; Bailey & Hourani, 1994; 1995). As described 
previously, suramin acts as an antagonist at cloned P2X^, P2Yj and P2Y^ receptors, 
but not at rat or human P2Y^ receptors (Valera et al., 1994; Charlton et al., 1996a; 
1996b; Bogdanov et al., 1998). Suramin has also been shown to be a potent inhibitor 
of the diadenosine polyphosphate hydrolase present in the Torpedo electric organ
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(Pintor er fl/., 1997) and the effects of suramin on the degradation of the diadenosine 
polyphosphates Ap^A and Ap^A by the guinea-pig vas deferens were studied here.
Studies were also performed to determine the extent to which soluble 
ectonucleotidases were released into the incubation medium by the guinea-pig vas 
deferens by placing ATP (100|iM) in buffer which had previously contained a portion 
of the guinea-pig vas deferens from the bisected prostatic or epididymal portion.
5.2. Methods
Male Dunkin-Hartley guinea-pigs (350-400g) were killed by cervical dislocation, the 
abdomen was opened and the whole vasa deferentia dissected out. The vas deferens 
was then cleared of connective tissue and either 3cm lengths were removed for whole 
tissue studies or each vas deferens was bisected exactly in half for studies on prostatic 
and epididymal portions or varying lengths of tissue were removed from both the 
prostatic and epididymal portions for studies on the effect of tissue weight on the half- 
life of ATP. Each tissue was then placed in 1.5ml of warmed (37°C) Krebs solution 
of the following composition (mM): NaCl 118.0, KCl 4.8, MgCl^ 1.2, NaHCOg 
25.0, KH2 PO4  1.2, CaCl^ 2.5 and glucose 11.0, gassed with 95% 0/5%  CO2 . Each 
tissue was placed in a separate tube containing 1.5ml of warmed (37°C) Krebs 
solution and equilibrated for 60 minutes.
All tissues were then incubated for a further 60 minutes in Krebs buffer containing 
either 15p,l of water or ImM suramin added in a volume of 15|il with frequent changes 
of Krebs solution and drugs or water being readded at each change. Tissues were 
then transferred to tubes containing 1.5ml Krebs solution with ATP, AP4 A or Ap^A
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(lOOjiM) and either 15|il water or ImM suramin added in a volume of 15|il. Aliquots 
(50jil) of incubation buffer were taken at 0, 2, 5, 10, 20, and 30 minutes, placed 
immediately on ice prior to being frozen at -20°C for later analysis by h.p.l.c. (see 
section 2.4.).
For studies on the bisected guinea-pig vas deferens, prostatic and epididymal portions 
of the vasa deferentia were placed in separate tubes containing 1.5ml warmed and 
gassed Krebs buffer and equilibrated for 60 minutes. Prostatic and epididymal 
portions of the same vas deferens were incubated in parallel with the same stock 
solutions of ATP (100|iM) and under identical experimental conditions. Following 
equilibration, tissues were placed in unused vials holding 1.5ml Krebs solution 
containing lOOjxM ATP, added as a 15pl volume. Aliquots (50p.l) of incubation 
buffer were taken at 0, 2, 5, 10, 20, and 30 minutes, placed immediately on ice prior 
to being frozen at -20°C for later analysis by h.p.l.c. (see section 2.4.).
Studies were also performed using varying weights of tissue from both the prostatic 
and epididymal portions of the guinea-pig vas deferens, in which each portion of the 
vasa deferentia was cut into portions as required, blotted dry using clean absorbent 
paper towels and weighed. Each portion was then transferred to unused vials holding 
1.5ml Krebs solution containing 100|iM ATP, added as a 15|il volume. Aliquots 
(50p.l) of incubation buffer were taken at 0, 2, 5, 10, 20, and 30 minutes, placed 
immediately on ice prior to being frozen at -20°C for later analysis by h.p.l.c. (see 
section 2.4.). Half-lives and rate constants for the degradation of ATP were 
calculated for each tissue portion from the linear plot of log concentration against time 
and the mean and s.e.mean of these values used for the comparison of rates of 
breakdown for each portion of the bisected vas deferens by unpaired Student t-test.
212
To check for leakage of enzymes, tissues (whole vas deferens and prostatic and 
epididymal portions) which had been washed and incubated with suramin (ImM) or 
water (15|li1) as above, were then incubated for a further 60 minutes with no washes, 
the tissues were then removed, ATP, Ap^A or Ap^A (lOOpM) were then added to the 
buffer which had previously contained the tissue, and samples taken for analysis at 0 
and 30 minutes.
Nucleotides, nucleosides, diadenosine polyphosphates and their metabolites were 
detected by ultraviolet absorbance (u.v.) at their optimum wavelengths (see Table
2.1.) using a Shimadzu SPD-lOA u.v./visible detector, and were quantified by the 
area of their individual absorbance peaks, which was linearly related to their 
concentration (see section 2.3.). The results were displayed graphically as the mean 
and standard error of the mean (s.e.mean) of the concentration.
5.2.1. Materials
ATP, ADP, AMP, adenosine, inosine, Ap^A, Ap^A and tetrabutylammonium 
hydrogen sulphate were obtained from the Sigma Chemical Company, Poole, UK. 
Acetonitiile (hplc grade) and all buffer salts (analytical grade) were obtained from 
Fisher Scientific, Loughborough, UK. Suramin was a generous gift from Bayer UK.
5.2.2. Statistics and Data Analysis
Concentration-time curves were constructed from the non-transformed data. Semi-log 
plots of the log concentration versus time data were constmcted. From these the half- 
life (ti/2 ) of the substrate was determined from the straight line fit by determining the 
time in minutes for the initial concentration of the substrate to decrease by 50%. The
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rate constant for each individual reaction was calculated from the half-life using the 
equation = 0.693/t /^2-
The absolute levels of all substrates and degradation products were compared at all 
time points sampled between control and treated tissues using 2-way ANOVA. The 
tj/ 2  for each substrate and the k^ g^ for each reaction were compared for control and 
suramin-treated tissues using an unpaired Student t-test.
5.3. Results
The guinea-pig vas deferens degraded ATP, Ap^A and Ap^A (lOOfxM) to give rise to 
the expected products ADP, AMP adenosine and inosine in the case of ATP; ATP, 
ADP, AMP, adenosine and inosine for Ap^A and AP4 , ADP, AMP, adenosine and 
inosine in the case of Ap^A. Following a 30 minute incubation period the absolute 
level of ATP had decreased to 6.9 ± l.lp,M and 39.1 ± 3.7|iM in the absence and 
presence of ImM suramin, respectively (Figure 5.1.) (P < 0.01). The half-life of 
ATP was 7.54 ± 1.37 minutes in the absence and 15.7 ± 2.46 minutes in the presence 
of suramin (ImM) (P<0.05) (Table 5.1.; Figure 5.4. (a) and (b)). The pattern 
of metabolite accumulation following ATP breakdown was similar in the absence and 
presence of suramin, with ADP, AMP adenosine and inosine all being detected, and 
inosine being the major metabolite in the incubation medium (Figure 5.1.). AP4A 
was degraded at a slower rate than was ATP, although the pattern of metabolites 
produced was similar in that ATP itself was detected along with ADP, AMP, 
adenosine and with inosine again being the major metabolite (Figure 5 .2 .) . 
Following a 30 minute incubation period the absolute level of AP4 A had decreased to 
37.3 ± 5.4pM and 53.7 ± 7.7pM in the absence and presence of ImM suramin, 
respectively (Figure 5.2.) (P < 0.01). The half-life for AP4 A degradation was 24.3 
± 3.75 minutes in the absence of suramin and 61.3 ± 9.98 minutes in the presence of
214
ImM suramin (P<0.01) (Table 5.1.; Figure 5.5. (a) and (b)). Similarly, the 
half-life of Ap^A was found to be 38.9 ±4.11 minutes and 67.4 ± 7.62 minutes 
(P<0.01) in the absence and presence of ImM suramin, respectively (Table 5.1.; 
Figure 5.6. (a) and (b)). Following a 30 minute incubation period the absolute 
level of ApgA had decreased to 51.6 ± 1.2pM and 60.8 ± 1.1 |iM in the absence and 
presence of ImM suramin, respectively (Figure 5.3.) (P < 0.01). The above results 
indicate that the extracellular degradation of ATP was much more rapid by the guinea- 
pig vas deferens than that of Ap^A and Ap^A (P > 0.05)
Incubation of ATP, AP^A and Ap^A with incubation buffer which had previously 
contained the guinea-pig vas deferens resulted in the degradation of all three 
substrates. However, in all cases the degradation was much slower than that in the 
presence of tissue. Following a 30 minute incubation period in the absence of tissue 
58.9 ± 3.4pM ATP remained in the absence of ImM suramin, whereas in the presence 
of ImM suramin the ATP level in the incubation medium remained at 83.5 ± 3.1|iM 
(P < 0.05) (Figure 5.7. (a)). The amounts of Ap^A and Ap^A remaining after 
incubation with buffer which had previously contained the guinea-pig vas deferens 
were similar for both ligands, being 71.0 ± 1.6|liM and 85.7 ± 2.9p.M for Ap^A (P < 
0.05) and 69.6 ± 3.2|xM and 87.2 ± 3.1pM for Ap^A (P < 0.05) in the absence and 
presence of ImM suramin, respectively (Figure 5.7. (b); (c)). For ATP, Ap^A 
and Ap^A there was a significant reduction in the amount of inosine detected in the 
incubation buffer between control and suramin-treated tissues (P < 0.01) and for ATP 
(P < 0.05) and Ap^A (P < 0.01) there was also a significant decrease in the levels of 
extracellular adenosine detected between control and suramin-treated tissues, whereas 
no such difference in adenosine production was observed in the case of Ap^A.
The bisected guinea-pig vas deferens degraded extracellular ATP, with a similar 
pattern of breakdown products detectable in the incubation medium to the whole 
guinea-pig vas (Figure 5.8. (a) and (b)). Following a 30 minute incubation time
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the absolute level of ATP in the incubation buffer was 31.1 ± 4.8|iM in the presence 
of the prostatic portion and 41.1 ± 3.3p,M in the presence of the epididymal portion. 
The half-life of ATP in the presence of the prostatic portion of the guinea-pig vas 
deferens was 16.4 ±1.9 minutes with a rate constant of 0.042 ± 0.005 min'% whereas 
the half-life in the presence of the epididymal portion 24.0 ±3.8 minutes with a rate 
constant 0.029 ± 0.004 min'\ which was significantly different from that for the 
prostatic portion (P< 0.05). However, when the relative weights of the tissues (35 ± 
Img and 18 ± Img for the prostatic and epididymal portions, respectively, are taken 
into account, the rate constants per gram were 1.2 ± 0.15 and 1.7 ± 0.24 min'  ^ g '\  
respectively. These values are not significantly different (P < 0.05).
When taking the tissue wet weight into account and disregarding the portion of the vas 
deferens from which the segment originated, the correlation between tissue wet weight 
and half-life of ATP was highly significant (r = 0.67, P < 0.001) (Figure 5.9. (a)). 
However, when the portions of the two ends of the vas deferens were taken in 
isolation there was a significant correlation between the half-life of ATP and tissue wet 
weight from the epididymal portion (r = 0.785, P < 0.01), whereas those portions 
from the prostatic portion did not exhibit a significant correlation between tissue wet 
weight and half-life of extracellular ATP (r = 0.398) (Figure 5.9. (b); (c)).
216
The rate of ATP degradation was significantly different between control and suramin- 
treated tissues (P < 0.05).
Figure 5.1. Effect o f Suramin on the Degradation o f ATP by the Guinea-Pig
Vas Deferens
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Degradation of ATP (100|xM) (■) by the guinea-pig vas deferens and the 
appearance of its metabolites ADP (#), AMP (À), adenosine (□) and 
inosine (♦) in the absence (a) and presence (b) of suramin (ImM). Each 
point is the mean of at least 3 determinations and the vertical bars represent 
s.e.mean. Statistical analysis was performed between control and suramin- 
treated tissues using 2-way repeated measures ANOVA. For abbreviations 
see main body of text.
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The level of Ap^A was significantly different between control and suramin-treated tissues 
(P < 0.01).
Figure 5.2. Effect o f Suramin on the Degradation o f Ap^A by the Guinea-Pig
Vas Deferens
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Degradation of Ap^A (lOOpM) (A) by the guinea-pig vas deferens and the 
appearance of its metabolites ATP (■), ADP (• ) , AMP (À), adenosine (□) 
and inosine (♦) in the absence (a) and presence (b) of suramin (ImM). 
Each point is the mean of at least 3 determinations and the vertical bars 
represent s.e.mean. Statistical analysis was performed between control and 
suramin-treated tissues using 2-way repeated measures ANOVA. For 
abbreviations see main body of text.
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The level of Ap^A was significantly different between control and suramin-treated tissues 
(P < 0.01).
Figure 5.3. Effect o f Suramin on the Degradation o f Ap^A by the Guinea-Pig
Vas Deferens
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Degradation of Ap^A (lOOpM) (T) by the guinea-pig vas deferens and the 
appearance of its metabolites AP^ (O), ATP (■), ADP (•) , AMP (A), adenosine 
(□) and inosine (♦) in the absence (a) and presence (b) of suramin (ImM). 
Each point is the mean of at least 3 determinations and the vertical bars represent 
s.e.mean. Statistical analysis was performed between control and suramin-treated 
tissues using 2-way repeated measures ANOVA. For abbreviations see main body 
of text.
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The rate of ATP degradation was significantly different between control and suramin- 
treated tissues (P < 0.05).
Figure 5.4. Effect o f Suramin on the H alf-life for the Degradation o f ATP by
the W hole Guinea-Pig Vas Deferens
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Half-life for the degradation of ATP from an initial concentration of lOOpM 
following incubation with the whole guinea-pig vas deferens in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 determinations 
and the error bars were smaller than the symbol size in each case. Statistical analysis 
was performed between control and suramin-treated tissues using unpaired Student t- 
test. For abbreviations see main body of text.
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The level of Ap.A was significantly different between control and suramin-treated tissues 
(P <0.01).
Figure 5.5. Effect o f Suramin on the Half-life for the Degradation o f Ap^A
by the W hole Guinea-Pig Vas Deferens
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Half-life for the degradation of Ap^A from an initial concentration of lOOpM 
following incubation with the whole guinea-pig vas deferens in the absence (a) and 
presence (b) of ImM suramin. Each point is the mean of at least 3 
determinationsand the error bars were smaller than the symbol size in each case. 
Statistical analysis was performed between control and suramin-treated tissues using 
unpaired Student t-test. For abbreviations see main body of text.
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The level of Ap^A was significantly different between control and suramin-treated tissues 
(P<0.01).
F igure 5.6. Effect o f Suramin on the Half-life for the Degradation o f Ap^A
by the W hole Guinea-Pig Vas Deferens
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Half-life for the degradation of Ap^A from an initial concentration of lOOpM 
following incubation with the whole guinea-pig vas deferens in the absence (a) and 
presence (b) of ImM suramin. Each semi-log plot is the mean of at least 3 
determinations and the error bars were smaller than the symbol size in each case. 
Statistical analysis was performed between control and suramin-treated tissues using 
unpaired Student t-test. For abbreviations see main body of text.
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F igure 5.7. Effect o f Suramin on the M etabolism o f (a) ATP, (b) Ap^A and
(c) Ap^A by Enzymes Released into the Buffer by the Guinea-Pig Vas
Deferens
ATP ADP AMP ADENOSINE INOSINE
(c)
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Ap.A AP ATP ADP AMP ADENOSINE INOSINE
Degradation of (a) ATP, (b) Ap^A and (c) Ap^A and the appearance of their
metabolites following a 30 minute incubation period with Krebs buffer which had 
previously contained the guinea-pig vas deferens for 1 hour in the absence (open 
columns) and presence (closed columns) of ImM suramin. Each column is the mean 
of at least 3 determinations and the vertical bars represent s.e.mean. Statistical 
analysis was performed between control and suramin-treated tissues using Students 
unpaired t-test (* P < 0.05; ** P < 0.01). For abbreviations see main body of text.
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Figure 5.8. Degradation o f ATP by the (a) Prostatic and (b) Epididymal
Portions o f the Bisected Guinea-Pig Vas Deferens
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Degradation of ATP (lOOpM) (■) and the appearance of its metabolites ADP (•) , 
AMP (À), adenosine (□) and inosine (♦) by the prostatic (a) and epididymal (b) 
portions of the bisected guinea-pig vas deferens. Each point is the mean of at least 
8 determinations and the vertical bars represent s.e.mean. Statistical analysis was 
performed between prostatic and epididymal portions using repeated measures 2- 
way ANOVA. For abbreviations see main body of text.
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Figure 5.9. Correlation between Tissue Wet Weight and Half-life for the 
Degradation of ATP by the (a) Whole, (b) Prostatic and (c) Epididymal 
Portions of the Bisected Guinea-Pig Vas Deferens
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Correlation between tissue wet weight and the half-life for the degradation of ATP 
(lOOpM) (■) for the whole (a), prostatic (b) and epididymal (c) portions of the 
bisected guinea-pig vas deferens. For abbreviations see main body of text.
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5.4. Discussion
The pattern of extracellular ATP degradation was similar for both the prostatic and 
epididymal portions of the guinea-pig vas deferens, with both adenosine and inosine 
being detected in the largest amounts after a 30 minute incubation period. The 
breakdown of the diadenosine polyphosphates, Ap^A and Ap^A, was significantly 
slower than that of ATP, as previously determined in other smooth muscle tissues 
such as the rat colon muscularis mucosae (Hourani et al., 1998; see Chapter 3 of this 
thesis).
However, the rate of breakdown of ATP was greater at the prostatic end than the 
epididymal end, suggesting that different rates of extracellular degradation are not 
responsible for the higher observed potency of ATP at the prostatic end of the guinea- 
pig vas deferens. Indeed, if the observed differences in potency were due solely to 
different rates of degradation, then the opposite finding would be expected, that is, a 
higher rate of breakdown of ATP at the epididymal end. That different rates of 
breakdown are not responsible for the observed differences in pharmacological 
potency was suggested by Sneddon & Machaly (1992) based on their observation that 
AMPCPP, a stable analogue of ATP, is also more potent at the prostatic than at the 
epididymal end, and the findings here therefore support this suggestion. The 
difference in potency may, therefore, reflect a greater density of P2Xj receptors at the 
prostatic end of the tissue.
The difference in the rate of breakdown of ATP at the two ends of the guinea-pig vas 
deferens does not appear to be due to any true differences in the absolute levels of 
ectonucleotidase present along the length of the vas deferens, but rather to reflect the 
fact that the prostatic end of the tissue is considerably larger than the epididymal end, 
as the differences in the rate constants for breakdown were removed when these were
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expressed in terms of the wet weight of the tissue. Indeed, comparison of the half-life 
for ATP in portions of the vas deferens of different sizes showed a good correlation 
between tissue weight and half-life, suggesting that the difference between the two 
ends is indeed simply a reflection of the greater size of the prostatic end. A similar 
relationship between tissue weight and the rate of hydrolysis of ATP was found in 
segments of the rat mesenteric artery (Plesner, 1997). There does not, therefore, 
appear to be a differential distribution of ectonucleotidases at the two ends of the 
tissue, in contrast to the differential distribution of receptors for ATP, noradrenaline 
and adenosine (Sneddon & Machaly, 1992; Brownhill et al., 1996). The amount of 
adenosine generated extracellularly from neuronally-released ATP is likely, therefore, 
to be differ throughout the length of the vas deferens and the responses to both ATP 
and adenosine may be different at the two ends due to the relative receptor densities.
Interestingly, however, when the gradients of the plots for the prostatic and 
epididymal tissue weights against ATP half-lives are examined in isolation a difference 
is revealed. Those for the whole vas deferens and the prostatic portion were similar, 
whereas that for the epididymal portion was much greater. The difference between the 
gradients may be due, at least in part, to the fact that tissues of a lower weight, and 
therefore a smaller size, have a greater surface area to volume ratio and below a given 
tissue weight the relationship between the wet weight of the tissue section and the half- 
life of ATP breakdown changes at a different rate up to an optimal tissue size, beyond 
which the change in the level of ectonucleotidase activity no longer has a linear 
relationship with the increase in tissue size and, more importantly, surface area to 
volume ratio. Furthermore, the difference in the gradients may be due to the fact that 
no note was taken of where the sections were taken in relation to the distal or proximal 
end of either the epididymal or the prostatic portion. Additionally, a gradient not 
differing significantly from unity between tissue weight and half-life for extracellular 
ATP degradation assumes a linear relationship between the decrease in the level of
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ectonucleotidase activity and the distance along the length of the vas deferens from the 
distal end of the prostatic portion.
In the presence of suramin (ImM) the rate of extracellular breakdown of ATP, Ap^A 
and ApgA were all decreased, indicating that the enzymes responsible for the 
breakdown of these substrates in the guinea-pig vas deferens are sensitive to suramin. 
This corresponds with the findings for Ap^A and Ap^A metabolism by the rat colon 
muscularis mucosae, but not for ATP breakdown which was not significantly affected 
by suramin in the rat colon muscularis mucosae (see Chapter 3 of this thesis), and 
for the degradation of Ap^A and Ap^A by the Torpedo electric organ in which 
diadenosine polyphosphate hydrolase has been reported to be particularly sensitive to 
inhibition by suramin (Mateo et ah, 1996). Previous studies have shown that suramin 
(ImM) decreased the extent of extracellular ATP degradation by the guinea-pig vas 
deferens (Bailey & Hourani, 1994). However, in the previous study the level of ATP 
remaining after 30 minutes incubation was 45|iM, whereas in the present study the 
level of ATP remaining after the same incubation period was less than lOpM in each 
case. This probably reflects the smaller incubation volume used in the studies 
presented in this thesis, 1.5ml as opposed to 3ml, which were used in order to 
approximate more accurately to the situation as regards extracellular breakdown in the 
vicinity of the receptor.
Interestingly, as was the case in the rat colon muscularis mucosae, the absolute levels 
of the metabolites of both Ap^A and Ap^A detected in the incubation medium were 
much lower than would normally be expected from the extent of breakdown of the 
parent compound, since a single molecule of Ap^A or Ap^A would be expected 
following degradation to yield a molecule of AMP plus the corresponding nucleotide 
ATP or AP4 , respectively . Again, this may be due to the uptake and final degradation 
of the products adenosine and inosine occurring at such a rapid rate that they do not
230
accumulate to any measurable extent, ultimately resulting in their elimination from the 
extracellular compartment and/or destruction of the purine moiety.
Following incubation with buffer which had previously contained the guinea-pig vas 
deferens ATP, Ap^A and Ap^A were all degraded to a significantly lesser extent than 
in the presence of tissue, and the breakdown of all three were again inhibited 
significantly (P < 0.05) by ImM suramin. These results are similar for those seen 
with the rat vas deferens (Chapter 4 of this thesis), with the levels of all three 
substrates being similar following a 30 minute incubation period, suggesting that 
enzyme leakage from the intracellular compartment of the guinea-pig vas deferens does 
not contribute greatly to the extracellular degradation of ATP, Ap^A and Ap^A, unlike 
the situation in the rat colon muscularis mucosae (Chapter 3 in this thesis), where the 
contribution to extracellular hydrolysis from enzyme leakage is much greater.
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Chapter 6
RAT DUODENUM
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6 .1 . In tro d u ctio n
Two families of P2 receptors have so far been identified: the P2Y receptors which are G 
protein-coupled and the P2X receptors which are cation channels. The number of 
subtypes within the two groups has continued to grow in recent years. To date within 
the P2Y family, five subtypes have been clearly shown to represent nucleotide 
receptors; namely P2Yp P2 Y2 , P2Y ,^ P2Yg and P2Y^ (see Boarder & Hourani, 1998; 
Harden et al., 1998; Weisman et al., 1998). It is believed that of these the P2Y, 
receptor probably represents the receptor previously defined as the P^y purinoceptor, at 
which 2MeSATP is more potent than ATP and the stable analogue AMPCPP less 
potent. The functionally-defined P^ y receptor has been generally associated with the 
relaxation of smooth muscle prepartations, whereas the previously-named P^ x subtype 
mediates contraction, and is thought to correspond to the cloned P2X, subtype of ion 
channel receptors (see Bumstock & Kennedy, 1985; Valera et al., 1994; Collo et al., 
1996; Evans et al., 1998; Hourani et al., 1998).
An additional, functionally-defined P2 receptor had been described (Gordon, 1986), the 
Pjy receptor, via which ADP induces blood platelet aggregation and at which ATP is an 
antagonist. There are, however, conflicting reports as to whether the multiple effects of 
ADP on platelets, namely shape change, aggregation, increases in cytoplasmic Ca^ "^  and 
inhibition of adenylate cyclase, can be explained by interaction with a single receptor 
subtype, and a number of models have been proposed which include two or more ADP 
receptors (see Colman et al., 1992; Hourani & Hall, 1994; 1996; Gachet gr al., 1996; 
Hourani, 1996; Hourani etal., 1996; Mills, 1996; Boarder & Hourani, 1998). It was 
recently reported that the P^ y receptor may in fact be the P2Y, receptor, as studies of the 
human P2Y, receptor expressed in Jurkat cells showed that although ATP, 2MeSATP 
and 2-chloroadenosine 5’-triphosphate (ClATP) appeared to be agonists, when freshly 
purified they acted as competitive antagonists of ADP-induced Ca^ "^  mobilisation (Léon
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et a l, 1997; Hechler e /«/., 1998). In addition, the P2Y, receptor was shown to be 
expressed in human platelets (Léon etal., 1997).
In addition to the G protein-coupled P2Y receptor, the presence of a P2X, receptor 
causing rapid influx of calcium has been suggested (Mackenzie et a l, 1996) and 
platelets have been shown to express mRNA for this receptor (Vial et al., 1997; Scase 
et al., 1998), although the functional significance of this remains to be elucidated. The 
structure-activity relationships of responses of platelets to adenine nucleotides most 
closely resembles those of the P2Yj receptor among the family of P2Y receptors cloned 
to date, in that uridine nucleotides are only very weakly active and 2 -substituted 
analogues of ADP and ATP are more potent than the unsubstituted compounds, 
whereas methylene substitution in the phosphate chain reduces potency (Hourani & 
Cusack, 1991; Hourani & Hall, 1996).
A major obstacle in the identification of P2Y receptor has been the lack of selective 
agonists and antagonists for the different subtypes produced from cloning studies. 
Recently, however, a series of adenine nucleotide derivatives have become 
commercially available, including adenosine 3’-phosphate 5 ’ -phosphosulphate 
(A3’P5’PS), and have been proposed to act as specific P2Yj antagonists, with no effect 
on P2 Y2 , P2 Y4  or P2Yg receptors and also on the proposed, but as yet unidentified P2Y 
receptor on C6  glioma cells, which is similar to the P2Y, receptor but is coupled to the 
inhibition of adenylate cyclase rather than stimulation of phospholipase C (PLC) (Boyer 
etal., 1996; Schachter etal., 1996). Additionally, in human platelets these compounds 
have been shown to inhibit the effects of ADP in causing shape change and intracellular 
Ca^  ^ mobilisation, but not its ability to inhibit adenylate cyclase, supporting the 
suggestion (Colman, 1992) that this action of ADP may be mediated by a separate 
receptor (Jin et al., 1998). However, this study did not allow assessment of the nature 
and selectivity of this inhibition, and did not investigate the ability of these compounds 
to inhibit platelet aggregation induced by ADP. A recent study in rabbit platelets
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confirmed these findings and also showed inhibition of ADP-induced platelet 
aggregation by A3’P5’PS (Savi et al., 1998). Recently it has been reported that 
A3’P5’PS selectively antagonised in an apparently competitive manner ADP-induced 
platelet aggregation, as well as the ability of ADP to cause shape change and increases 
in intracellular Ca^  ^levels in platelets. However, there was no effect of A3’P5’PS on 
the inhibition of stimulated adenylate cyclase by ADP, confirming the suggestion that 
this response is mediated by means of a different receptor subtype (Park et a l, 1998).
The P2 receptor antagonist, suramin, inhibits the responses of ADP (Hourani et al., 
1992; Hourani & Hall, 1994) and has been shown to have some selectivity for P2Y, 
receptors over P2Y^ and P2Y^ receptors (Charlton et a l, 1996a; 1996b; Boarder & 
Hourani, 1998), although it is also known to be active on P2X subtypes and has many 
other effects (Voogd et a l, 1993), including the inhibition of ectonucleotidases 
responsible for the removal of adenine nucleotides (Hourani & Chown, 1989; Leff et 
al., 1990; Bailey & Hourani, 1985; see Chapters 3 and 5 of this thesis). Since 
A3’P5’PS is a structural analogue of ADP, the effect of suramin on the responses of 
this tissue to A3’P5’PS and on its extracellular breakdown was studied.
The rat isolated duodenum is a smooth muscle preparation believed to contain P2Yj 
receptors (Nicholls et al., 1990; Windscheif et al., 1995; Hourani et al., 1998), the 
present study investigated the effects of A3’P5’PS in this tissue and the effect of 
suramin on these responses. Since it has previously been reported that 
ectonucleotidases present on a number of smooth muscle preparations, such as the rat 
whole duodenum, result in the breakdown of ATP (Hourani et al., 1991) and this can 
affect the observed responses to nucleotides (Welford et al., 1986; 1987; Kennedy & 
Leff, 1995), the breakdown of A3’P5’PS by ectonucleotidases present in this tissue 
both in the absence and presence of suramin were also investigated.
235
6 .2 . M eth o d s
6.2.1, Pharmacological Studies
Male Wistar albino rats (200-250g) were killed by cervical dislocation, the abdomen 
was opened and the duodenum removed by cutting at the base of the pylorus and at 
1.5cm from this point. The duodenum was then cleared of connective tissue and 
washed thoroughly with Krebs solution by passing Krebs buffer through the lumen 
using a plastic Pasteur pipette ( 1 cm).
Tissues were then mounted in 3ml organ baths containing warmed (37°C) Krebs 
solution of the following composition (mM): NaCl 118.0, KCl 4.8, MgSO^ 1.2, 
NaHCOg 2.5, KH2 PO4  1.2, CaCl2  2.5 and glucose 11.0, gassed with 95% 0J^%  CO2  
and maintained at 37°C by means of a water jacket surrounding the organ bath. Cotton 
threads (Silko, 60 gauge) were tied around each end of the segment of duodenum so 
that the lumen was sealed. Resting tensions of Ig were applied to the tissues and 
isometric responses were recorded with a Grass FT03 transducer and displayed on a 
Grass 79D polygraph.
All concentration-response curves were constructed in a non-cumulative manner, with 5 
washouts of the organ baths between doses. The rat duodenum was spontaneously 
active, however, the size of the spontaneous contractions were variable and tended to 
decrease with time making relaxant responses to A3’P5’PS difficult to quantify. 
Therefore, tissues were pre-contracted with carbachol so that inhibitory responses could 
be more easily measured. A concentration-response curve to carbachol was constructed 
in order to determine a suitable dose for pre-contracting the tissue could be chosen. A 
concentration of 3pM carbachol gave a contraction that was approximately 40% of the 
maximum response, whilst producing reproducible, rhythmic contractions. At the start 
of each experiment contractions to carbachol were irregular and for this reason tissues
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were challenged with three doses of 3|xM carbachol prior to the addition of the agonist. 
After this, steady rhythmic contractions to carbachol were obtained and those tissues 
not exhibiting reproducible contractions were discarded at this point. Inhibitory 
responses were quantified by pre-contracting the duodenum with carbachol (3p.M) 
(contact time 1.5min) and challenging with A3’P5’PS (contact time Imin) in the 
absence and presence of suramin (lOOpM). Contractions to carbachol were measured 
from the peak of spontaneous activity to the highest point of carbachol contraction. 
Relaxations were measured as the reduction in this peak height and expressed as % 
inhibition of carbachol contraction. The dose cycle for the addition of the agonist was 
10 minutes, and no tachyphylaxis was observed to either carbachol or A3’P5’PS 
throughout the length of each experiment.
6.2.2. Degradation Studies
The duodenum was removed from animals as described above (see Section 6 .2 .1 .) • 
Tissues were then placed in 1.5ml of warmed (37°C) Krebs solution of the following 
composition (mM): NaCl 118.0, KCl 4.8, MgSO^ 1.2, NaHCO^ 2.5, KH^PO^ 1.2, 
CaClj 2.5 and glucose 11.0, gassed with 95% 0^/5% COj. Cotton threads (Silko, 60 
gauge) were tied around each end of the segment of duodenum so that the lumen was 
sealed, as for the pharmacological studies (see Section 6 .2.1.). Each tissue was 
placed in a separate tube containing 1.5ml of warmed (37°C) Krebs solution and 
equilibrated for 60 minutes with frequent changes of buffer prior to the addition of 
drugs.
Tissues were then transferred to tubes with 1.5ml warmed (37°C) Krebs buffer 
containing lOOpM A3’P5’PS and either lOOp^ M suramin or 15pl water. Aliquots 
(50p.l) of incubation buffer were then removed at 0, 2, 5, 10, 20, and 30 minutes, 
placed immediately on ice prior to being frozen at -20°C for later analysis by h.p.l.c.
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See Section 2.2. of this thesis for a detailed description of sample preparation and 
h.p.l.c. analyses.
To check for the leakage of enzymes from the tissue, sections of rat whole duodenum 
were prepared by exactly the method described previously, and incubated in Krebs 
buffer for 60 minutes. Following incubation, tissues were removed and either ATP or 
A3’P5’PS were added to the incubation buffer at a concentration of lOOjiM and 50jil 
samples taken for h.p.l.c. analysis as described above.
6.2.3. Materials
ATP, A3’P5’PS, carbachol and tetrabutylammonium hydrogen sulphate (h.p.l.c. 
grade) were obtained from Sigma Chemical Company, Poole, UK. Acetonitrile 
(h.p.l.c. grade), potassium hydroxide and all buffer salts (analytical grade) were 
obtained from Fischer Scientific, Loughborough, UK. 95% 0^5%  CO  ^gas cylinders 
were supplied by British Oxygen Company, Guildford, UK.
6.2.4. Statistics and Data Analysis
Concentration-time curves were constructed from the non-transformed data. Curves 
from control and suramin-treated tissues were compared using unpaired Student t-test.
The absolute levels of all the substrates and degradation products were compared at all 
time points sampled between control and suramin-treated samples using 2 -way repeated 
measures ANOVA followed by Dunnett’s post-hoc test.
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6 .3 . R e su lts
Preincubation with A3’P5’PS caused a dose-dependent relaxation of the carbachol pre­
contracted rat isolated duodenum (Figures 6.1.; 6.4.) which was inhibited by 
suramin (lOOpM) (Figures 6.1.; 6.4.).
ATP and A3’P5’PS were degraded by the rat duodenum (Figure 6.2. (a), (b)), 
although the rate and extent to which A3’P5’PS was degraded was much less than that 
for ATP. The rates at which both ligands were degraded were comparable at time 
points between 0-5 minutes post incubation, the levels of both ATP and A3’P5’PS 
being in the range of 55-65pM after 5 minutes. However, between 5 and 30 minutes 
there was a significant difference between the level of ATP in the incubation buffer, 
which approached zero (< 5pM), and that for A3’P5’PS which was reduced to only 
20pM (P < 0.05). In addition, whereas the pattern and level of metabolites produced 
by the breakdown of ATP was comparable to those produced by other smooth muscle 
preparations such as the rat colon muscularis mucosae (see Chapter 3), in that inosine 
was the major breakdown product with little or no adenosine being detected, the 
degradation of A3’P5’PS was accompanied by the production of A3’P5’P, with no 
other products of breakdown being detectable in the incubation buffer. Furthermore, 
the level of A3’P5’P did not exceed 40pM, from a starting value of approximately 
20pM in each experiment.
Preincubation of the rat whole duodenum with suramin (lOOpM) resulted in almost no 
detectable degradation of A3’P5’PS and correspondingly no increase from the starting 
level of A3’P5’P, which was typically in the region of 20|liM (Figure 6.2. (c)). 
Again, no other products of breakdown were detectable in the incubation buffer. There 
was a significant difference between the extent of degradation of A3’P5’PS in the 
absence and presence of suramin (lOOpM) (P < 0.05 at 2 minutes; P < 0.01 between 
5-30 minutes).
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The degradation of ATP and A3’P5’PS by Krebs buffer which had previously 
contained the rat whole duodenum was also recorded (Figure 6.3. (a), (b)). In the 
absence of tissue ATP was degraded to ADP, AMP and inosine. However, in the 
absence of tissue the level of AMP observed was much higher than that in the presence 
of the rat duodenum, with a corresponding reduction in the observed level of inosine. 
Preincubation with suramin, however, lowered the extent of ATP degradation from less 
than 20pM remaining after 30 minutes for control tissues to gretaer than 60pM ATP 
remaining after 30 minutes for suramin-treated tissues (P < 0.001) and the level of 
AMP produced was comparable to those seen in the presence of tissue, being in the 
region of 10-15p,M. Similarly, A3’P5’PS was degraded to a lesser degree in the 
absence of tissue, 40pM remaining after 30 minutes as opposed to 20pM in the 
presence of tissue. The only breakdown product detected in the incubation buffer was 
A3’P5’P, as was the case in the presence of the rat duodenum. Preincubation with 
lOOpM suramin resulted in a decrease in the extent to which A3’P5’PS was degraded, 
with greater than 75pM remaining after 30 minutes incubation with buffer which had 
previously contained rat whole duodenum.
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Figure 6.1. Relaxant Effects of A3'P5'PS on the Rat Whole Duodenum in the 
Absence and Presence of Suramin
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Inhibitory effects of A3'P5PS on the adult rat duodenum expressed as % inhibition of 
the contraction induced by carbachol (3pM) in the absence (■) and presence (#) of 
suramin (lOOpM). Each point is the mean of at least 12 determinations and the 
vertical bars show s.e.mean. Statistical analysis was performed between control and 
suramin-treated tissues using Student unpaired t-test (*P < 0.05; **P < 0.01). For 
abbreviations see main body of text.
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Figure 6.2. Degradation of (a) ATP, (b) A3'P5'PS in the Absence of 
Suramin and (c) A3'P5'PS in the Presence of Suramin by the Rat Whole 
Duodenum
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Degradation of (a) ATP (■) (100|iM), (b) A3 P5 PS (★) (lOOjiM) in the absence of 
suramin and (c) A3'P5'PS (★) (100|xM) in the presence of 100|liM suramin and the 
appearance of their metabolites ADP (#), AMP (A), adenosine (□), inosine (♦) and 
A3'P5'P (Q) by the rat whole duodenum. Each point is the mean of at least 3 
determinations and the vertical bars show s.e.mean. Statistical analysis was 
performed between control and suramin-treated tissues using repeated measures 2 - 
way ANOVA (*P < 0.05; **P < 0.01). For abbreviations see main body of text.
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Figure 6.3. Effect o f Suramin on the Degradation o f (a) ATP and (b) A3'P5'PS by
Enzymes Released into the Buffer by the Rat W hole Duodenum
P. 40
ATP ADP AMP INOSINE
u 40
A3'P5'PS A3P5P
Degradation of (a) ATP and (b) A3'P5'PS and the appearance of their metabolites 
following a 30 minute incubation period with Krebs buffer which had previously 
contained the rat whole duodenum for 1 hour in the absence (open columns) and 
presence (closed columns) of lOOpM suramin. Each column is the mean of at least 
3 determinations and the vertical bars show s.e.mean. For abbreviations see main 
body of text. Statistical analysis was performed between control and suramin- 
treated tissues using Students unpaired t-test (** P < 0.01; *** P < 0.001).
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figure 6.4. RcprcsciUaiivc Traces of llic Relaxant Responses of liie Rat Whole 
Duodenum to A3T5TS in the Absenee and Presenee of Suramin
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CCh E3
Ig Ig
30s 30s
Representative traces showing the effect of A3’P5’PS on the rat whole duodenum, (a) 
Contractile response of the rat whole duodenum to carbachol (CCh) (0.1 }iM). (b)
Relaxant effect of A3’P5’PS (E3) (30pM) on the rat whole duodenum pre-contracted 
with CCh ( 3.0pM) in the absence of suramin (lOOpM). (c) Relaxant effect of 
A3’P5’PS (M) (30pM) on the rat whole duodenum pre-contracted with CCh (O.lpM) 
in the presence of suramin (lOOpM).
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6 .4 . D isc u ss io n
The results presented here suggest that A3’P5’PS is an agonist at the P2Y receptor(s) 
mediating relaxation of the carbachol-precontracted rat whole duodenum. This provides 
contrary evidence from the observation that in human platelets A3’P5’PS inhibits the 
major functional responses of platelets to ADP, namely aggregation, shape change and 
also the increase in intracellular Ca^ "^ , which is believed to be the underlying mechanism 
for these responses (Park et al., 1998) and in itself provides support to the suggestion 
that the P2Y receptor mediating these responses is the P2Yj receptor (the “Pj^ “receptor) 
(Léon et al., 1997), as A3’P5’PS is selective for the P2Y, receptor over the P2 Y2 , 
P2 Y4 , and P2Yg (Boyer etal., 1996). The apparent pAj values reported for A3’P5’PS 
(lOpM) for the inhibition of platelet aggregation, shape change and increases in 
intracellular Ca^ "^  levels are 5.2, 6.0 and 5.4, respectively, and for lOOpM A3’P5’PS
5.2, 5.8 and 5.0, respectively (Park et a l, 1998), and these were somewhat lower than 
the previously reported pKg value of 6.46 at the turkey erythrocyte P2Yj receptor 
(Boyer et a i, 1996). The potency of A3’P5’PS in mediating relaxation responses of 
the carbachol-preconctracted rat duodenum is approximately three-fold less than that for 
ATP (Park et al., 1998). In addition the same authors reported no effect of 
preincubation with A3’P5’PS on the relaxant responses induced by ATP in this tissue.
Interestingly, however, A3’P5’PS clearly has its limitations as an antagonist in whole 
tissue preparations. The unexpected behaviour exhibited in the rat duodenum, where 
A3’P5’PS acts as an agonist, mediating relaxation of the carbachol-precontracted whole 
duodenum would seem to be in direct conflict with its reported antagonist action at the 
P2Y, receptor present on human platelets. The compound was originally reported to be 
only a weak partial agonist at P2Y, receptors in turkey erythrocytes, but not at the 
cloned human P2Y, receptor (Boyer et a/., 1996). Its appearance as an agonist in the 
rat whole duodenum may reflect a higher density of receptors or a more efficient 
coupling mechanism of the receptors present in this tissue than in human platelets or the
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other cell types tested (Boyer et al., 1996). The selectivity for A3’P5’PS was 
previously established by its reported inability to inhibit responses mediated via P2X, 
receptors in rat and mouse vas deferens and urinary bladder (Park et a l, 1998).
The extracellular breakdown of A3’P5’PS by enzymes which were released into the 
buffer resulted in the production of A3’P5’P only, as was the case in the presence of 
the tissue. However, the extent to which A3’P5’PS was broken down was much less 
than that for ATP, with more than twice the amount of A3’P5’PS compared to ATP 
remaining after 30 minutes incubation. Both the degradation of ATP and A3’P5’PS by 
enzymes released from the tissue into the incubation medium was greatly inhibited by 
suramin (lOOpM) (P < 0.001). In the case of ATP the degradation products AMP (P < 
0.001) and inosine (P < 0.01), but not ADP, were significantly reduced. The sole 
product of A3’P5’PS metabolism, namely A3’P5’P, was also reduced significantly (P 
< 0 .0 1 ) in the presence of suramin.
It should be carefully noted that the major metabolite of A3’P5’PS is A3’P5’P, and that 
this was found to be present up to approximately 20% of the supplied A3’P5’PS. The  ^
presence of A3’P5’P as an impurity of the A3’P5’PS supplied at this level should be , 
carefully considered when assessing the functional responses of these compounds 
(Figure 6.2. (b), (c)). Another potential obstacle in the use of A3’P5’PS as a 
selective agonist or antagonist in whole tissue and in vivo studies is that it is clearly 
degraded by extracellular enzymes, probably ectonucleotidases, present on the cell 
surface of smooth muscle tissues. Furthermore, the only identifiable breakdown 
product detected by h.p.l.c. was A3’P5’P which has been reported to have similar 
activity to the parent compound on C6  glioma cells (Boyer et al, 1996).
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Chapter 7
GENERAL DISCUSSION
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7 .1 . G en era l D iscu ssio n
The extracellular breakdown of adenosine triphosphate (ATP) was studied in vitro in a 
number of smooth muscle preparations which have been shown to possess PI 
receptors and/or P2 receptors. The tissues were chosen precisely for the reason that 
the rate of breakdown of the substrate along with the rate and extent of production of 
metabolites, which may themselves act upon their own receptors may have important 
implications in the responses of these tissues to various agonists dependent upon the 
population of receptors present in each particular tissue. The effects of a number of 
regulators of ATP, UTP, adenine polyphosphate and adenosine metabolism and 
adenosine uptake were investigated in these tissues in order to determine the existence 
of regulatory mechanisms on the rate of breakdown and pattern of metabolites seen in 
the presence of the smooth muscle tissues studied. The primary aim of this thesis is to 
study the extracellular metabolism of pharmacologically active adenine and pyrimidine 
nucleotides and nucleosides and diadenosine polyphosphates using the technique of 
h.p.l.c. in an attempt to relate the extent and pattern of their breakdown with their 
activities at cell surface receptors in those tissues.
ATP has long been known to be the molecule from which cells within all organisms 
derive energy. The subsequent, more recent, discovery that this molecule was 
released from certain nerve endings and is capable of interacting with cell surface 
located receptor proteins stimulated a burgeoning field of purinoceptor research. The 
suggestion of a role for ATP as a co-transmitter was initially questioned to the degree 
that it failed, at least for a number of years, to gain widespread acceptance and led to 
these nerves first being termed “non-adrenergic, non-cholinergic” (NANC) nerves, 
since the responses were resistant to blockade by inhibitors of the classical 
neurotransmitters, noradrenaline (NA) and acetylcholine (ACh) (Burnstock, 1963; for 
review see Burnstock, 1981). The proposal that ATP acted as a neurotransmitter 
molecule for which there existed specific cell surface receptors carried with it the
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question of the nature of the removal mechanism responsible for the termination of its 
action. It was known that the highly hydrophilic ATP molecule would not easily cross 
cell membranes andat that point no transport mechanism had been identified for 
adenine nucleotides. The knowledge that numerous intracellular enzymes existed in 
the intricate and interwoven pathways of energy production within cells and that 
cellular damage and/or cell death leads to the release of large numbers of enzymes, 
some of which are responsible for the degradation of purine and pyrimidine 
nucleotides, prompted the suggestion that enzymatic degradation would be the likeliest 
explanation for the termination of neurotransmission via purinergic nerves. This 
combined with their ubiquitous distribution and frequent co-localisation with P2 
receptors was a further indication that their plenary function is involved in nucleotide 
signalling (Plesner, 1995). Were these enzymes soluble, released from intact nerve 
cells under a controlled mechanism as opposed to release only occurring following 
damage to the cell wall? If so, were the enzyme and the substrate stored in separate 
vesicles or the same vesicles with the enzyme stored in an inactive state until release? 
These questions have been largely answered with the discovery of a novel soluble 
ectonucleotidase released from nerve endings in which ATP and ectonucleotidases are 
stored within different vesicles within the nerve ending (Todorov et al., 1996).
As with other tissues, such as the guinea-pig taenia caeci, the rat colon muscularis 
mucosae contains both PI and P2 receptors mediating the same functional responses. 
In each case the P2 receptor has the pharmacological structure-activity relationship 
typical of a clasical P2Y receptor (i.e. 2MeSATP > ATP > AMPCPP). However, the 
rat colon muscularis mucosae exhibits contractile responses to these agonists, whereas 
the guinea-pig taenia caeci relaxes. In addition, the pyrimidine nucleotide, UTP, is 
active in the rat colon muscularis mucosae but not in the guinea-pig taenia (Pier & 
Hollingsworth, 1995), indicating a UTP responsive P2Y receptor (P2Y^ and/or 
P2 Y4 ?) in the rat colon.
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The agonist potency order for nucleotides in the rat colon muscularis mucosae is 
reported to be Ap^A > Ap^A > ATP > AP4  > Ap^A > UTP) (Hourani et al., 1998). It 
was believed, however, that this masked a difference in the receptors by which these 
compounds were exerting their effects. For example, the P2 receptor antagonist 
suramin (lOOjiM), caused a parallel right shift in the dose-response curves to only 
ATP and UTP, only the higher concentrations of Ap^A, AP4 A and AP4  and no 
consistent inhibition of responses to Ap^A. In contrast to the situation in the guinea- 
pig taenia caeci, where all agonist dose-response curves were right-shifted by suramin 
in a concentration-dependent manner (Hourani et al., 1998). This, coupled with the 
observation that an Aj receptor selective concentration of DPCPX (lOnM) antagonised 
responses to Ap^A, AP4 A and AP4 , but not those to ATP and UTP, has led to the 
proposal that the former of these agonists cause their responses via Aj receptors in 
the rat colon muscularis mucosae, presumably following their breakdown to adenosine 
by the action of ectonucleotidases. Paradoxically, higher concentrations of suramin 
(ImM) powerfully inhibited UTP-mediated responses, whilst not affecting responses 
to other agonists and responses to ATP being slightly enhanced (except at 300p.M 
ATP where inhibition occurred). The authors concluded that the combined actions of 
suramin as a P2 receptor antagonist and also as an inhibitor of ectonucleotidases was 
clouding the issue of P2 receptor-mediated mechanisms underlying the responses of 
this tissue to these agonists. The powerful inhibiton of UTP-mediated responses by 
suramin has been taken as an indication by these authors of the presence of P2 Y2 , 
rather than P2 Y4 , receptors in this tissue (Charlton et al., 1996a ; b).
The extent to which extracellular breakdown of all these agonists were tested in the rat 
colon muscularis mucosae, a process which has obvious implications on the activity of 
the agonists in this tissue. Of equal importance is the question of the eventual fate of 
the agonists and whether the degradation products arising from them are themselves 
active at receptors present in this tissue. Could the combined action of suramin as an
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ectonucleotidase inhibitor and P2 receptor antagonist explain the apparent 
discrepancies in the agonist potency orders for the rat colon muscularis mucosae?
Clearly, the rat colon muscularis mucosae possesses ectonucleotidase activity as all the 
agonists studied were found to be degraded, albeit to varying degrees, in the presence 
of this tissue. AP4  and the diadenosine polyphosphates were degraded much more 
slowly and to a lesser extent than was ATP or UTP, which was degraded at an even 
faster rate than ATP, which is in agreement with other reports (Pohl et al., 1991; 
Ogilvie 1992; Rodriguez-Pascual et al., 1992; Pintor et al., 1996). The effect of 
preincubation of the tissues with suramin (ImM) was to decrease the extent to which 
all the agonists were degraded, although the effect on ATP breakdown did not reach 
statistical significance. This slight inhibition of ATP metabolism could perhaps 
explain the enhancement of functional resp onses of the rat colon muscularis mucosae 
to this agonist by this concentration of suramin. Furthermore, the degradation of both 
AP4  and all the diadenosine polyphosphates tested (Ap^A - Ap^A) was significantly 
inhibited by preincubation with ImM suramin, as has been reported in plasma 
membranes isolated from Torpedo synaptic terminals (Mateo et al., 1996). This 
would explain the lack of effect of this concentraion of suramin on the functional 
responses to these agonists. In contrast to these data, UTP, the agonist which 
exhibited the most rapid degradation in the presence of this tissue, breakdown was 
significantly inhibited by suramin (ImM), although no enhancement of functional 
responses to this agonist were reported (Hourani et al., 1998), only a dose-dependent 
inhibition.
Following the breakdown of ATP, no adenosine was detectable in the incubation 
buffer in the presence of either control or suramin-treated tissues. This observation 
maybe due to the fact that no adenosine is produced, but a more likely explanation is 
that an extremely efficient removal mechanism is in operation in this tissue, since 
adenine nucleotide salvage pathways are ubiquitous to most tissues. This removal
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mechanism may be via two possible routes. The first is removal by ecto-adenosine 
deaminase leading to the production of inosine and/or intracellular transport via 
nucleoside transporter proteins present on the cell surface.
The inhibition of responses to the diadenosine polyphosphates by an Aj receptor- 
selective concentration of DPCPX (lOnM) is therefore surprising since they have a 
greater stability than the other agonists. That these agonists exhibit actions at 
adenosine receptors is not in itself surprising, as on of the potential ultimate 
breakdown products of the assymetrical cleavage of the phosphate chains is adenosine, 
and although none was detectable in the incubation medium in these studies, the 
removal mechanisms previously discussed may account for this apparent conflict.
The rat colon muscularis mucosae has indeed been shown in these studies to have an 
efficient removal mechanism for adenosine, since in a further series of experiments the 
effect of the adenosine deaminase inhibitor, EHNA, was to decrease the amount of 
inosine in the incubation buffer with an accompanying detectable level of adenosine, a 
reaction which under control conditions proceeds so rapidly that adenosine is 
undetectable. Adenosine deaminase was originally thought to exist purely as a 
cytosolic enzyme but has more recently been shown to exhibit extracellular activity in a 
number of systems including, inportantly for these studies, the rat gastrointestinal tract 
(Franco et al., 1988). In contrast to the enzymatic removal of adenosine, the 
nucleoside transport inhibitor NBTI, resulted neither in an increase in the level of 
inosine in the incubation medium nor any detectable levels of adenosine. The fact that 
the concentration of NBTI used should be sufficient to inhibit both sensitive and 
insensitive nucleoside transporters (Thom & Jarvis, 1996) suggests that the primary, 
if not the sole, mechanism for the removal of adenosine from the extracellular 
environment of the rat colon muscularis mucosae is that of enzymatic degradation by 
adenosine deaminase. In addition, the lack of effect of the xanthine oxidase inhibitor 
allopurinol, an enzyme which is downstream from adenosine deaminase and which 
results in the conversion of inosine to hypoxanthine (see Figure 1.1.), indicates that
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this enzyme is not important in the removal of inosine from the extracellular 
compartment. However, a cautionary note should be added in that the concentration 
used here (l|xM) should have been sufficient to result in inhibition as the reported Kj 
value the nM range, although the kinetics of this enzyme are not simple and inded there 
are reports that preincubation with allopurinol may result in inactivation of xanthine 
oxidase (Elion, 1978).
The influence of tissue weight on the extracellular degradation of ATP is another issue 
examined in this thesis. The guinea-pig vas deferens possesses different populations 
of both adenosine (Aj and A2 ) and P2 receptors at the prostatic and epididymal ends, 
the prostatic end containing the major population of P2 receptors (P2Xj) and 
prejunctional inhibitory Aj, postjunctional stimulatory Aj and postjunctional inhibitory 
A2  receptors, whereas the epididymal end contains only the pre- and postjunctional Aj 
receptors (Brownhill et al., 1996). In addition, the weights of the two ends of the 
bisected vas are significantly different, with the prostatic portion being heavier than the 
epididymal. The relative levels of ectonucleotidases and ,therefore, of the degradation 
rates of ATP to adenosine and inosine were examined. Firstly, unlike the rat colon 
and the rat vas deferens, a major product of the breakdown of ATP by the guinea-pig 
vas deferens was adenosine, clearly important in a tissue containing a mixed 
population of both PI and P2 receptors. Furthermore, ectonucleotidases have been 
shown to be released from the guinea-pig vas deferens upon electrical stimulation of 
nerves (Todorov et al., 1997). The breakdown of ATP would reasonably be expected 
to reduce its observed potency and to lead to the generation of adenosine which overall 
has an inhibitory effect on ATP-mediated responses, and indeed inhibition of ecto- 
ATPase enhances responses seen to ATP and the purinergic component of electrical 
nerve stimulation (Westfall etal., 1996).
As described above there appears to be a species difference in the major products 
resulting from extracellular ATP metabolism between the rat and guinea-pig, with
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inosine being the major metabolite in the rat and adenosine in the guinea-pig. Again 
this may be due to the presence of more efficient removal mechanisms in the rat than 
the guinea-pig.
In none of the tissues studies was their evidence for a significant level of 
ectonucleotidase release from tissues during a 60 minute incubation period, indeed the 
level of soluble ectonucleotidases from unstimulated tissues previously shown to 
release these enzymes following periods of electrical nerve stimulation, such as the 
guinea-pig vas deferens, were significantly lower in activity than those from 
gastrointesnal tissues such as the rat colon. This suggests that the ectonucleotidases 
released from tissues such as the guinea-pig vas deferens are indeed under the 
regulation of physiological mechanisms as opposed to simple passive diffusion 
processes.
In contrast to previous reports of ecto-5’nucleotidase inhibition by the K\.pp channel 
blocker glibenclamide in rat heart (Sato et al., 1997), no effects were detected in the 
studies here on the rate and extent of ATP metabolism or on the pattern of the products 
arising from this degradation by the rat vas deferens following preincubation with 
either glibenclamide or another K\^p inhibitor, glipizide. One explanation for this may 
be that there are tissue differences in the enzyme levels between these two tissues and 
that these effects of K\^p channel antagonists are not universal.
Protein kinase C activation by NA and calcium-dependent protein kinase stimulation 
by A23187 had no discernible effects on the rate or pattern of extracellular ATP 
metabolism by the rat vas deferens, although forskolin (a potent activator of 
intracellular cAMP levels via adenylate cyclase activity) and SNP significantly 
increased the levels of AMP in the extracellular compartment, suggesting an inhibition 
of ecto-5’nucleotidase possibly as a result of cyclic nucleotide-dependent protein 
kinases. In neither case did this result in a reduction of the rate or extent of ATP 
degradation over a 30 minute period as the half-life for ATP was unaffected. Neither
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was there any inhibitory feedback effect of this build up of AMP on the levels of ADP 
in the buffer and, therefore, it was concluded that there is no effect of the extracellular 
accumulation of AMP by this tissue on the ectonucleotidases responsible for the 
cleavage of the y and p phosphates of ATP. This effect of forskolin and SNP in 
inhibiting ecto-5’nucleotidase and therefore potentially reducing adenosine production 
may indictae some physiological control of adenosine production by agents which, like 
adenosine itself, act via increasing levels of cyclic nucleotides within cells.
7.2. Future Work
The development of selective PI and P2 receptor agonists and antagonists is an 
approach which may result in furthering our understanding of the location and of the 
physiological and pathological roles for these receptor systems. One of the obstacles 
in the past has been the lack of selective ligands, especially for P2X and P2Y 
receptors.
The development of transgenic animals lacking adenosine and/or ATP receptors, or a 
single or multiple extracellular nucleotidases will allow the elucidation of their role in 
both normal physiological processes and in the pathology and progress of pathological 
conditions. For example, transgenic mice have been developed which are deficient in 
the P2Yi receptor (Fabre et ah, 1999), the enzyme CD39/ATP diphosphohydrolase 
(Fnjyoji et al, 1999) and the adenosine A^  ^ receptor (Ledent et al., 1997). The 
expansion of the production of these and other transgenic animals, possibly deficient 
in multiple receptors and/or enzymes, has and will lead to the elucidation of nucleoside 
and nucleotide receptor system pharmacology and physiology.
Further investigation between the interplay of nucleotide receptors and extracellular 
enzymatic degradation of ATP, via ADP, AMP, adenosine and inosine is obviously of 
vital importance in a system where the major ligands used in receptor studies
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performed in both intact tissues and in cloned receptors are, in the main, structural 
analogues of ATP and, therefore, either potential substrates for ecto-ATPases or 
effectively enzymatically stable. The importance of the presence and level of activity 
ofvarious enzymes involved in the termination of the action of ATP is greatly increased 
in those tissues where heterogeneous populations of receptors for both ATP and 
adenosine coexist, such as those tissues used in this thesis, including the guinea-pig 
vas deferens and the rat colon muscularis mucosae.
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